Hematogenous	O
metastasis	O
in	O
gastric	O
cancer	O
requires	O
isolated	O
tumor	O
cells	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
.	O

PURPOSE	O
:	O
Recent	O
studies	O
of	O
cancer	O
metastasis	O
have	O
focused	O
on	O
the	O
role	O
of	O
premetastatic	O
gene	O
expression	O
and	O
circulating	O
tumor	O
cells	O
.	O

We	O
did	O
a	O
blind	O
prospective	O
study	O
in	O
gastric	O
cancer	O
to	O
assess	O
the	O
significance	O
of	O
isolated	O
tumor	O
cells	O
(	O
ITC	O
)	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
1	O
(	O
VEGFR	O
-	O
1	O
)	O
is	O
expressed	O
within	O
the	O
bone	O
marrow	O
at	O
tumor	O
-	O
specific	O
,	O
premetastatic	O
sites	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Both	O
bone	O
marrow	O
and	O
peripheral	O
blood	O
samples	O
from	O
810	O
gastric	O
cancer	O
patients	O
were	O
collected	O
at	O
the	O
Central	O
Hospital	O
,	O
National	O
Cancer	O
Center	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
samples	O
were	O
transferred	O
to	O
Kyushu	O
University	O
Hospital	O
(	O
Beppu	O
,	O
Japan	O
)	O
where	O
they	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
reverse	O
transcription	O
-	O
PCR	O
for	O
three	O
epithelial	O
cell	O
markers	O
,	O
carcinoembryonic	O
antigen	O
,	O
cytokeratin	O
-	O
19	O
,	O
and	O
cytokeratin	O
-	O
7	O
,	O
as	O
well	O
as	O
VEGFR	O
-	O
1	O
.	O

RESULTS	O
:	O
ITCs	O
were	O
observed	O
in	O
peripheral	O
blood	O
and	O
bone	O
marrow	O
even	O
in	O
early	O
stages	O
of	O
gastric	O
cancer	O
.	O

The	O
frequency	O
of	O
ITC	O
in	O
bone	O
marrow	O
was	O
significantly	O
associated	O
with	O
the	O
stage	O
of	O
disease	O
by	O
ANOVA	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Gastric	O
cancer	O
metastasized	O
when	O
ITCs	O
were	O
observed	O
in	O
the	O
presence	O
of	O
VEGFR	O
-	O
1	O
.	O

In	O
the	O
380	O
patients	O
who	O
were	O
ITC	O
negative	O
and	O
showed	O
low	O
VEGFR	O
-	O
1	O
expression	O
,	O
synchronous	O
(	O
at	O
the	O
time	O
of	O
surgery	O
)	O
and	O
heterochronous	O
(	O
recurrent	O
)	O
metastases	O
were	O
not	O
observed	O
.	O

CONCLUSIONS	O
:	O
ITCs	O
circulate	O
even	O
in	O
early	O
stages	O
of	O
disease	O
.	O

Furthermore	O
,	O
elevated	O
expression	O
of	O
VEGFR	O
-	O
1	O
facilitates	O
the	O
establishment	O
of	O
hematogenous	O
metastases	O
in	O
gastric	O
cancer	O
.	O

This	O
study	O
indicates	O
that	O
the	O
simultaneous	O
presence	O
of	O
ITC	O
and	O
VEGFR	O
-	O
1	O
expression	O
at	O
premetastatic	O
sites	O
is	O
clinically	O
significant	O
for	O
disease	O
progression	O
.	O

Analysis	O
of	O
processivity	O
of	O
mungbean	O
dideoxynucleotide	O
-	O
sensitive	O
DNA	O
polymerase	O
and	O
detection	O
of	O
the	O
activity	O
and	O
expression	O
of	O
the	O
enzyme	O
in	O
the	O
meristematic	O
and	O
meiotic	O
tissues	O
and	O
following	O
DNA	O
damaging	O
agent	O
.	O

Analysis	O
of	O
the	O
processivity	O
of	O
mungbean	O
ddNTP	O
-	O
sensitive	O
DNA	O
polymerase	O
showed	O
the	O
incorporation	O
of	O
approximately	O
35	O
-	O
40	O
nucleotides	O
per	O
binding	O
event	O
in	O
the	O
replication	O
assays	O
involving	O
M13	O
ss	O
DNA	O
template	O
with	O
5	O
'	O
-	O
labeled	O
17	O
-	O
mer	O
primer	O
.	O

Optimal	O
processivity	O
was	O
obtained	O
with	O
100	O
-	O
150	O
mM	O
KCl	O
and	O
6	O
-	O
8	O
mM	O
Mg2	O
+	O
at	O
pH	O
7	O
.	O
5	O
.	O

The	O
enzyme	O
showed	O
preference	O
for	O
Mg2	O
+	O
over	O
Mn2	O
+	O
as	O
the	O
metal	O
activator	O
for	O
processivity	O
.	O

2	O
'	O
,	O
3	O
'	O
dideoxythymidine	O
5	O
'	O
triphosphate	O
(	O
ddTTP	O
)	O
and	O
rat	O
DNA	O
pol	O
beta	O
antibody	O
strongly	O
influenced	O
distributive	O
synthesis	O
.	O

Considerable	O
enhancement	O
in	O
processivity	O
was	O
noticed	O
at	O
1mM	O
ATP	O
and	O
2	O
-	O
4	O
mM	O
spermidine	O
while	O
higher	O
concentrations	O
of	O
spermidine	O
caused	O
distributive	O
synthesis	O
.	O

The	O
enzyme	O
was	O
found	O
to	O
be	O
active	O
in	O
both	O
meristematic	O
and	O
meiotic	O
tissues	O
and	O
distinctly	O
induced	O
by	O
EMS	O
treatment	O
.	O

DNA	O
-	O
binding	O
assays	O
revealed	O
distinct	O
binding	O
ability	O
of	O
the	O
enzyme	O
to	O
template	O
/	O
primer	O
and	O
damaged	O
DNA	O
substrate	O
.	O

Together	O
these	O
observations	O
illustrate	O
the	O
probable	O
involvement	O
of	O
the	O
enzyme	O
in	O
replication	O
and	O
repair	O
machinery	O
in	O
higher	O
plants	O
.	O

Acute	O
ethanol	O
exposure	O
disrupts	O
VEGF	O
receptor	O
cell	O
signaling	O
in	O
endothelial	O
cells	O
.	O

Physiological	O
angiogenesis	O
is	O
regulated	O
by	O
various	O
factors	O
,	O
including	O
signaling	O
through	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
receptors	O
.	O

We	O
previously	O
reported	O
that	O
a	O
single	O
dose	O
of	O
ethanol	O
(	O
1	O
.	O
4	O
g	O
/	O
kg	O
)	O
,	O
yielding	O
a	O
blood	O
alcohol	O
concentration	O
of	O
100	O
mg	O
/	O
dl	O
,	O
significantly	O
impairs	O
angiogenesis	O
in	O
murine	O
wounds	O
,	O
despite	O
adequate	O
levels	O
of	O
VEGF	O
,	O
suggesting	O
direct	O
effects	O
of	O
ethanol	O
on	O
endothelial	O
cell	O
signaling	O
(	O
40	O
)	O
.	O

To	O
examine	O
the	O
mechanism	O
by	O
which	O
ethanol	O
influences	O
angiogenesis	O
in	O
wounds	O
,	O
we	O
employed	O
two	O
different	O
in	O
vitro	O
angiogenesis	O
assays	O
to	O
determine	O
whether	O
acute	O
ethanol	O
exposure	O
(	O
100	O
mg	O
/	O
dl	O
)	O
would	O
have	O
long	O
-	O
lasting	O
effects	O
on	O
VEGF	O
-	O
induced	O
capillary	O
network	O
formation	O
.	O

Ethanol	O
exposure	O
resulted	O
in	O
reduced	O
VEGF	O
-	O
induced	O
cord	O
formation	O
on	O
collagen	O
and	O
reduced	O
capillary	O
network	O
structure	O
on	O
Matrigel	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
ethanol	O
exposure	O
decreased	O
expression	O
of	O
endothelial	O
VEGF	O
receptor	O
-	O
2	O
,	O
as	O
well	O
as	O
VEGF	O
receptor	O
-	O
2	O
phosphorylation	O
in	O
vitro	O
.	O

Inhibition	O
of	O
ethanol	O
metabolism	O
by	O
4	O
-	O
methylpyrazole	O
partially	O
abrogated	O
the	O
effect	O
of	O
ethanol	O
on	O
endothelial	O
cell	O
cord	O
formation	O
.	O

However	O
,	O
mice	O
treated	O
with	O
t	O
-	O
butanol	O
,	O
an	O
alcohol	O
not	O
metabolized	O
by	O
alcohol	O
dehydrogenase	O
,	O
exhibited	O
no	O
change	O
in	O
wound	O
vascularity	O
.	O

These	O
results	O
suggest	O
that	O
products	O
of	O
ethanol	O
metabolism	O
are	O
important	O
factors	O
in	O
the	O
development	O
of	O
ethanol	O
-	O
induced	O
changes	O
in	O
endothelial	O
cell	O
responsiveness	O
to	O
VEGF	O
.	O

In	O
vivo	O
,	O
ethanol	O
exposure	O
caused	O
both	O
decreased	O
angiogenesis	O
and	O
increased	O
hypoxia	O
in	O
wounds	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
demonstrated	O
a	O
direct	O
effect	O
of	O
ethanol	O
on	O
the	O
response	O
to	O
hypoxia	O
in	O
endothelial	O
cells	O
,	O
as	O
ethanol	O
diminished	O
nuclear	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
protein	O
levels	O
.	O

Together	O
,	O
the	O
data	O
establish	O
that	O
acute	O
ethanol	O
exposure	O
significantly	O
impairs	O
angiogenesis	O
and	O
suggest	O
that	O
this	O
effect	O
is	O
mediated	O
by	O
changes	O
in	O
endothelial	O
cell	O
responsiveness	O
to	O
both	O
VEGF	O
and	O
hypoxia	O
.	O

Management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
:	O
therapeutic	O
issues	O
.	O

PURPOSE	O
:	O
The	O
staging	O
of	O
colorectal	O
cancer	O
,	O
therapeutic	O
decision	O
making	O
in	O
the	O
management	O
of	O
early	O
and	O
advanced	O
colorectal	O
cancer	O
,	O
and	O
dilemmas	O
posed	O
by	O
drug	O
-	O
related	O
toxicity	O
are	O
discussed	O
.	O

SUMMARY	O
:	O
Staging	O
of	O
colorectal	O
cancer	O
occurs	O
after	O
surgery	O
and	O
is	O
based	O
on	O
the	O
extent	O
of	O
disease	O
invasiveness	O
and	O
dissemination	O
.	O

Surgery	O
is	O
the	O
primary	O
treatment	O
for	O
stage	O
I	O
disease	O
.	O

Adjuvant	O
chemotherapy	O
is	O
recommended	O
after	O
resection	O
in	O
selected	O
high	O
-	O
risk	O
patients	O
with	O
stage	O
II	O
disease	O
and	O
in	O
all	O
patients	O
with	O
stage	O
III	O
disease	O
.	O

Convenience	O
of	O
administration	O
,	O
tolerability	O
,	O
and	O
patient	O
factors	O
not	O
necessarily	O
age	O
may	O
be	O
considerations	O
in	O
decisions	O
about	O
adjuvant	O
therapy	O
after	O
resection	O
.	O

Treatment	O
of	O
stage	O
IV	O
colorectal	O
cancer	O
is	O
based	O
on	O
the	O
type	O
of	O
prior	O
therapy	O
and	O
patient	O
-	O
specific	O
factors	O
.	O

Recently	O
,	O
significant	O
improvements	O
in	O
survival	O
have	O
been	O
achieved	O
through	O
the	O
use	O
of	O
combination	O
chemotherapy	O
and	O
monoclonal	O
antibody	O
regimens	O
.	O

Bevacizumab	O
in	O
combination	O
with	O
chemotherapy	O
is	O
first	O
-	O
line	O
therapy	O
for	O
stage	O
IV	O
disease	O
.	O

Age	O
alone	O
should	O
not	O
preclude	O
the	O
use	O
of	O
chemotherapy	O
in	O
stage	O
IV	O
colorectal	O
cancer	O
,	O
although	O
the	O
ability	O
to	O
tolerate	O
drug	O
-	O
related	O
toxicity	O
may	O
be	O
a	O
consideration	O
.	O

The	O
optimal	O
duration	O
of	O
chemotherapy	O
in	O
patients	O
with	O
early	O
and	O
metastatic	O
colorectal	O
cancer	O
is	O
unclear	O
.	O

CONCLUSION	O
:	O
The	O
optimal	O
approach	O
to	O
the	O
treatment	O
of	O
colorectal	O
cancer	O
depends	O
on	O
several	O
considerations	O
,	O
including	O
patient	O
-	O
specific	O
factors	O
.	O

Serum	O
and	O
urine	O
levels	O
of	O
interleukin	O
-	O
8	O
in	O
patients	O
with	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Angiogenesis	O
plays	O
an	O
important	O
role	O
in	O
many	O
types	O
of	O
cancer	O
.	O

Interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
known	O
to	O
be	O
a	O
pro	O
-	O
inflammatory	O
and	O
pro	O
-	O
angiogenic	O
cytokine	O
,	O
and	O
IL	O
-	O
8	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
tumor	O
progression	O
,	O
prognosis	O
and	O
survival	O
in	O
several	O
types	O
of	O
cancers	O
.	O

However	O
,	O
the	O
role	O
of	O
IL	O
-	O
8	O
in	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
has	O
not	O
been	O
fully	O
determined	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
usefulness	O
of	O
measuring	O
serum	O
and	O
urine	O
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	O
.	O

We	O
developed	O
reference	O
intervals	O
for	O
serum	O
and	O
urine	O
IL	O
-	O
8	O
level	O
in	O
131	O
control	O
individuals	O
.	O

We	O
measured	O
serum	O
IL	O
-	O
8	O
and	O
urine	O
IL	O
-	O
8	O
levels	O
in	O
patients	O
with	O
NHL	O
,	O
and	O
we	O
compared	O
the	O
concentrations	O
with	O
those	O
of	O
control	O
individuals	O
.	O

The	O
reference	O
intervals	O
for	O
serum	O
IL	O
-	O
8	O
and	O
urine	O
IL	O
-	O
8	O
corrected	O
by	O
creatinine	O
(	O
Cr	O
)	O
were	O
15	O
.	O
9	O
-	O
430	O
.	O
3	O
pg	O
/	O
mL	O
and	O
0	O
.	O
0	O
-	O
28	O
.	O
4	O
pg	O
/	O
mg	O
Cr	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
were	O
significantly	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
48	O
.	O
9	O
+	O
/	O
-	O
194	O
.	O
4	O
vs	O
.	O
5	O
.	O
2	O
+	O
/	O
-	O
13	O
.	O
8	O
pg	O
/	O
mg	O
Cr	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
serum	O
IL	O
-	O
8	O
concentrations	O
between	O
NHL	O
patients	O
and	O
controls	O
(	O
159	O
.	O
2	O
+	O
/	O
-	O
40	O
.	O
4	O
vs	O
.	O
99	O
.	O
6	O
+	O
/	O
-	O
107	O
.	O
1	O
pg	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
099	O
)	O
.	O

Receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
gave	O
0	O
.	O
83	O
and	O
0	O
.	O
43	O
ROC	O
area	O
values	O
for	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
and	O
serum	O
IL	O
-	O
8	O
,	O
respectively	O
.	O

There	O
was	O
no	O
correlation	O
between	O
the	O
serum	O
and	O
urine	O
concentrations	O
of	O
IL	O
-	O
8	O
and	O
clinical	O
variables	O
,	O
the	O
only	O
exception	O
being	O
the	O
international	O
prognostic	O
index	O
(	O
IPI	O
)	O
,	O
which	O
showed	O
a	O
marginal	O
correlation	O
with	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
levels	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

This	O
study	O
indicated	O
that	O
urine	O
IL	O
-	O
8	O
/	O
Cr	O
levels	O
might	O
be	O
useful	O
as	O
a	O
diagnostic	O
marker	O
of	O
NHL	O
.	O

Adenomatoid	O
tumour	O
of	O
the	O
liver	O
.	O

An	O
unusual	O
primary	O
adenomatoid	O
tumour	O
arising	O
in	O
the	O
normal	O
liver	O
is	O
described	O
.	O

Hepatectomy	O
was	O
performed	O
,	O
and	O
the	O
patient	O
is	O
alive	O
and	O
free	O
of	O
disease	O
1	O
year	O
postsurgery	O
.	O

Grossly	O
,	O
the	O
tumour	O
showed	O
a	O
haemorrhagic	O
cut	O
surface	O
with	O
numerous	O
microcystic	O
structures	O
.	O

Histological	O
examination	O
revealed	O
cystic	O
or	O
angiomatoid	O
spaces	O
of	O
various	O
sizes	O
lined	O
by	O
cuboidal	O
,	O
low	O
-	O
columnar	O
,	O
or	O
flattened	O
epithelioid	O
cells	O
with	O
vacuolated	O
cytoplasm	O
and	O
round	O
to	O
oval	O
nuclei	O
.	O

The	O
epithelioid	O
cells	O
were	O
entirely	O
supported	O
by	O
proliferated	O
capillaries	O
and	O
arteries	O
together	O
with	O
collagenous	O
stroma	O
.	O

Immunohistochemical	O
studies	O
showed	O
that	O
the	O
epithelioid	O
cells	O
were	O
strongly	O
positive	O
for	O
a	O
broad	O
spectrum	O
of	O
cytokeratins	O
(	O
AE1	O
/	O
AE3	O
,	O
CAM5	O
.	O
2	O
,	O
epithelial	O
membrane	O
antigen	O
and	O
cytokeratin	O
7	O
)	O
and	O
mesothelial	O
markers	O
(	O
calretinin	O
,	O
Wilms	O
'	O
tumour	O
1	O
and	O
D2	O
-	O
40	O
)	O
.	O

These	O
cells	O
were	O
negative	O
for	O
Hep	O
par	O
-	O
1	O
,	O
carcinoembryonic	O
antigen	O
,	O
neural	O
cell	O
adhesion	O
molecule	O
,	O
CD34	O
,	O
CD31	O
and	O
HMB45	O
.	O

Atypically	O
,	O
abundant	O
capillaries	O
were	O
observed	O
;	O
however	O
,	O
the	O
cystic	O
proliferation	O
of	O
epithelioid	O
cells	O
with	O
vacuoles	O
and	O
immunohistochemical	O
profile	O
of	O
the	O
epithelioid	O
element	O
were	O
consistent	O
with	O
hepatic	O
adenomatoid	O
tumour	O
.	O

Research	O
advances	O
of	O
endostatin	O
and	O
its	O
short	O
internal	O
fragments	O
.	O

Endostatin	O
,	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	O
XVIII	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

At	O
present	O
,	O
there	O
are	O
a	O
large	O
number	O
of	O
research	O
papers	O
on	O
endostatin	O
.	O

However	O
,	O
the	O
action	O
mechanism	O
of	O
endostatin	O
is	O
still	O
a	O
matter	O
of	O
ongoing	O
discussion	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
elucidate	O
its	O
origin	O
and	O
elementary	O
structure	O
,	O
and	O
to	O
discuss	O
its	O
structure	O
basis	O
of	O
activity	O
and	O
action	O
mechanisms	O
based	O
on	O
the	O
latest	O
research	O
.	O

Furthermore	O
,	O
some	O
published	O
studies	O
reporting	O
the	O
antiangiogenic	O
effects	O
of	O
endostatin	O
-	O
derived	O
peptides	O
were	O
also	O
reviewed	O
.	O

It	O
is	O
proposed	O
that	O
the	O
amino	O
acid	O
sequence	O
of	O
endostatin	O
contains	O
both	O
angiosuppressive	O
and	O
angiostimulatory	O
domains	O
.	O

Short	O
endostatin	O
fragments	O
may	O
be	O
exploited	O
as	O
a	O
new	O
angiogenesis	O
inhibitor	O
for	O
therapeutic	O
applications	O
,	O
in	O
substitution	O
of	O
the	O
full	O
length	O
endostatin	O
.	O

These	O
studies	O
on	O
endostatin	O
fragments	O
also	O
shed	O
light	O
on	O
our	O
understanding	O
of	O
the	O
molecular	O
action	O
mechanisms	O
of	O
endostatin	O
.	O

Microscopic	O
technique	O
for	O
the	O
detection	O
of	O
nitric	O
oxide	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
vascular	O
homeostasis	O
.	O

The	O
importance	O
of	O
NO	O
in	O
the	O
vasculature	O
is	O
demonstrated	O
by	O
several	O
experimental	O
conditions	O
,	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
angiogenesis	O
.	O

Thus	O
,	O
the	O
NO	O
metabolic	O
pathway	O
in	O
endothelial	O
cells	O
could	O
be	O
one	O
of	O
the	O
main	O
contributing	O
factors	O
for	O
angiogenesis	O
.	O

Although	O
several	O
methods	O
have	O
been	O
used	O
for	O
measuring	O
in	O
vitro	O
angiogenesis	O
,	O
a	O
proper	O
technique	O
has	O
not	O
been	O
developed	O
for	O
identifying	O
in	O
vivo	O
NO	O
-	O
dependent	O
angiogenesis	O
.	O

This	O
chapter	O
provides	O
a	O
new	O
intravital	O
microscopic	O
method	O
for	O
detecting	O
and	O
measuring	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
a	O
mouse	O
model	O
.	O

This	O
technique	O
showed	O
strong	O
abdominal	O
neovascularization	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
eNOS	O
knockout	O
mice	O
,	O
locally	O
injected	O
with	O
VEGF	O
,	O
as	O
well	O
as	O
stimulation	O
of	O
angiogenesis	O
in	O
NO	O
donor	O
-	O
injected	O
mice	O
.	O

This	O
technique	O
also	O
revealed	O
the	O
inhibitory	O
effect	O
of	O
the	O
NOS	O
inhibitor	O
N	O
(	O
G	O
)	O
-	O
iminoethyl	O
-	O
L	O
-	O
ornithine	O
in	O
VEGF	O
-	O
mediated	O
in	O
vivo	O
angiogenesis	O
.	O

This	O
chapter	O
describes	O
intravital	O
microscopy	O
as	O
a	O
new	O
imaging	O
technique	O
for	O
detecting	O
NO	O
-	O
dependent	O
angiogenesis	O
in	O
an	O
animal	O
model	O
.	O

The	O
tyrosine	O
kinase	O
inhibitor	O
cediranib	O
blocks	O
ligand	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Solid	O
tumors	O
express	O
a	O
range	O
of	O
factors	O
required	O
to	O
sustain	O
their	O
growth	O
and	O
promote	O
their	O
dissemination	O
.	O

Among	O
these	O
are	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
A	O
(	O
VEGF	O
-	O
A	O
)	O
,	O
the	O
key	O
angiogenic	O
stimulant	O
,	O
and	O
VEGF	O
-	O
C	O
,	O
a	O
primary	O
mediator	O
of	O
lymphangiogenesis	O
.	O

Small	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
offer	O
the	O
potential	O
to	O
inhibit	O
more	O
than	O
one	O
kinase	O
and	O
impede	O
tumor	O
growth	O
by	O
multiple	O
mechanisms	O
.	O

However	O
,	O
their	O
potency	O
toward	O
individual	O
targets	O
can	O
vary	O
.	O

Cediranib	O
(	O
RECENTIN	O
;	O
AZD2171	O
)	O
is	O
an	O
inhibitor	O
of	O
VEGF	O
signaling	O
that	O
has	O
been	O
shown	O
in	O
experimental	O
models	O
to	O
prevent	O
VEGF	O
-	O
A	O
-	O
induced	O
angiogenesis	O
and	O
primary	O
tumor	O
growth	O
,	O
yet	O
the	O
effects	O
of	O
cediranib	O
on	O
VEGF	O
receptor	O
(	O
VEGFR	O
)	O
-	O
3	O
-	O
mediated	O
endothelial	O
cell	O
function	O
and	O
lymphangiogenesis	O
are	O
unknown	O
.	O

To	O
better	O
understand	O
the	O
activity	O
of	O
cediranib	O
against	O
VEGFR	O
-	O
3	O
and	O
its	O
associated	O
signaling	O
events	O
compared	O
with	O
its	O
activity	O
against	O
VEGFR	O
-	O
2	O
,	O
we	O
used	O
the	O
receptor	O
-	O
specific	O
ligands	O
VEGF	O
-	O
E	O
and	O
VEGF	O
-	O
C156S	O
.	O

In	O
human	O
endothelial	O
cells	O
,	O
cediranib	O
inhibited	O
VEGF	O
-	O
E	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
VEGF	O
-	O
C156S	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
3	O
at	O
concentrations	O
of	O
less	O
than	O
/	O
=	O
1nmol	O
/	O
L	O
and	O
inhibited	O
activation	O
of	O
downstream	O
signaling	O
molecules	O
.	O

Additionally	O
,	O
cediranib	O
blocked	O
VEGF	O
-	O
C156S	O
-	O
induced	O
and	O
VEGF	O
-	O
E	O
-	O
induced	O
proliferation	O
,	O
survival	O
,	O
and	O
migration	O
of	O
lymphatic	O
and	O
blood	O
vascular	O
endothelial	O
cells	O
.	O

In	O
vivo	O
,	O
cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
d	O
)	O
prevented	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
VEGF	O
-	O
E	O
-	O
expressing	O
and	O
VEGF	O
-	O
C156S	O
-	O
expressing	O
adenoviruses	O
,	O
respectively	O
.	O

Cediranib	O
(	O
6	O
mg	O
/	O
kg	O
/	O
day	O
)	O
also	O
blocked	O
angiogenesis	O
and	O
lymphangiogenesis	O
induced	O
by	O
adenoviruses	O
expressing	O
VEGF	O
-	O
A	O
or	O
VEGF	O
-	O
C	O
and	O
compromised	O
the	O
blood	O
and	O
lymphatic	O
vasculatures	O
of	O
VEGF	O
-	O
C	O
-	O
expressing	O
tumors	O
.	O

Cediranib	O
may	O
,	O
therefore	O
,	O
be	O
an	O
effective	O
means	O
of	O
preventing	O
tumor	O
progression	O
,	O
not	O
only	O
by	O
inhibiting	O
VEGFR	O
-	O
2	O
activity	O
and	O
angiogenesis	O
,	O
but	O
also	O
by	O
concomitantly	O
inhibiting	O
VEGFR	O
-	O
3	O
activity	O
and	O
lymphangiogenesis	O
.	O

Effects	O
of	O
cyclooxygenase	O
-	O
2	O
non	O
-	O
selective	O
and	O
selective	O
inhibitors	O
on	O
proliferation	O
inhibition	O
and	O
apoptosis	O
induction	O
of	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
aspirin	O
and	O
nimesulide	O
on	O
cell	O
proliferation	O
,	O
apoptosis	O
and	O
its	O
potential	O
mechanisms	O
in	O
EC9706	B
and	O
EC109	B
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

EC9706	B
and	O
EC109	B
cells	O
were	O
incubated	O
with	O
varying	O
concentrations	O
of	O
aspirin	O
and	O
nimesulide	O
,	O
and	O
the	O
effects	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
were	O
monitored	O
by	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethyl	O
-	O
thiazol	O
-	O
2yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
and	O
flow	O
cytometry	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
assays	O
were	O
used	O
to	O
investigate	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
Bax	O
.	O

Prostaglandin	O
E2	O
production	O
was	O
measured	O
by	O
enzyme	O
linked	O
immunosorbent	O
assay	O
.	O

Pretreatment	O
with	O
aspirin	O
and	O
nimesulide	O
inhibited	O
EC9706	B
and	O
EC109	B
cell	O
growth	O
in	O
a	O
time	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
accompanied	O
with	O
a	O
decrease	O
of	O
prostaglandin	O
E2	O
production	O
.	O

In	O
EC9706	B
cells	O
,	O
the	O
mechanism	O
of	O
aspirin	O
and	O
nimesulide	O
induced	O
growth	O
inhibition	O
was	O
a	O
consequence	O
of	O
cell	O
cycle	O
arrest	O
at	O
the	O
G	O
(	O
0	O
)	O
/	O
G	O
(	O
1	O
)	O
check	O
point	O
.	O

In	O
EC109	B
cells	O
,	O
growth	O
arrest	O
was	O
by	O
induction	O
of	O
apoptosis	O
,	O
associated	O
with	O
downregulation	O
of	O
Bcl	O
-	O
2	O
,	O
but	O
not	O
Bax	O
.	O

In	O
conclusion	O
,	O
aspirin	O
and	O
nimesulide	O
could	O
inhibit	O
cell	O
proliferation	O
and	O
induce	O
apoptosis	O
in	O
esophageal	O
squamous	O
carcinoma	O
cells	O
.	O

Cyclooxygenase	O
-	O
2	O
inhibitor	O
may	O
be	O
a	O
promising	O
therapeutic	O
agent	O
for	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

Contemporary	O
perspectives	O
on	O
vital	O
pulp	O
therapy	O
:	O
views	O
from	O
the	O
endodontists	O
and	O
pediatric	O
dentists	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
level	O
of	O
agreement	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
at	O
a	O
pulp	O
therapy	O
symposium	O
conjointly	O
sponsored	O
by	O
the	O
American	O
Association	O
of	O
Endodontists	O
(	O
AAE	O
)	O
and	O
the	O
American	O
Academy	O
of	O
Pediatric	O
Dentistry	O
(	O
AAPD	O
)	O
on	O
November	O
2	O
-	O
3	O
,	O
2007	O
.	O

Presymposium	O
and	O
postsymposium	O
tests	O
were	O
administered	O
,	O
and	O
respondent	O
answers	O
were	O
compared	O
between	O
pediatric	O
dentists	O
and	O
endodontists	O
.	O

Opinions	O
on	O
3	O
areas	O
were	O
sought	O
:	O
pulp	O
therapy	O
for	O
cariously	O
involved	O
primary	O
teeth	O
;	O
indirect	O
pulp	O
treatment	O
(	O
IPT	O
)	O
for	O
cariously	O
involved	O
immature	O
permanent	O
teeth	O
;	O
and	O
innovative	O
treatment	O
options	O
including	O
pulpal	O
revascularization	O
and	O
regeneration	O
.	O

Results	O
were	O
analyzed	O
with	O
chi2	O
tests	O
.	O

Comparisons	O
of	O
presymposium	O
and	O
postsymposium	O
responses	O
and	O
between	O
the	O
2	O
groups	O
of	O
attendees	O
indicated	O
that	O
the	O
pediatric	O
dentistry	O
and	O
endodontic	O
communities	O
agree	O
that	O
formocresol	O
will	O
be	O
replaced	O
as	O
a	O
primary	O
tooth	O
pulpotomy	O
agent	O
,	O
that	O
mineral	O
trioxide	O
is	O
the	O
first	O
choice	O
to	O
take	O
its	O
place	O
,	O
that	O
IPT	O
in	O
primary	O
teeth	O
holds	O
hope	O
as	O
a	O
replacement	O
for	O
pulpotomy	O
,	O
and	O
that	O
IPT	O
is	O
an	O
acceptable	O
pulp	O
therapy	O
technique	O
for	O
cariously	O
involved	O
young	O
permanent	O
teeth	O
.	O

Both	O
groups	O
believe	O
that	O
pulp	O
revascularization	O
and	O
regeneration	O
will	O
be	O
viable	O
treatment	O
modalities	O
in	O
the	O
future	O
.	O

The	O
AAE	O
and	O
the	O
AAPD	O
are	O
positioned	O
to	O
begin	O
preparation	O
of	O
best	O
practice	O
guidelines	O
that	O
share	O
common	O
language	O
and	O
treatment	O
recommendations	O
for	O
pulp	O
therapies	O
performed	O
by	O
both	O
specialties	O
.	O

Neurotrophin	O
p75	O
receptor	O
(	O
p75NTR	O
)	O
promotes	O
endothelial	O
cell	O
apoptosis	O
and	O
inhibits	O
angiogenesis	O
:	O
implications	O
for	O
diabetes	O
-	O
induced	O
impaired	O
neovascularization	O
in	O
ischemic	O
limb	O
muscles	O
.	O

Diabetes	O
impairs	O
endothelial	O
function	O
and	O
reparative	O
neovascularization	O
.	O

The	O
p75	O
receptor	O
of	O
neurotrophins	O
(	O
p75	O
(	O
NTR	O
)	O
)	O
,	O
which	O
is	O
scarcely	O
present	O
in	O
healthy	O
endothelial	O
cells	O
(	O
ECs	O
)	O
,	O
becomes	O
strongly	O
expressed	O
by	O
capillary	O
ECs	O
after	O
induction	O
of	O
peripheral	O
ischemia	O
in	O
type	O
-	O
1	O
diabetic	O
mice	O
.	O

Here	O
,	O
we	O
show	O
that	O
gene	O
transfer	O
-	O
induced	O
p75	O
(	O
NTR	O
)	O
expression	O
impairs	O
the	O
survival	O
,	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
capacities	O
of	O
cultured	O
ECs	O
and	O
endothelial	O
progenitor	O
cells	O
(	O
EPCs	O
)	O
and	O
inhibits	O
angiogenesis	O
in	O
vitro	O
.	O

Moreover	O
,	O
intramuscular	O
p75	O
(	O
NTR	O
)	O
gene	O
delivery	O
impairs	O
neovascularization	O
and	O
blood	O
flow	O
recovery	O
in	O
a	O
mouse	O
model	O
of	O
limb	O
ischemia	O
.	O

These	O
disturbed	O
functions	O
are	O
associated	O
with	O
suppression	O
of	O
signaling	O
mechanisms	O
implicated	O
in	O
EC	O
survival	O
and	O
angiogenesis	O
.	O

In	O
fact	O
,	O
p75	O
(	O
NTR	O
)	O
depresses	O
the	O
VEGF	O
-	O
A	O
/	O
Akt	O
/	O
eNOS	O
/	O
NO	O
pathway	O
and	O
additionally	O
reduces	O
the	O
mRNA	O
levels	O
of	O
ITGB1	O
[	O
beta	O
(	O
1	O
)	O
integrin	O
]	O
,	O
BIRC5	O
(	O
survivin	O
)	O
,	O
PTTG1	O
(	O
securin	O
)	O
and	O
VEZF1	O
.	O

Diabetic	O
mice	O
,	O
which	O
typically	O
show	O
impaired	O
postischemic	O
muscular	O
neovascularization	O
and	O
blood	O
perfusion	O
recovery	O
,	O
have	O
these	O
defects	O
corrected	O
by	O
intramuscular	O
gene	O
transfer	O
of	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
p75	O
(	O
NTR	O
)	O
.	O

Collectively	O
,	O
our	O
data	O
newly	O
demonstrate	O
the	O
antiangiogenic	O
action	O
of	O
p75	O
(	O
NTR	O
)	O
and	O
open	O
new	O
avenues	O
for	O
the	O
therapeutic	O
use	O
of	O
p75	O
(	O
NTR	O
)	O
inhibition	O
to	O
combat	O
diabetes	O
-	O
induced	O
microvascular	O
liabilities	O
.	O

Intraoperative	O
handling	O
and	O
wound	O
healing	O
of	O
arthroscopic	O
portal	O
wounds	O
:	O
a	O
clinical	O
study	O
comparing	O
nylon	O
suture	O
with	O
wound	O
closure	O
strips	O
.	O

This	O
prospective	O
,	O
single	O
-	O
centre	O
study	O
compared	O
wound	O
closure	O
methods	O
in	O
patients	O
undergoing	O
arthroscopy	O
.	O

Closure	O
of	O
arthroscopic	O
portal	O
wounds	O
with	O
sterile	O
adhesive	O
strips	O
is	O
effective	O
and	O
convenient	O
for	O
wound	O
management	O
.	O

The	O
method	O
was	O
associated	O
with	O
a	O
reduced	O
potential	O
for	O
infection	O
,	O
faster	O
renewal	O
of	O
tensile	O
strength	O
,	O
greater	O
cost	O
effectiveness	O
,	O
and	O
better	O
cosmetic	O
effects	O
comparing	O
with	O
suture	O
closure	O
.	O

This	O
method	O
of	O
wound	O
closure	O
may	O
also	O
reduce	O
the	O
incidence	O
of	O
needle	O
stick	O
injury	O
in	O
the	O
theatre	O
environment	O
.	O

Thereby	O
the	O
incidence	O
of	O
percutaneous	O
exposure	O
following	O
a	O
surgical	O
procedure	O
may	O
not	O
facilitate	O
transmission	O
of	O
blood	O
borne	O
pathogens	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
hepatitis	O
C	O
virus	O
and	O
hepatitis	O
B	O
virus	O
.	O

As	O
a	O
result	O
it	O
may	O
reduce	O
litigation	O
in	O
today	O
'	O
s	O
changing	O
healthcare	O
climate	O
.	O

Tumor	O
endothelial	O
cell	O
targeted	O
cyclic	O
RGD	O
-	O
modified	O
heparin	O
derivative	O
:	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

PURPOSE	O
:	O
We	O
prepared	O
tumor	O
endothelium	O
targeted	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
(	O
cRGD	O
-	O
HL	O
)	O
by	O
coupling	O
heparin	O
-	O
lithocholic	O
acid	O
(	O
HL	O
)	O
with	O
cRGDyK	O
,	O
and	O
evaluated	O
inhibition	O
effects	O
of	O
cRGD	O
-	O
HL	O
on	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

METHODS	O
:	O
To	O
evaluate	O
antiangiogenic	O
activity	O
of	O
cRGD	O
-	O
HL	O
,	O
we	O
performed	O
tests	O
on	O
endothelial	O
cell	O
adhesion	O
and	O
migration	O
to	O
vitronectin	O
,	O
tube	O
formation	O
,	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
,	O
and	O
in	O
vivo	O
Matrigel	O
plug	O
assay	O
.	O

The	O
antitumor	O
activity	O
of	O
cRGD	O
-	O
HL	O
was	O
also	O
evaluated	O
by	O
monitoring	O
tumor	O
growth	O
and	O
microvessel	O
formation	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC7	O
)	O
tumor	O
.	O

RESULTS	O
:	O
The	O
cRGD	O
-	O
HL	O
significantly	O
inhibited	O
adhesion	O
and	O
migration	O
of	O
endothelial	O
cells	O
to	O
vitronectin	O
,	O
and	O
tubular	O
structures	O
of	O
endothelial	O
cells	O
.	O

Compared	O
to	O
cRGDyK	O
and	O
HL	O
,	O
cRGD	O
-	O
HL	O
has	O
high	O
binding	O
affinity	O
to	O
purified	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
.	O

The	O
enhanced	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
confirmed	O
in	O
Matrigel	O
assay	O
by	O
showing	O
the	O
significant	O
inhibition	O
of	O
bFGF	O
-	O
driven	O
angiogenesis	O
and	O
blood	O
vessel	O
formation	O
.	O

It	O
was	O
thought	O
that	O
potent	O
antiangiogenic	O
effect	O
of	O
cRGD	O
-	O
HL	O
was	O
probably	O
due	O
to	O
the	O
interference	O
of	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
-	O
mediated	O
interaction	O
,	O
resulting	O
in	O
the	O
enhanced	O
antitumoral	O
activity	O
against	O
SCC7	B
tumor	O
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
cRGD	O
-	O
modified	O
heparin	O
derivative	O
enhanced	O
anti	O
-	O
angiotherapeutic	O
effects	O
against	O
solid	O
tumor	O
,	O
and	O
therefore	O
,	O
it	O
could	O
be	O
applied	O
to	O
treat	O
various	O
cancers	O
and	O
angiogenic	O
diseases	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

The	O
role	O
of	O
platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
factor	O
/	O
thymidine	O
phosphorylase	O
in	O
tumor	O
behavior	O
.	O

Platelet	O
-	O
derived	O
endothelial	O
cell	O
growth	O
-	O
factor	O
(	O
PD	O
-	O
ECGF	O
)	O
is	O
similar	O
to	O
the	O
pyrimidine	O
enzyme	O
thymidine	O
phosphorylase	O
(	O
TP	O
)	O
.	O

A	O
high	O
TP	O
expression	O
at	O
tumor	O
sites	O
is	O
correlated	O
with	O
tumor	O
growth	O
,	O
induction	O
of	O
angiogenesis	O
,	O
and	O
metastasis	O
.	O

Therefore	O
,	O
high	O
TP	O
is	O
most	O
likely	O
associated	O
with	O
a	O
poor	O
prognosis	O
.	O

TP	O
is	O
not	O
only	O
expressed	O
in	O
tumor	O
cells	O
but	O
also	O
in	O
tumor	O
surrounding	O
tissues	O
,	O
such	O
as	O
tumor	O
infiltrating	O
macrophages	O
.	O

TP	O
catalyzes	O
the	O
conversion	O
of	O
thymidine	O
to	O
thymine	O
and	O
doxyribose	O
-	O
1	O
-	O
phosphate	O
(	O
dR	O
-	O
1	O
-	O
P	O
)	O
.	O

The	O
latter	O
in	O
its	O
parent	O
form	O
or	O
in	O
its	O
sugar	O
form	O
,	O
deoxyribose	O
(	O
dR	O
)	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
angiogenesis	O
.	O

It	O
may	O
modulate	O
cellular	O
energy	O
metabolism	O
or	O
be	O
a	O
substrate	O
in	O
a	O
chemical	O
reaction	O
generating	O
reactive	O
oxygen	O
species	O
.	O

L	O
-	O
deoxyribose	O
(	O
L	O
-	O
dR	O
)	O
and	O
thymidine	O
phosphorylase	O
inhibitor	O
(	O
TPI	O
)	O
can	O
reverse	O
these	O
effects	O
.	O

The	O
mechanism	O
of	O
TP	O
induction	O
is	O
not	O
yet	O
completely	O
clear	O
,	O
but	O
TNF	O
,	O
IL10	O
and	O
other	O
cytokines	O
have	O
been	O
clearly	O
shown	O
to	O
induce	O
its	O
expression	O
.	O

The	O
various	O
complex	O
interactions	O
of	O
TP	O
give	O
it	O
an	O
essential	O
role	O
in	O
cellular	O
functioning	O
and	O
,	O
hence	O
,	O
it	O
is	O
an	O
ideal	O
target	O
in	O
cancer	O
therapy	O
.	O

[	O
Inhibitory	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	O
carcinoma	O
in	O
mice	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
adenovirus	O
-	O
mediated	O
endostatin	O
gene	O
transfer	O
on	O
transplanted	O
lung	O
cancer	O
in	O
mice	O
and	O
its	O
mechanism	O
of	O
action	O
.	O

METHODS	O
:	O
Transplant	O
tumor	O
model	O
was	O
induced	O
by	O
subcutaneous	O
inoculation	O
of	O
2	O
x	O
10	O
(	O
6	O
)	O
Lewis	O
lung	O
cancer	O
(	O
LLC	O
)	O
cells	O
into	O
the	O
back	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
mice	O
were	O
treated	O
by	O
intratumoral	O
injection	O
of	O
2	O
x	O
10	O
(	O
9	O
)	O
pfu	O
Ad	O
-	O
mEndostatin	O
.	O

The	O
expression	O
of	O
endostatin	O
in	O
situ	O
and	O
its	O
maintaining	O
time	O
were	O
detected	O
by	O
immunohistochemistry	O
and	O
Western	O
Blot	O
,	O
respectively	O
.	O

The	O
endostatin	O
level	O
in	O
serum	O
was	O
determined	O
by	O
ELISA	O
.	O

The	O
inhibition	O
of	O
tumor	O
growth	O
and	O
changes	O
of	O
survival	O
were	O
recorded	O
and	O
the	O
microvessel	O
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
histochemical	O
stainingwith	O
CD31	O
and	O
CD105	O
antibodies	O
.	O

The	O
tumor	O
apoptosis	O
was	O
observed	O
by	O
electron	O
microscopy	O
.	O

RESULTS	O
:	O
In	O
comparison	O
with	O
controls	O
,	O
intratumoral	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
significantly	O
inhibited	O
the	O
tumor	O
growth	O
and	O
metastasis	O
,	O
and	O
prolonged	O
the	O
survival	O
rate	O
of	O
mice	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Strong	O
positive	O
expression	O
of	O
mEndostatin	O
was	O
seen	O
in	O
the	O
tumor	O
tissue	O
after	O
injection	O
of	O
Ad	O
-	O
mEndostatin	O
,	O
immunhistochemically	O
ostained	O
by	O
mouse	O
endostatin	O
monoclonal	O
antibody	O
,	O
while	O
the	O
control	O
groups	O
showed	O
only	O
very	O
low	O
expression	O
or	O
absence	O
.	O

Serum	O
endostatin	O
concentration	O
was	O
1540	O
+	O
/	O
-	O
560	O
ng	O
/	O
ml	O
at	O
the	O
second	O
week	O
of	O
administration	O
,	O
the	O
expression	O
of	O
endostatin	O
diminished	O
a	O
month	O
later	O
.	O

The	O
microvessel	O
density	O
(	O
MVD	O
)	O
)	O
decreased	O
from	O
42	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
8	O
to	O
10	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
2	O
per	O
x	O
200	O
magnificetion	O
microscopic	O
field	O
by	O
CD10	O
staining	O
and	O
from	O
68	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
5	O
to	O
37	O
.	O
5	O
+	O
/	O
-	O
4	O
.	O
6	O
by	O
CD31	O
staining	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

More	O
apoptotic	O
tumor	O
cells	O
were	O
seen	O
under	O
the	O
transmission	O
electron	O
microscope	O
.	O

CONCLUSION	O
:	O
Endostatin	O
gene	O
therapy	O
mediated	O
by	O
adenoviral	O
vector	O
efficiently	O
induces	O
expression	O
of	O
endostatin	O
in	O
vivo	O
,	O
and	O
inhibits	O
the	O
growth	O
and	O
metastasis	O
of	O
tumor	O
.	O

It	O
is	O
concluded	O
that	O
its	O
action	O
is	O
targeted	O
to	O
tumor	O
neovasculature	O
and	O
the	O
mechanism	O
is	O
inhibition	O
of	O
tumor	O
angiogenesis	O
.	O

Investigation	O
of	O
the	O
effect	O
of	O
kaolin	O
and	O
tissue	O
-	O
factor	O
-	O
activated	O
citrated	O
whole	O
blood	O
,	O
on	O
clot	O
-	O
forming	O
variables	O
,	O
as	O
evaluated	O
by	O
thromboelastography	O
.	O

BACKGROUND	O
:	O

The	O
Thrombelastograph	O
(	O
TEG	O
;	O
Haemoscope	O
Corp	O
.	O
)	O
analyzes	O
clot	O
formation	O
in	O
whole	O
blood	O
(	O
WB	O
)	O
and	O
treatment	O
based	O
on	O
this	O
analysis	O
has	O
been	O
shown	O
to	O
reduce	O
transfusion	O
requirements	O
in	O
liver	O
and	O
cardiac	O
surgery	O
when	O
compared	O
to	O
conventional	O
coagulation	O
analysis	O
.	O

Implementing	O
TEG	O
as	O
a	O
routine	O
laboratory	O
-	O
based	O
analysis	O
,	O
however	O
,	O
requires	O
validation	O
of	O
the	O
activators	O
employed	O
and	O
the	O
effect	O
of	O
storage	O
of	O
the	O
WB	O
sample	O
in	O
citrate	O
before	O
analysis	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O

The	O
effect	O
of	O
kaolin	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
1	O
:	O
17	O
,	O
000	O
,	O
or	O
TF	O
1	O
:	O
42	O
,	O
500	O
on	O
TEG	O
clotting	O
time	O
(	O
R	O
)	O
,	O
Angle	O
(	O
velocity	O
of	O
clot	O
formation	O
)	O
,	O
and	O
maximum	O
clot	O
strength	O
(	O
amplitude	O
[	O
MA	O
]	O
)	O
were	O
evaluated	O
,	O
together	O
with	O
day	O
-	O
to	O
-	O
day	O
variation	O
,	O
the	O
coefficient	O
of	O
variance	O
(	O
CV	O
%	O
)	O
,	O
and	O
the	O
effect	O
of	O
citrate	O
storage	O
time	O
.	O

RESULTS	O
:	O

Clot	O
formation	O
variables	O
were	O
equally	O
affected	O
by	O
TF	O
1	O
:	O
17	O
,	O
000	O
and	O
kaolin	O
activation	O
,	O
whereas	O
R	O
was	O
significantly	O
longer	O
when	O
TF	O
1	O
:	O
42	O
,	O
500	O
was	O
used	O
.	O

The	O
CV	O
for	O
the	O
different	O
variables	O
varied	O
from	O
3	O
to	O
13	O
percent	O
with	O
no	O
significant	O
differences	O
between	O
assays	O
.	O

Storage	O
of	O
citrated	O
WB	O
significantly	O
affected	O
the	O
TEG	O
variables	O
in	O
a	O
hypercoagulable	O
direction	O
.	O

Only	O
the	O
R	O
,	O
however	O
,	O
was	O
significantly	O
affected	O
(	O
12	O
%	O
)	O
when	O
samples	O
rested	O
for	O
0	O
and	O
30	O
minutes	O
were	O
evaluated	O
with	O
kaolin	O
as	O
the	O
activator	O
.	O

CONCLUSION	O
:	O

The	O
TEG	O
assays	O
evaluated	O
were	O
reproducible	O
and	O
present	O
with	O
an	O
acceptable	O
CV	O
%	O
for	O
routine	O
clinical	O
practice	O
.	O

Kaolin	O
and	O
TF	O
1	O
:	O
17	O
,	O
000	O
equally	O
affected	O
the	O
clot	O
formation	O
variables	O
.	O

Storage	O
of	O
WB	O
for	O
up	O
to	O
30	O
minutes	O
in	O
citrate	O
did	O
not	O
,	O
except	O
for	O
R	O
,	O
affect	O
clot	O
formation	O
variables	O
when	O
kaolin	O
was	O
used	O
as	O
activator	O
allowing	O
for	O
immediate	O
analysis	O
when	O
the	O
sample	O
arrives	O
in	O
the	O
laboratory	O
.	O

Reversal	O
of	O
the	O
malignant	O
phenotype	O
of	O
ovarian	O
cancer	O
A2780	B
cells	O
through	O
transfection	O
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
.	O

OBJECTIVE	O
:	O
PTEN	O
(	O
phosphatase	O
and	O
tensin	O
homologue	O
deleted	O
on	O
chromosome	O
10	O
)	O
is	O
a	O
tumor	O
suppressor	O
gene	O
identified	O
on	O
human	O
chromosome	O
10q23	O
.	O

Substantial	O
studies	O
have	O
demonstrated	O
that	O
PTEN	O
can	O
inhibit	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
many	O
cancer	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
upregulation	O
of	O
PTEN	O
gene	O
by	O
transfection	O
wild	O
-	O
type	O
PTEN	O
gene	O
to	O
ovarian	O
cancer	O
cells	O
can	O
inhibit	O
growth	O
and	O
migration	O
and	O
to	O
explore	O
the	O
potential	O
for	O
PTEN	O
gene	O
therapy	O
of	O
ovarian	O
cancers	O
.	O

METHOD	O
:	O
Wild	O
-	O
type	O
and	O
phosphatase	O
-	O
inactive	O
(	O
C124A	O
)	O
PTEN	O
plasmids	O
were	O
transfected	O
into	O
ovarian	O
epithelial	O
cancer	O
A2780	B
cells	O
,	O
and	O
their	O
effects	O
on	O
cell	O
apoptosis	O
,	O
cell	O
proliferation	O
,	O
cell	O
migration	O
and	O
cell	O
invasion	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
analysis	O
,	O
TUNEL	O
assay	O
,	O
MTT	O
assay	O
,	O
wound	O
-	O
healing	O
assay	O
and	O
transwell	O
assay	O
.	O

RESULTS	O
:	O
Both	O
wild	O
-	O
type	O
and	O
mutant	O
PTEN	O
can	O
upregulate	O
the	O
expression	O
of	O
PTEN	O
gene	O
dramatically	O
;	O
however	O
,	O
it	O
is	O
wild	O
-	O
type	O
PTEN	O
not	O
phosphatase	O
-	O
inactive	O
PTEN	O
that	O
can	O
induce	O
apoptosis	O
and	O
decrease	O
cell	O
migration	O
,	O
invasion	O
and	O
proliferation	O
in	O
ovarian	O
cancer	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
results	O
demonstrated	O
that	O
PTEN	O
had	O
played	O
an	O
important	O
role	O
in	O
the	O
cell	O
proliferation	O
,	O
cell	O
migration	O
and	O
invasion	O
dependent	O
on	O
its	O
phosphatase	O
activity	O
.	O

Enhanced	O
expression	O
of	O
PTEN	O
by	O
gene	O
transfer	O
is	O
sufficient	O
to	O
reverse	O
the	O
malignant	O
phenotype	O
of	O
ovarian	O
cancer	O
cells	O
and	O
transfection	O
of	O
ovarian	O
cancer	O
cells	O
with	O
wild	O
-	O
type	O
PTEN	O
gene	O
might	O
be	O
another	O
novel	O
approach	O
for	O
therapeutic	O
intervention	O
in	O
ovarian	O
cancer	O
.	O

Artemisinin	O
inhibits	O
tumor	O
lymphangiogenesis	O
by	O
suppression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
.	O

We	O
have	O
previously	O
reported	O
that	O
dihydroartemisinin	O
is	O
found	O
to	O
have	O
a	O
potent	O
ability	O
in	O
influencing	O
lymphatic	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
artemisinin	O
on	O
tumor	O
growth	O
,	O
lymphangiogenesis	O
,	O
metastasis	O
and	O
survival	O
in	O
mouse	O
Lewis	O
lung	O
carcinoma	O
(	O
LLC	O
)	O
models	O
.	O

We	O
found	O
that	O
orally	O
administered	O
artemisinin	O
inhibited	O
lymph	O
node	O
and	O
lung	O
metastasis	O
and	O
prolonged	O
survival	O
without	O
retarding	O
tumor	O
growth	O
.	O

Consistent	O
with	O
the	O
decrease	O
in	O
lymph	O
node	O
metastasis	O
,	O
tumor	O
lymphangiogenesis	O
and	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
was	O
significantly	O
decreased	O
in	O
artemisinin	O
-	O
treated	O
mice	O
,	O
as	O
compared	O
to	O
control	O
mice	O
.	O

Furthermore	O
,	O
IL	O
-	O
1beta	O
-	O
induced	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
and	O
upregulation	O
of	O
VEGF	O
-	O
C	O
mRNA	O
and	O
protein	O
in	O
LLC	O
cells	O
was	O
also	O
suppressed	O
by	O
artemisinin	O
or	O
by	O
the	O
p38	O
MAPK	O
inhibitor	O
SB	O
-	O
203580	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
could	O
serve	O
as	O
a	O
mediator	O
of	O
proinflammatory	O
cytokine	O
-	O
induced	O
VEGF	O
-	O
C	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
artemisinin	O
may	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
lymph	O
node	O
metastasis	O
by	O
downregulating	O
VEGF	O
-	O
C	O
and	O
reducing	O
tumor	O
lymphangiogenesis	O
.	O

Allogeneic	O
injection	O
of	O
fetal	O
membrane	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
induces	O
therapeutic	O
angiogenesis	O
in	O
a	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
.	O

Bone	O
marrow	O
-	O
derived	O
mesenchymal	O
stem	O
cells	O
(	O
BM	O
-	O
MSC	O
)	O
have	O
been	O
demonstrated	O
to	O
be	O
an	O
attractive	O
therapeutic	O
cell	O
source	O
for	O
tissue	O
regeneration	O
and	O
repair	O
.	O

However	O
,	O
it	O
remains	O
unknown	O
whether	O
or	O
not	O
allogeneic	O
transplantation	O
of	O
mesenchymal	O
stem	O
cells	O
(	O
MSC	O
)	O
derived	O
from	O
fetal	O
membranes	O
(	O
FM	O
)	O
,	O
which	O
are	O
generally	O
discarded	O
as	O
medical	O
waste	O
after	O
delivery	O
,	O
has	O
therapeutic	O
potential	O
.	O

FM	O
-	O
MSC	O
were	O
obtained	O
from	O
Lewis	O
rats	O
and	O
had	O
surface	O
antigen	O
expression	O
and	O
multipotent	O
potential	O
partly	O
similar	O
to	O
those	O
of	O
BM	O
-	O
MSC	O
.	O

Compared	O
with	O
BM	O
-	O
MSC	O
,	O
FM	O
-	O
MSC	O
secreted	O
a	O
comparable	O
amount	O
of	O
hepatocyte	O
growth	O
factor	O
despite	O
a	O
small	O
amount	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
.	O

FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
both	O
expressed	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
but	O
not	O
MHC	O
class	O
II	O
antigens	O
and	O
did	O
not	O
elicit	O
allogeneic	O
lymphocyte	O
proliferation	O
in	O
mixed	O
lymphocyte	O
culture	O
.	O

FM	O
-	O
MSC	O
or	O
BM	O
-	O
MSC	O
obtained	O
from	O
Lewis	O
rats	O
were	O
injected	O
into	O
a	O
MHC	O
-	O
mismatched	O
August	O
-	O
Copenhagen	O
-	O
Irish	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
.	O

Three	O
weeks	O
after	O
injection	O
,	O
blood	O
perfusion	O
and	O
capillary	O
density	O
were	O
significantly	O
higher	O
in	O
the	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
groups	O
than	O
in	O
the	O
phosphate	O
-	O
buffered	O
saline	O
group	O
,	O
and	O
allogeneic	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
were	O
still	O
observed	O
.	O

In	O
nonischemic	O
hind	O
limb	O
tissues	O
,	O
allogeneic	O
FM	O
-	O
MSC	O
and	O
BM	O
-	O
MSC	O
injection	O
were	O
associated	O
with	O
a	O
comparatively	O
small	O
amount	O
of	O
T	O
lymphocyte	O
infiltration	O
,	O
compared	O
with	O
the	O
injection	O
of	O
allogeneic	O
splenic	O
lymphocytes	O
.	O

In	O
conclusion	O
,	O
allogeneic	O
FM	O
-	O
MSC	O
injection	O
did	O
not	O
elicit	O
a	O
lymphocyte	O
proliferative	O
response	O
and	O
provided	O
significant	O
improvement	O
in	O
a	O
rat	O
model	O
of	O
hind	O
limb	O
ischemia	O
,	O
comparable	O
to	O
the	O
response	O
to	O
BM	O
-	O
MSC	O
.	O

Thus	O
,	O
allogeneic	O
injection	O
of	O
FM	O
-	O
MSC	O
may	O
be	O
a	O
new	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
severe	O
peripheral	O
vascular	O
disease	O
.	O

Disclosure	O
of	O
potential	O
conflicts	O
of	O
interest	O
is	O
found	O
at	O
the	O
end	O
of	O
this	O
article	O
.	O

Regulation	O
of	O
the	O
Warburg	O
effect	O
in	O
early	O
-	O
passage	O
breast	O
cancer	O
cells	O
.	O

Malignancy	O
in	O
cancer	O
is	O
associated	O
with	O
aerobic	O
glycolysis	O
(	O
Warburg	O
effect	O
)	O
evidenced	O
by	O
increased	O
trapping	O
of	O
[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
(	O
FdG	O
)	O
in	O
patients	O
imaged	O
by	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

[	O
(	O
18	O
)	O
F	O
]	O
deoxyglucose	O
uptake	O
correlates	O
with	O
glucose	O
transporter	O
(	O
GLUT	O
-	O
1	O
)	O
expression	O
,	O
which	O
can	O
be	O
regulated	O
by	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O

We	O
have	O
previously	O
reported	O
in	O
established	O
breast	O
lines	O
that	O
HIF	O
-	O
1alpha	O
levels	O
in	O
the	O
presence	O
of	O
oxygen	O
leads	O
to	O
the	O
Warburg	O
effect	O
.	O

However	O
,	O
glycolysis	O
and	O
GLUT	O
-	O
1	O
can	O
also	O
be	O
induced	O
independent	O
of	O
HIF	O
-	O
1alpha	O
by	O
other	O
factors	O
,	O
such	O
as	O
c	O
-	O
Myc	O
and	O
phosphorylated	O
Akt	O
(	O
pAkt	O
)	O
.	O

This	O
study	O
investigates	O
HIF	O
-	O
1alpha	O
,	O
c	O
-	O
Myc	O
,	O
pAkt	O
,	O
and	O
aerobic	O
glycolysis	O
in	O
low	O
-	O
passage	O
breast	O
cancer	O
cells	O
under	O
the	O
assumption	O
that	O
these	O
represent	O
the	O
in	O
vivo	O
condition	O
better	O
than	O
established	O
lines	O
.	O

Similar	O
to	O
in	O
vivo	O
FdG	O
-	O
PET	O
or	O
primary	O
breast	O
cancers	O
,	O
rates	O
of	O
glycolysis	O
were	O
diverse	O
,	O
being	O
higher	O
in	O
cells	O
expressing	O
both	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
and	O
lower	O
in	O
cell	O
lines	O
low	O
or	O
negative	O
in	O
both	O
transcription	O
factors	O
.	O

No	O
correlations	O
were	O
observed	O
between	O
glycolytic	O
rates	O
and	O
pAkt	O
levels	O
.	O

Two	O
of	O
12	O
cell	O
lines	O
formed	O
xenografts	O
in	O
mice	O
.	O

Both	O
were	O
positive	O
for	O
HIF	O
-	O
1alpha	O
and	O
phosphorylated	O
c	O
-	O
Myc	O
,	O
and	O
only	O
one	O
was	O
positive	O
for	O
pAkt	O
.	O

Glycolysis	O
was	O
affected	O
by	O
pharmacological	O
regulation	O
of	O
c	O
-	O
Myc	O
and	O
HIF	O
-	O
1alpha	O
.	O

These	O
findings	O
suggest	O
that	O
c	O
-	O
Myc	O
and	O
/	O
or	O
HIF	O
-	O
1alpha	O
activities	O
are	O
both	O
involved	O
in	O
the	O
regulation	O
of	O
glycolysis	O
in	O
breast	O
cancers	O
.	O

Bevacizumab	O
and	O
irinotecan	O
therapy	O
in	O
glioblastoma	O
multiforme	O
:	O
a	O
series	O
of	O
13	O
cases	O
.	O

OBJECT	O
:	O
Endothelial	O
proliferation	O
has	O
been	O
recognized	O
as	O
a	O
marker	O
of	O
high	O
-	O
grade	O
or	O
aggressive	O
glioma	O
.	O

Bevacizumab	O
is	O
a	O
humanized	O
immunoglobulin	O
G1	O
monoclonal	O
antibody	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
that	O
has	O
been	O
shown	O
to	O
have	O
activity	O
in	O
malignant	O
gliomas	O
when	O
combined	O
with	O
irinotecan	O
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
series	O
of	O
13	O
patients	O
with	O
recurrent	O
heavily	O
pretreated	O
malignant	O
glioma	O
that	O
was	O
treated	O
with	O
the	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
.	O

METHODS	O
:	O
Standard	O
therapy	O
with	O
primary	O
resection	O
followed	O
by	O
adjuvant	O
chemotherapy	O
and	O
radiation	O
had	O
failed	O
in	O
all	O
patients	O
.	O

The	O
median	O
number	O
of	O
therapies	O
applied	O
,	O
including	O
initial	O
surgery	O
,	O
was	O
5	O
(	O
range	O
3	O
-	O
7	O
therapies	O
)	O
.	O

Nine	O
patients	O
were	O
started	O
on	O
bevacizumab	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
m2	O
every	O
2	O
weeks	O
.	O

Four	O
patients	O
received	O
bevacizumab	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
m2	O
;	O
irinotecan	O
was	O
given	O
at	O
a	O
dose	O
of	O
125	O
mg	O
/	O
m2	O
every	O
week	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
Of	O
the	O
13	O
treated	O
patients	O
,	O
10	O
(	O
77	O
%	O
)	O
had	O
a	O
radiologically	O
demonstrated	O
partial	O
response	O
and	O
3	O
(	O
23	O
%	O
)	O
had	O
stable	O
disease	O
.	O

Six	O
patients	O
(	O
46	O
%	O
)	O
had	O
a	O
clinical	O
response	O
.	O

The	O
median	O
time	O
to	O
disease	O
progression	O
while	O
on	O
treatment	O
was	O
24	O
weeks	O
.	O

The	O
median	O
overall	O
survival	O
was	O
27	O
weeks	O
.	O

The	O
disease	O
progressed	O
in	O
8	O
patients	O
,	O
despite	O
an	O
initial	O
response	O
.	O

Five	O
patients	O
are	O
still	O
responding	O
to	O
therapy	O
.	O

Six	O
of	O
the	O
8	O
patients	O
whose	O
disease	O
progressed	O
have	O
died	O
.	O

Bevacizumab	O
was	O
discontinued	O
in	O
2	O
patients	O
because	O
of	O
nonfatal	O
intracranial	O
bleeding	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
is	O
safe	O
and	O
has	O
excellent	O
activity	O
even	O
in	O
this	O
relapsed	O
,	O
heavily	O
pretreated	O
population	O
of	O
patients	O
with	O
high	O
-	O
grade	O
malignant	O
glioma	O
,	O
most	O
of	O
whom	O
would	O
not	O
be	O
candidates	O
for	O
clinical	O
trials	O
.	O

Intracerebral	O
grafting	O
of	O
cultured	O
autologous	O
skin	O
fibroblasts	O
into	O
the	O
rat	O
striatum	O
:	O
an	O
assessment	O
of	O
graft	O
size	O
and	O
ultrastructure	O
.	O

To	O
identify	O
a	O
suitable	O
donor	O
cell	O
population	O
for	O
gene	O
therapy	O
applications	O
to	O
the	O
central	O
nervous	O
system	O
,	O
primary	O
fibroblasts	O
isolated	O
from	O
skin	O
biopsies	O
and	O
maintained	O
in	O
culture	O
are	O
employed	O
as	O
autologous	O
cells	O
for	O
intracerebral	O
grafting	O
within	O
the	O
adult	O
rat	O
striatum	O
.	O

Results	O
from	O
the	O
present	O
investigation	O
reveal	O
that	O
cultured	O
primary	O
skin	O
fibroblasts	O
cease	O
to	O
proliferate	O
once	O
they	O
reach	O
confluence	O
;	O
these	O
cells	O
are	O
thus	O
contact	O
inhibited	O
in	O
vitro	O
.	O

Following	O
implantation	O
within	O
the	O
striatum	O
,	O
the	O
volume	O
of	O
the	O
primary	O
fibroblast	O
grafts	O
,	O
stained	O
immunohistochemically	O
for	O
fibronectin	O
,	O
does	O
not	O
differ	O
significantly	O
at	O
3	O
and	O
8	O
weeks	O
.	O

The	O
graft	O
size	O
is	O
dependent	O
on	O
the	O
density	O
of	O
the	O
cell	O
suspension	O
,	O
but	O
not	O
dependent	O
on	O
either	O
the	O
number	O
of	O
passages	O
the	O
cells	O
are	O
taken	O
through	O
in	O
culture	O
prior	O
to	O
grafting	O
or	O
on	O
the	O
postoperative	O
survival	O
period	O
.	O

Ultrastructural	O
evidence	O
reveals	O
that	O
at	O
8	O
weeks	O
the	O
grafts	O
are	O
composed	O
primarily	O
of	O
collagen	O
and	O
fibroblasts	O
with	O
rough	O
endoplasmic	O
reticulum	O
and	O
vesicles	O
.	O

Reactive	O
astrocytic	O
processes	O
and	O
phagocytic	O
cells	O
are	O
also	O
present	O
in	O
the	O
grafts	O
.	O

The	O
grafts	O
are	O
extensively	O
vascularized	O
with	O
capillaries	O
composed	O
of	O
nonfenestrated	O
endothelium	O
;	O
intercellular	O
junctions	O
are	O
evident	O
at	O
sites	O
of	O
apposition	O
between	O
endothelial	O
cells	O
.	O

It	O
is	O
concluded	O
that	O
primary	O
skin	O
fibroblasts	O
are	O
able	O
to	O
survive	O
for	O
at	O
least	O
8	O
weeks	O
following	O
intracerebral	O
implantation	O
and	O
continue	O
to	O
synthesize	O
collagen	O
and	O
fibronectin	O
in	O
vivo	O
.	O

Also	O
,	O
the	O
grafts	O
maintain	O
a	O
constant	O
volume	O
between	O
3	O
and	O
8	O
weeks	O
,	O
thereby	O
indicating	O
that	O
primary	O
skin	O
fibroblasts	O
do	O
not	O
produce	O
tumors	O
.	O

Finally	O
,	O
dynamic	O
host	O
-	O
to	O
-	O
graft	O
interactions	O
-	O
-	O
including	O
phagocytic	O
migration	O
,	O
astrocytic	O
hypertrophy	O
and	O
infiltration	O
within	O
the	O
grafts	O
,	O
and	O
angiogenesis	O
-	O
-	O
are	O
features	O
that	O
constitute	O
the	O
structural	O
integration	O
of	O
primary	O
skin	O
fibroblasts	O
grafted	O
within	O
the	O
adult	O
rat	O
central	O
nervous	O
system	O
.	O

[	O
TESE	O
and	O
mTESE	O
.	O
Therapeutic	O
options	O
in	O
male	O
infertility	O
due	O
to	O
testicular	O
azoospermia	O
]	O
.	O

Modern	O
techniques	O
of	O
testicular	O
sperm	O
extraction	O
(	O
TESE	O
)	O
make	O
it	O
possible	O
for	O
an	O
infertile	O
man	O
to	O
father	O
a	O
child	O
.	O

The	O
operations	O
are	O
standardized	O
to	O
a	O
large	O
extent	O
and	O
the	O
underlying	O
morphological	O
alterations	O
of	O
spermatogenesis	O
also	O
appear	O
to	O
be	O
sufficiently	O
known	O
.	O

Current	O
research	O
is	O
focused	O
on	O
prognostic	O
factors	O
for	O
the	O
testicular	O
material	O
that	O
determine	O
the	O
sperm	O
retrieval	O
rate	O
and	O
success	O
rates	O
after	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	O
injection	O
(	O
IVF	O
-	O
ICSI	O
)	O
.	O
TESE	O
and	O
microTESE	O
are	O
accepted	O
standard	O
operations	O
for	O
testicular	O
sperm	O
retrieval	O
for	O
IVF	O
/	O
ICSI	O
.	O

Predictions	O
for	O
effective	O
sperm	O
recovery	O
are	O
addressed	O
.	O

Demographic	O
consequences	O
of	O
terrestrial	O
habitat	O
loss	O
for	O
pool	O
-	O
breeding	O
amphibians	O
:	O
predicting	O
extinction	O
risks	O
associated	O
with	O
inadequate	O
size	O
of	O
buffer	O
zones	O
.	O

Much	O
of	O
the	O
biodiversity	O
associated	O
with	O
isolated	O
wetlands	O
requires	O
aquatic	O
and	O
terrestrial	O
habitat	O
to	O
maintain	O
viable	O
populations	O
.	O

Current	O
federal	O
wetland	O
regulations	O
in	O
the	O
United	O
States	O
do	O
not	O
protect	O
isolated	O
wetlands	O
or	O
extend	O
protection	O
to	O
surrounding	O
terrestrial	O
habitat	O
.	O

Consequently	O
,	O
some	O
land	O
managers	O
,	O
city	O
planners	O
,	O
and	O
policy	O
makers	O
at	O
the	O
state	O
and	O
local	O
levels	O
are	O
making	O
an	O
effort	O
to	O
protect	O
these	O
wetland	O
and	O
neighboring	O
upland	O
habitats	O
.	O

Balancing	O
human	O
land	O
-	O
use	O
and	O
habitat	O
conservation	O
is	O
challenging	O
,	O
and	O
well	O
-	O
informed	O
land	O
-	O
use	O
policy	O
is	O
hindered	O
by	O
a	O
lack	O
of	O
knowledge	O
of	O
the	O
specific	O
risks	O
of	O
varying	O
amounts	O
of	O
habitat	O
loss	O
.	O

Using	O
projections	O
of	O
wood	O
frog	O
(	O
Rana	O
sylvatica	O
)	O
and	O
spotted	O
salamander	O
(	O
Ambystoma	O
maculatum	O
)	O
populations	O
,	O
we	O
related	O
the	O
amount	O
of	O
high	O
-	O
quality	O
terrestrial	O
habitat	O
surrounding	O
isolated	O
wetlands	O
to	O
the	O
decline	O
and	O
risk	O
of	O
extinction	O
of	O
local	O
amphibian	O
populations	O
.	O

These	O
simulations	O
showed	O
that	O
current	O
state	O
-	O
level	O
wetland	O
regulations	O
protecting	O
30	O
m	O
or	O
less	O
of	O
surrounding	O
terrestrial	O
habitat	O
are	O
inadequate	O
to	O
support	O
viable	O
populations	O
of	O
pool	O
-	O
breeding	O
amphibians	O
.	O

We	O
also	O
found	O
that	O
species	O
with	O
different	O
life	O
-	O
history	O
strategies	O
responded	O
differently	O
to	O
the	O
loss	O
and	O
degradation	O
of	O
terrestrial	O
habitat	O
.	O

The	O
wood	O
frog	O
,	O
with	O
a	O
short	O
life	O
span	O
and	O
high	O
fecundity	O
,	O
was	O
most	O
sensitive	O
to	O
habitat	O
loss	O
and	O
isolation	O
,	O
whereas	O
the	O
longer	O
-	O
lived	O
spotted	O
salamander	O
with	O
lower	O
fecundity	O
was	O
most	O
sensitive	O
to	O
habitat	O
degradation	O
that	O
lowered	O
adult	O
survival	O
rates	O
.	O

Our	O
model	O
results	O
demonstrate	O
that	O
a	O
high	O
probability	O
of	O
local	O
amphibian	O
population	O
persistence	O
requires	O
sufficient	O
terrestrial	O
habitat	O
,	O
the	O
maintenance	O
of	O
habitat	O
quality	O
,	O
and	O
connectivity	O
among	O
local	O
populations	O
.	O

Our	O
results	O
emphasize	O
the	O
essential	O
role	O
of	O
adequate	O
terrestrial	O
habitat	O
to	O
the	O
maintenance	O
of	O
wetland	O
biodiversity	O
and	O
ecosystem	O
function	O
and	O
offer	O
a	O
means	O
of	O
quantifying	O
the	O
risks	O
associated	O
with	O
terrestrial	O
habitat	O
loss	O
and	O
degradation	O
.	O

Endosialin	O
/	O
TEM	O
1	O
/	O
CD248	O
is	O
a	O
pericyte	O
marker	O
of	O
embryonic	O
and	O
tumor	O
neovascularization	O
.	O

The	O
formation	O
of	O
functional	O
,	O
mature	O
blood	O
vessels	O
depends	O
on	O
the	O
interaction	O
between	O
endothelial	O
cells	O
and	O
pericytes	O
.	O

Commonality	O
exists	O
in	O
the	O
processes	O
involved	O
in	O
vasculature	O
development	O
between	O
tissues	O
whether	O
healthy	O
or	O
diseased	O
.	O

Endosialin	O
/	O
TEM	O
1	O
is	O
a	O
cell	O
membrane	O
protein	O
that	O
is	O
expressed	O
in	O
blood	O
vessels	O
during	O
embryogenesis	O
and	O
tumorigenesis	O
but	O
not	O
in	O
normal	O
mature	O
vessels	O
.	O

Antibodies	O
developed	O
to	O
human	O
endosialin	O
were	O
used	O
to	O
investigate	O
endosialin	O
expression	O
and	O
function	O
in	O
human	O
prenatal	O
brain	O
pericytes	O
and	O
pericytes	O
residing	O
in	O
tumors	O
.	O

Anti	O
-	O
endosialin	O
was	O
capable	O
of	O
preventing	O
pericyte	O
tube	O
formation	O
in	O
culture	O
and	O
inhibited	O
migration	O
.	O

Brain	O
pericytes	O
in	O
culture	O
had	O
higher	O
levels	O
of	O
endosialin	O
/	O
TEM	O
1	O
than	O
TEMs	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4	O
,	O
-	O
5	O
,	O
-	O
7	O
,	O
and	O
-	O
8	O
.	O

Immunocytochemistry	O
revealed	O
that	O
endosialin	O
was	O
present	O
in	O
the	O
cytoplasmic	O
body	O
and	O
in	O
the	O
elongated	O
extensions	O
essential	O
to	O
pericyte	O
function	O
.	O

Transgenic	O
mice	O
engineered	O
to	O
express	O
human	O
endosialin	O
bred	O
on	O
an	O
immunocompromised	O
background	O
allowed	O
the	O
growth	O
of	O
human	O
tumor	O
xenografts	O
.	O

In	O
human	O
colon	O
carcinoma	O
Colo205	O
and	O
HT29	B
xenografts	O
grown	O
in	O
human	O
endosialin	O
-	O
transgenic	O
mice	O
,	O
endosialin	O
expression	O
was	O
largely	O
confined	O
to	O
NG2	O
-	O
expressing	O
perivascular	O
cells	O
and	O
not	O
CD31	O
-	O
positive	O
endothelial	O
cells	O
.	O

Similar	O
methods	O
applied	O
to	O
human	O
ovarian	O
and	O
colon	O
tumors	O
confirmed	O
endosialin	O
expression	O
by	O
pericytes	O
.	O

The	O
data	O
indicate	O
that	O
endosialin	O
is	O
strongly	O
expressed	O
by	O
pericytes	O
during	O
periods	O
of	O
active	O
angiogenesis	O
during	O
embryonic	O
and	O
tumor	O
development	O
.	O

Anti	O
-	O
endosialin	O
antibodies	O
may	O
have	O
value	O
in	O
identifying	O
vasculature	O
in	O
malignant	O
tissues	O
.	O

With	O
the	O
appropriate	O
agent	O
,	O
targeting	O
endosialin	O
may	O
interfere	O
with	O
blood	O
vessel	O
growth	O
during	O
tumor	O
development	O
.	O

The	O
role	O
of	O
p53	O
in	O
pigmentation	O
,	O
tanning	O
and	O
melanoma	O
.	O

p53	O
has	O
a	O
central	O
role	O
in	O
skin	O
pigmentation	O
and	O
may	O
impact	O
on	O
melanoma	O
at	O
all	O
stages	O
,	O
however	O
,	O
as	O
it	O
'	O
s	O
mutation	O
frequency	O
in	O
melanoma	O
is	O
low	O
,	O
it	O
'	O
s	O
role	O
has	O
been	O
somewhat	O
under	O
-	O
appreciated	O
.	O

During	O
normal	O
skin	O
function	O
,	O
p53	O
in	O
the	O
keratinocyte	O
is	O
a	O
transducer	O
of	O
the	O
skin	O
tanning	O
signal	O
and	O
an	O
essential	O
component	O
of	O
what	O
is	O
effectively	O
a	O
keratinocyte	O
-	O
melanocyte	O
signaling	O
cycle	O
that	O
regulates	O
skin	O
pigmentation	O
.	O

It	O
is	O
clear	O
that	O
this	O
cycle	O
functions	O
optimally	O
in	O
skin	O
of	O
dark	O
pigmentation	O
.	O

When	O
melanin	O
biosynthesis	O
is	O
genetically	O
disrupted	O
in	O
skin	O
of	O
white	O
complexion	O
,	O
we	O
propose	O
that	O
this	O
cycle	O
operates	O
as	O
a	O
promoter	O
of	O
melanocyte	O
proliferation	O
.	O

The	O
cell	O
autonomous	O
function	O
of	O
p53	O
in	O
melanocytes	O
is	O
not	O
well	O
described	O
,	O
however	O
,	O
the	O
balance	O
of	O
the	O
evidence	O
suggests	O
that	O
p53	O
is	O
an	O
effective	O
tumor	O
suppressor	O
and	O
the	O
myriad	O
of	O
mechanisms	O
by	O
which	O
the	O
p53	O
pathway	O
may	O
be	O
dysregulated	O
in	O
tumors	O
attests	O
to	O
it	O
importance	O
as	O
a	O
tumor	O
suppressor	O
.	O

In	O
this	O
review	O
,	O
we	O
outline	O
the	O
known	O
mechanisms	O
that	O
impair	O
p53	O
itself	O
and	O
its	O
immediate	O
regulators	O
or	O
target	O
genes	O
during	O
melanomagenesis	O
.	O

Due	O
to	O
the	O
importance	O
of	O
this	O
pathway	O
,	O
it	O
is	O
clear	O
that	O
p53	O
disruptions	O
may	O
relate	O
directly	O
to	O
a	O
patient	O
'	O
s	O
prognosis	O
.	O

This	O
pathway	O
will	O
continue	O
to	O
be	O
a	O
focus	O
of	O
investigation	O
,	O
particularly	O
with	O
respect	O
to	O
targeted	O
experimental	O
chemotherapeutics	O
.	O

Quantitative	O
retention	O
-	O
biological	O
activity	O
relationship	O
study	O
by	O
micellar	O
liquid	O
chromatography	O
.	O

In	O
a	O
previous	O
paper	O
,	O
the	O
usefulness	O
of	O
micellar	O
liquid	O
chromatography	O
(	O
MLC	O
)	O
in	O
predicting	O
octanol	O
-	O
water	O
partition	O
coefficients	O
of	O
organic	O
compounds	O
was	O
reported	O
.	O

This	O
paper	O
is	O
the	O
first	O
successful	O
report	O
of	O
a	O
quantitative	O
retention	O
-	O
activity	O
relationship	O
study	O
using	O
the	O
retention	O
factor	O
in	O
MLC	O
for	O
predicting	O
the	O
biological	O
activity	O
of	O
a	O
group	O
of	O
phenolic	O
compounds	O
.	O

Excellent	O
correlation	O
was	O
obtained	O
between	O
the	O
capacity	O
factor	O
in	O
MLC	O
and	O
the	O
bioactivity	O
(	O
measured	O
as	O
log	O
1	O
/	O
C	O
,	O
where	O
C	O
is	O
the	O
50	O
%	O
inhibitory	O
growth	O
concentration	O
)	O
of	O
26	O
para	O
-	O
substituted	O
phenols	O
.	O

A	O
single	O
MLC	O
retention	O
parameter	O
is	O
capable	O
of	O
describing	O
the	O
bioactivity	O
of	O
phenols	O
,	O
while	O
three	O
conventional	O
molecular	O
descriptors	O
(	O
log	O
P	O
(	O
ow	O
)	O
,	O
pKa	O
,	O
and	O
R	O
)	O
are	O
needed	O
to	O
achieve	O
a	O
similar	O
correlation	O
.	O

This	O
indicates	O
that	O
both	O
hydrophobic	O
and	O
electronic	O
interactions	O
are	O
incorporated	O
in	O
a	O
single	O
MLC	O
retention	O
parameter	O
,	O
which	O
is	O
due	O
to	O
the	O
amphiphilic	O
nature	O
of	O
surfactants	O
in	O
the	O
system	O
.	O

In	O
situations	O
like	O
this	O
,	O
QRAR	O
is	O
a	O
suitable	O
alternative	O
to	O
QSAR	O
since	O
measuring	O
MLC	O
retention	O
is	O
much	O
easier	O
than	O
measuring	O
different	O
molecular	O
descriptors	O
needed	O
to	O
build	O
the	O
QSAR	O
model	O
.	O

Addition	O
of	O
10	O
%	O
2	O
-	O
propanol	O
to	O
a	O
micellar	O
system	O
(	O
hybrid	O
system	O
)	O
proved	O
to	O
be	O
the	O
best	O
chromatographic	O
system	O
for	O
the	O
best	O
estimation	O
of	O
the	O
phenols	O
bioactivity	O
.	O

Other	O
chromatographic	O
factors	O
such	O
as	O
pH	O
and	O
stationary	O
phase	O
also	O
showed	O
significant	O
effect	O
on	O
the	O
correlation	O
between	O
capacity	O
factor	O
k	O
'	O
and	O
log	O
1	O
/	O
C	O
.	O

Enhancement	O
of	O
docetaxel	O
-	O
induced	O
cytotoxicity	O
and	O
apoptosis	O
by	O
all	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
through	O
downregulation	O
of	O
survivin	O
(	O
BIRC5	O
)	O
,	O
MCL	O
-	O
1	O
and	O
LTbeta	O
-	O
R	O
in	O
hormone	O
-	O
and	O
drug	O
resistant	O
prostate	O
cancer	O
cell	O
line	O
,	O
DU	B
-	I
145	I
.	O

BACKGROUND	O
:	O
The	O
management	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
still	O
remains	O
as	O
an	O
important	O
challenge	O
of	O
daily	O
oncology	O
practice	O
.	O

Docetaxel	O
has	O
proved	O
to	O
be	O
a	O
first	O
line	O
treatment	O
choice	O
.	O

All	O
-	O
trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
could	O
potently	O
inhibit	O
the	O
growth	O
of	O
prostate	O
cancer	O
cells	O
in	O
vitro	O
and	O
its	O
combination	O
with	O
various	O
anticancer	O
agents	O
results	O
in	O
increased	O
cytotoxicity	O
.	O

Based	O
on	O
these	O
data	O
,	O
our	O
aim	O
was	O
to	O
examine	O
the	O
synergistic	O
/	O
additive	O
cytotoxic	O
and	O
apoptotic	O
effects	O
of	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
,	O
in	O
hormone	O
-	O
and	O
drug	O
refractory	O
human	O
DU	B
-	I
145	I
prostate	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
we	O
have	O
searched	O
for	O
the	O
underlying	O
mechanisms	O
of	O
apoptosis	O
by	O
demonstrating	O
apoptosis	O
-	O
related	O
genes	O
.	O

METHODS	O
:	O
XTT	O
cell	O
proliferation	O
assay	O
was	O
used	O
for	O
showing	O
cytotoxicity	O
.	O

For	O
verifying	O
apoptosis	O
,	O
both	O
DNA	O
Fragmentation	O
by	O
ELISA	O
assay	O
and	O
caspase	O
3	O
/	O
7	O
activity	O
measurement	O
were	O
used	O
.	O

For	O
detecting	O
the	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
docetaxel	O
-	O
ATRA	O
combination	O
,	O
OligoGeArray	O
which	O
consists	O
of	O
112	O
apoptosis	O
related	O
genes	O
was	O
used	O
.	O

RESULTS	O
:	O
Our	O
results	O
revealed	O
that	O
docetaxel	O
and	O
ATRA	O
were	O
synergistically	O
cytotoxic	O
and	O
apoptotic	O
in	O
DU	B
-	I
145	I
cells	O
,	O
in	O
a	O
dose	O
-	O
and	O
time	O
dependent	O
manner	O
.	O

It	O
was	O
also	O
shown	O
by	O
our	O
studies	O
that	O
apoptosis	O
was	O
induced	O
in	O
DU	B
-	I
145	I
prostate	O
carcinoma	O
cells	O
with	O
significant	O
cytotoxicity	O
,	O
no	O
matter	O
which	O
agent	O
applied	O
first	O
.	O

We	O
have	O
found	O
out	O
that	O
docetaxel	O
-	O
ATRA	O
combination	O
significantly	O
downregulates	O
survivin	O
(	O
BIRC5	O
)	O
,	O
myeloid	O
cell	O
leukemia	O
-	O
1	O
(	O
MCL	O
-	O
1	O
)	O
and	O
lymphotoxin	O
beta	O
-	O
receptor	O
(	O
LTbetaR	O
)	O
genes	O
,	O
which	O
all	O
three	O
have	O
pivotal	O
roles	O
in	O
regulation	O
of	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
,	O
we	O
strongly	O
suggest	O
that	O
docetaxel	O
and	O
ATRA	O
combination	O
is	O
a	O
good	O
candidate	O
for	O
this	O
challenging	O
era	O
of	O
daily	O
oncologic	O
practice	O
.	O

Also	O
,	O
the	O
combination	O
of	O
docetaxel	O
and	O
ATRA	O
might	O
allow	O
a	O
reduction	O
in	O
docetaxel	O
doses	O
and	O
by	O
this	O
way	O
may	O
diminish	O
docetaxel	O
adverse	O
effects	O
while	O
maintaining	O
the	O
therapeutic	O
effect	O
in	O
patients	O
with	O
HRPC	O
.	O

Thermostability	O
and	O
molecular	O
encapsulation	O
within	O
an	O
engineered	O
caged	O
protein	O
scaffold	O
.	O

Self	O
-	O
assembling	O
biological	O
complexes	O
such	O
as	O
viral	O
capsids	O
have	O
been	O
manipulated	O
to	O
function	O
in	O
innovative	O
nanotechnology	O
applications	O
.	O

The	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
from	O
Bacillus	O
stearothermophilus	O
forms	O
a	O
dodecahedral	O
complex	O
and	O
potentially	O
provides	O
another	O
platform	O
for	O
these	O
purposes	O
.	O

In	O
this	O
investigation	O
,	O
we	O
show	O
that	O
this	O
protein	O
assembly	O
exhibits	O
unusual	O
stability	O
and	O
can	O
be	O
modified	O
to	O
encapsulate	O
model	O
drug	O
molecules	O
.	O

To	O
distill	O
the	O
E2	O
protein	O
down	O
to	O
its	O
structural	O
scaffold	O
core	O
,	O
we	O
synthesized	O
a	O
truncated	O
gene	O
optimized	O
for	O
expression	O
in	O
Escherichia	O
coli	O
.	O

The	O
correct	O
assembly	O
and	O
dodecahedral	O
structure	O
of	O
the	O
resulting	O
scaffold	O
was	O
confirmed	O
with	O
dynamic	O
light	O
scattering	O
and	O
transmission	O
electron	O
microscopy	O
.	O

Using	O
circular	O
dichroism	O
and	O
differential	O
scanning	O
calorimetry	O
,	O
we	O
found	O
the	O
thermostability	O
of	O
the	O
complex	O
to	O
be	O
unusually	O
high	O
,	O
with	O
an	O
onset	O
temperature	O
of	O
unfolding	O
at	O
81	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
9	O
degrees	O
C	O
and	O
an	O
apparent	O
midpoint	O
unfolding	O
temperature	O
of	O
91	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
4	O
degrees	O
C	O
.	O

To	O
evaluate	O
the	O
potential	O
of	O
this	O
scaffold	O
for	O
encapsulation	O
of	O
guest	O
molecules	O
,	O
we	O
made	O
variants	O
at	O
residues	O
381	O
and	O
239	O
which	O
altered	O
the	O
physicochemical	O
properties	O
of	O
the	O
hollow	O
internal	O
cavity	O
.	O

These	O
mutants	O
,	O
yielding	O
60	O
and	O
120	O
mutations	O
within	O
this	O
cavity	O
,	O
assembled	O
into	O
the	O
correct	O
architecture	O
and	O
exhibited	O
high	O
thermostability	O
that	O
was	O
comparable	O
to	O
the	O
wild	O
-	O
type	O
scaffold	O
.	O

To	O
show	O
the	O
applicability	O
of	O
this	O
scaffold	O
,	O
two	O
different	O
fluorescent	O
dye	O
molecules	O
were	O
covalently	O
coupled	O
to	O
the	O
cysteine	O
mutant	O
at	O
site	O
381	O
.	O

We	O
demonstrate	O
that	O
these	O
mutations	O
can	O
introduce	O
non	O
-	O
native	O
functionality	O
and	O
enable	O
molecular	O
encapsulation	O
within	O
the	O
cavity	O
while	O
still	O
retaining	O
the	O
dodecahedral	O
structure	O
.	O

The	O
unusually	O
robust	O
nature	O
of	O
this	O
scaffold	O
and	O
its	O
amenability	O
to	O
internal	O
changes	O
reveal	O
its	O
potential	O
for	O
nanoscale	O
applications	O
.	O

Efficient	O
inhibition	O
of	O
ovarian	O
cancer	O
growth	O
and	O
prolonged	O
survival	O
by	O
transfection	O
with	O
a	O
novel	O
pro	O
-	O
apoptotic	O
gene	O
,	O
hPNAS	O
-	O
4	O
,	O
in	O
a	O
mouse	O
model	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
results	O
.	O

OBJECTIVE	O
:	O
We	O
transfected	O
ovarian	O
cancer	O
cells	O
and	O
administered	O
recombinant	O
plasmid	O
encoding	O
hPNAS	O
-	O
4	O
to	O
nude	O
mice	O
bearing	O
ovarian	O
cancer	O
,	O
aiming	O
to	O
evaluate	O
the	O
effect	O
of	O
hPNAS	O
-	O
4	O
against	O
ovarian	O
cancer	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
Ovarian	O
cancer	O
SKOV3	B
cells	O
were	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
plasmid	O
,	O
and	O
cell	O
proliferation	O
was	O
evaluated	O
by	O
MTT	O
assay	O
;	O
apoptosis	O
was	O
examined	O
by	O
DNA	O
ladder	O
,	O
Hoechst33258	O
staining	O
and	O
flow	O
-	O
cytometric	O
assays	O
.	O

Nude	O
mice	O
bearing	O
ovarian	O
cancers	O
were	O
treated	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
/	O
liposome	O
.	O

Tumor	O
growth	O
was	O
determined	O
and	O
survival	O
was	O
recorded	O
.	O

TUNEL	O
assay	O
and	O
microvessel	O
density	O
was	O
assessed	O
to	O
evaluate	O
apoptosis	O
and	O
angiogenesis	O
.	O

RESULTS	O
:	O
Both	O
inhibition	O
of	O
proliferation	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
induction	O
of	O
apoptosis	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
SKOV3	B
cells	O
transfected	O
with	O
hPNAS	O
-	O
4	O
-	O
p	O
in	O
vitro	O
.	O

In	O
hPNAS	O
-	O
4	O
-	O
p	O
-	O
treated	O
tumor	O
cells	O
in	O
vivo	O
,	O
tumor	O
growth	O
significantly	O
decreased	O
,	O
while	O
the	O
survival	O
time	O
of	O
tumor	O
-	O
bearing	O
mice	O
was	O
prolonged	O
compared	O
with	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
apoptosis	O
of	O
tumor	O
cells	O
and	O
decreased	O
angiogenesis	O
in	O
tumor	O
tissue	O
were	O
also	O
observed	O
.	O

CONCLUSIONS	O
:	O
Our	O
promising	O
results	O
on	O
the	O
potential	O
antitumor	O
effects	O
of	O
hPNAS	O
-	O
4	O
on	O
ovarian	O
cancer	O
in	O
vitro	O
and	O
in	O
vivo	O
may	O
be	O
explained	O
,	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
.	O

Consequently	O
,	O
hPNAS	O
-	O
4	O
has	O
potential	O
as	O
a	O
new	O
gene	O
therapy	O
for	O
human	O
ovarian	O
cancer	O
.	O

Diverse	O
cell	O
signaling	O
events	O
modulated	O
by	O
perlecan	O
.	O

Perlecan	O
is	O
a	O
ubiquitous	O
pericellular	O
proteoglycan	O
ideally	O
placed	O
to	O
mediate	O
cell	O
signaling	O
events	O
controlling	O
migration	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O

Its	O
control	O
of	O
growth	O
factor	O
signaling	O
usually	O
involves	O
interactions	O
with	O
the	O
heparan	O
sulfate	O
chains	O
covalently	O
coupled	O
to	O
the	O
protein	O
core	O
'	O
s	O
N	O
-	O
terminus	O
.	O

However	O
,	O
this	O
modular	O
protein	O
core	O
also	O
binds	O
with	O
relatively	O
high	O
affinity	O
to	O
a	O
number	O
of	O
growth	O
factors	O
and	O
surface	O
receptors	O
,	O
thereby	O
stabilizing	O
cell	O
-	O
matrix	O
links	O
.	O

This	O
review	O
will	O
focus	O
on	O
perlecan	O
-	O
growth	O
factor	O
interactions	O
and	O
describe	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
this	O
highly	O
conserved	O
proteoglycan	O
during	O
development	O
,	O
cancer	O
growth	O
,	O
and	O
angiogenesis	O
.	O

The	O
pro	O
-	O
angiogenic	O
capacities	O
of	O
perlecan	O
that	O
involve	O
proliferative	O
and	O
migratory	O
signals	O
in	O
response	O
to	O
bound	O
growth	O
factors	O
will	O
be	O
explored	O
,	O
as	O
well	O
as	O
the	O
anti	O
-	O
angiogenic	O
signals	O
resulting	O
from	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
known	O
as	O
endorepellin	O
and	O
integrins	O
that	O
control	O
adhesion	O
of	O
cells	O
to	O
the	O
extracellular	O
matrix	O
.	O

These	O
two	O
somewhat	O
diametrically	O
opposed	O
roles	O
will	O
be	O
discussed	O
in	O
light	O
of	O
new	O
data	O
emerging	O
from	O
various	O
fields	O
which	O
converge	O
on	O
perlecan	O
as	O
a	O
key	O
regulator	O
of	O
cell	O
growth	O
and	O
angiogenesis	O
.	O

Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
through	O
a	O
phosphomimetic	O
serine	O
727	O
promotes	O
prostate	O
tumorigenesis	O
independent	O
of	O
tyrosine	O
705	O
phosphorylation	O
.	O

Aberrantly	O
activated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
is	O
implicated	O
in	O
the	O
development	O
of	O
various	O
human	O
cancers	O
.	O

Y705	O
phosphorylation	O
is	O
conventionally	O
thought	O
to	O
be	O
required	O
for	O
Stat3	O
signal	O
-	O
dependent	O
activation	O
and	O
seems	O
to	O
play	O
an	O
essential	O
role	O
in	O
some	O
malignancies	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
Stat3	O
is	O
activated	O
through	O
novel	O
and	O
noncanonical	O
mechanisms	O
,	O
including	O
phosphorylation	O
at	O
S727	O
.	O

Here	O
,	O
we	O
investigate	O
S727	O
phosphorylation	O
of	O
Stat3	O
and	O
its	O
subsequent	O
effects	O
in	O
prostate	O
cancer	O
development	O
,	O
independent	O
of	O
Y705	O
phosphorylation	O
,	O
using	O
mutated	O
Stat3	O
in	O
the	O
human	O
prostate	O
cancer	O
cell	O
line	O
LNCaP	B
.	O

We	O
show	O
mutation	O
of	O
S727	O
to	O
the	O
phosphomimetic	O
residue	O
Glu	O
,	O
and	O
inactivation	O
of	O
Y705	O
(	O
Y705F	O
/	O
S727E	O
)	O
resulted	O
in	O
a	O
remarkable	O
growth	O
advantage	O
in	O
low	O
-	O
serum	O
,	O
enhanced	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
,	O
and	O
increased	O
tumorigenicity	O
in	O
nonobese	O
diabetic	O
/	O
severe	O
combined	O
immunodeficient	O
(	O
NOD	O
/	O
SCID	O
)	O
mice	O
,	O
possibly	O
by	O
direct	O
activation	O
of	O
downstream	O
proto	O
-	O
oncogenes	O
c	O
-	O
myc	O
,	O
mcl	O
-	O
1	O
,	O
and	O
survivin	O
.	O

Y705F	O
/	O
S727E	O
mutant	O
cells	O
were	O
more	O
invasive	O
than	O
Y705F	O
/	O
S727A	O
(	O
inactivation	O
of	O
Y705	O
and	O
S727	O
)	O
mutant	O
cells	O
,	O
and	O
more	O
Y705F	O
/	O
S727E	O
mutant	O
Stat3	O
was	O
localized	O
in	O
the	O
nuclei	O
relative	O
to	O
Y705F	O
/	O
S727A	O
mutant	O
Stat3	O
at	O
the	O
steady	O
state	O
.	O

Furthermore	O
,	O
the	O
Y705F	O
/	O
S727E	O
but	O
not	O
the	O
Y705F	O
/	O
S727A	O
mutant	O
induced	O
anchorage	O
-	O
independent	O
growth	O
of	O
noncancerous	O
prostate	O
epithelial	O
cells	O
(	O
RWPE	B
-	I
1	I
)	O
.	O

We	O
further	O
show	O
that	O
Stat3	O
is	O
phosphorylated	O
at	O
S727	O
in	O
65	O
%	O
of	O
malignant	O
prostate	O
tissues	O
(	O
n	O
=	O
20	O
)	O
relative	O
to	O
25	O
%	O
of	O
normal	O
prostate	O
tissues	O
(	O
n	O
=	O
4	O
)	O
.	O

Moreover	O
,	O
there	O
is	O
a	O
positive	O
correlation	O
between	O
phosphoS727	O
-	O
Stat3	O
expression	O
and	O
Gleason	O
score	O
in	O
these	O
prostate	O
cancer	O
tissues	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Our	O
data	O
suggest	O
for	O
the	O
first	O
time	O
that	O
S727	O
phosphorylation	O
is	O
sufficient	O
to	O
activate	O
Stat3	O
,	O
thereby	O
driving	O
prostate	O
tumorigenesis	O
independent	O
of	O
Y705	O
phosphorylation	O
.	O

Angiogenesis	O
associated	O
with	O
visceral	O
and	O
subcutaneous	O
adipose	O
tissue	O
in	O
severe	O
human	O
obesity	O
.	O

OBJECTIVE	O
:	O
The	O
expansion	O
of	O
adipose	O
tissue	O
is	O
linked	O
to	O
the	O
development	O
of	O
its	O
vasculature	O
.	O

However	O
,	O
the	O
regulation	O
of	O
adipose	O
tissue	O
angiogenesis	O
in	O
humans	O
has	O
not	O
been	O
extensively	O
studied	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
angiogenesis	O
associated	O
with	O
subcutaneous	O
adipose	O
tissue	O
(	O
SAT	O
)	O
and	O
visceral	O
adipose	O
tissue	O
(	O
VAT	O
)	O
from	O
the	O
same	O
obese	O
patients	O
in	O
an	O
in	O
vivo	O
model	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
Adipose	O
tissue	O
samples	O
from	O
visceral	O
(	O
VAT	O
)	O
and	O
subcutaneous	O
(	O
SAT	O
)	O
sites	O
,	O
obtained	O
from	O
36	O
obese	O
patients	O
(	O
mean	O
BMI	O
46	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
during	O
bariatric	O
surgery	O
,	O
were	O
layered	O
on	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
.	O

RESULTS	O
:	O
Both	O
SAT	O
and	O
VAT	O
expressed	O
angiogenic	O
factors	O
without	O
significant	O
difference	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
.	O

Adipose	O
tissue	O
layered	O
on	O
CAM	O
stimulated	O
angiogenesis	O
.	O

Angiogenic	O
stimulation	O
was	O
macroscopically	O
detectable	O
,	O
with	O
engulfment	O
of	O
the	O
samples	O
,	O
in	O
39	O
%	O
and	O
was	O
evidenced	O
by	O
angiography	O
in	O
59	O
%	O
of	O
the	O
samples	O
.	O

A	O
connection	O
between	O
CAM	O
and	O
adipose	O
tissue	O
vessels	O
was	O
evidenced	O
by	O
immunohistochemistry	O
,	O
with	O
recruitment	O
of	O
both	O
avian	O
and	O
human	O
endothelial	O
cells	O
.	O

The	O
angiogenic	O
potency	O
of	O
adipose	O
tissue	O
was	O
not	O
related	O
to	O
its	O
localization	O
(	O
with	O
an	O
angiogenic	O
stimulation	O
in	O
60	O
%	O
of	O
SAT	O
samples	O
and	O
61	O
%	O
of	O
VAT	O
samples	O
)	O
or	O
to	O
adipocyte	O
size	O
or	O
inflammatory	O
infiltrate	O
assessed	O
in	O
adipose	O
samples	O
before	O
the	O
graft	O
on	O
CAM	O
.	O

Stimulation	O
of	O
angiogenesis	O
by	O
adipose	O
tissue	O
was	O
nearly	O
abolished	O
by	O
bevacizumab	O
,	O
which	O
specifically	O
targets	O
human	O
VEGF	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
established	O
a	O
model	O
to	O
study	O
the	O
regulation	O
of	O
angiogenesis	O
by	O
human	O
adipose	O
tissue	O
.	O

This	O
model	O
highlighted	O
the	O
role	O
of	O
VEGF	O
in	O
angiogenesis	O
in	O
both	O
SAT	O
and	O
VAT	O
.	O

The	O
in	O
vivo	O
properties	O
of	O
STX243	O
:	O
a	O
potent	O
angiogenesis	O
inhibitor	O
in	O
breast	O
cancer	O
.	O

The	O
steroidal	O
-	O
based	O
drug	O
2	O
-	O
ethyloestradiol	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX243	O
)	O
has	O
been	O
developed	O
as	O
a	O
potent	O
antiangiogenic	O
and	O
antitumour	O
compound	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
whether	O
STX243	O
is	O
more	O
active	O
in	O
vivo	O
than	O
the	O
clinically	O
relevant	O
drug	O
2	O
-	O
methoxyoestradiol	O
(	O
2	O
-	O
MeOE2	O
)	O
and	O
the	O
structurally	O
similar	O
compound	O
2	O
-	O
MeOE2	O
-	O
3	O
,	O
17	O
-	O
O	O
,	O
O	O
-	O
bis	O
-	O
sulphamate	O
(	O
STX140	O
)	O
.	O

The	O
tumour	O
growth	O
inhibition	O
efficacy	O
,	O
antiangiogenic	O
potential	O
and	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
using	O
four	O
in	O
vivo	O
models	O
.	O

Both	O
STX243	O
and	O
STX140	O
were	O
capable	O
of	O
retarding	O
the	O
growth	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
xenograft	O
tumours	O
(	O
72	O
and	O
63	O
%	O
,	O
respectively	O
)	O
,	O
whereas	O
no	O
inhibition	O
was	O
observed	O
for	O
animals	O
treated	O
with	O
2	O
-	O
MeOE2	O
.	O

Further	O
tumour	O
inhibition	O
studies	O
showed	O
that	O
STX243	O
was	O
also	O
active	O
against	O
MCF	B
-	I
7	I
paclitaxel	O
-	O
resistant	O
tumours	O
.	O

Using	O
a	O
Matrigel	O
plug	O
-	O
based	O
model	O
,	O
in	O
vivo	O
angiogenesis	O
was	O
restricted	O
with	O
STX243	O
and	O
STX140	O
(	O
50	O
and	O
72	O
%	O
,	O
respectively	O
,	O
using	O
a	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
oral	O
dose	O
)	O
,	O
thereby	O
showing	O
the	O
antiangiogenic	O
activity	O
of	O
both	O
compounds	O
.	O

The	O
pharmacokinetics	O
of	O
STX243	O
were	O
examined	O
at	O
two	O
different	O
doses	O
using	O
adult	O
female	O
rats	O
.	O

The	O
compound	O
was	O
orally	O
bioavailable	O
(	O
31	O
%	O
after	O
a	O
single	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
dose	O
)	O
and	O
resistant	O
to	O
metabolism	O
.	O

These	O
results	O
show	O
that	O
STX243	O
is	O
a	O
potent	O
in	O
vivo	O
drug	O
and	O
could	O
be	O
clinically	O
effective	O
at	O
treating	O
a	O
number	O
of	O
oncological	O
conditions	O
.	O

M	O
-	O
CSF	O
signals	O
through	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
via	O
Sp1	O
to	O
induce	O
VEGF	O
production	O
and	O
induces	O
angiogenesis	O
in	O
vivo	O
.	O

BACKGROUND	O
:	O
M	O
-	O
CSF	O
recruits	O
mononuclear	O
phagocytes	O
which	O
regulate	O
processes	O
such	O
as	O
angiogenesis	O
and	O
metastases	O
in	O
tumors	O
.	O

VEGF	O
is	O
a	O
potent	O
activator	O
of	O
angiogenesis	O
as	O
it	O
promotes	O
endothelial	O
cell	O
proliferation	O
and	O
new	O
blood	O
vessel	O
formation	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
in	O
vitro	O
M	O
-	O
CSF	O
induces	O
the	O
expression	O
of	O
biologically	O
-	O
active	O
VEGF	O
from	O
human	O
monocytes	O
.	O

METHODOLOGY	O
AND	O
RESULTS	O
:	O
In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
molecular	O
mechanism	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
production	O
.	O

Using	O
a	O
construct	O
containing	O
the	O
VEGF	O
promoter	O
linked	O
to	O
a	O
luciferase	O
reporter	O
,	O
we	O
found	O
that	O
a	O
mutation	O
reducing	O
HIF	O
binding	O
to	O
the	O
VEGF	O
promoter	O
had	O
no	O
significant	O
effect	O
on	O
luciferase	O
production	O
induced	O
by	O
M	O
-	O
CSF	O
stimulation	O
.	O

Further	O
analysis	O
revealed	O
that	O
M	O
-	O
CSF	O
induced	O
VEGF	O
through	O
the	O
MAPK	O
/	O
ERK	O
signaling	O
pathway	O
via	O
the	O
transcription	O
factor	O
,	O
Sp1	O
.	O

Thus	O
,	O
inhibition	O
of	O
either	O
ERK	O
or	O
Sp1	O
suppressed	O
M	O
-	O
CSF	O
-	O
induced	O
VEGF	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

M	O
-	O
CSF	O
also	O
induced	O
the	O
nuclear	O
localization	O
of	O
Sp1	O
,	O
which	O
was	O
blocked	O
by	O
ERK	O
inhibition	O
.	O

Finally	O
,	O
mutating	O
the	O
Sp1	O
binding	O
sites	O
within	O
the	O
VEGF	O
promoter	O
or	O
inhibiting	O
ERK	O
decreased	O
VEGF	O
promoter	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
treated	O
human	O
monocytes	O
.	O

To	O
evaluate	O
the	O
biological	O
significance	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
,	O
we	O
used	O
an	O
in	O
vivo	O
angiogenesis	O
model	O
to	O
illustrate	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
recruit	O
mononuclear	O
phagocytes	O
,	O
increase	O
VEGF	O
levels	O
,	O
and	O
enhance	O
angiogenesis	O
.	O

Importantly	O
,	O
the	O
addition	O
of	O
a	O
neutralizing	O
VEGF	O
antibody	O
abolished	O
M	O
-	O
CSF	O
-	O
induced	O
blood	O
vessel	O
formation	O
.	O

CONCLUSION	O
:	O
These	O
data	O
delineate	O
an	O
ERK	O
-	O
and	O
Sp1	O
-	O
dependent	O
mechanism	O
of	O
M	O
-	O
CSF	O
induced	O
VEGF	O
production	O
and	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
ability	O
of	O
M	O
-	O
CSF	O
to	O
induce	O
angiogenesis	O
via	O
VEGF	O
in	O
vivo	O
.	O

Allergic	O
pulmonary	O
inflammation	O
promotes	O
the	O
recruitment	O
of	O
circulating	O
tumor	O
cells	O
to	O
the	O
lung	O
.	O

Allergen	O
-	O
induced	O
respiratory	O
inflammation	O
facilitates	O
and	O
/	O
or	O
elicits	O
the	O
extravasation	O
of	O
proinflammatory	O
leukocytes	O
by	O
well	O
-	O
understood	O
mechanisms	O
that	O
mediate	O
the	O
movement	O
of	O
multiple	O
cell	O
types	O
.	O

The	O
nonspecific	O
character	O
of	O
these	O
pathways	O
led	O
us	O
to	O
hypothesize	O
that	O
circulating	O
cancer	O
cells	O
use	O
similar	O
mechanisms	O
,	O
promoting	O
secondary	O
tumor	O
formation	O
at	O
distal	O
sites	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
frequency	O
of	O
metastasis	O
to	O
the	O
lung	O
as	O
a	O
function	O
of	O
allergic	O
pulmonary	O
inflammation	O
was	O
assessed	O
following	O
the	O
i	O
.	O
v	O
.	O
injection	O
of	O
B16	B
-	I
F10	I
melanoma	O
cells	O
in	O
mice	O
.	O

These	O
studies	O
showed	O
that	O
allergen	O
-	O
induced	O
pulmonary	O
inflammation	O
resulted	O
in	O
a	O
>	O
3	O
-	O
fold	O
increase	O
in	O
lung	O
metastases	O
.	O

This	O
increase	O
was	O
dependent	O
on	O
CD4	O
(	O
+	O
)	O
T	O
-	O
cell	O
activities	O
;	O
however	O
,	O
it	O
occurred	O
independent	O
of	O
the	O
induced	O
eosinophilia	O
associated	O
with	O
allergen	O
provocation	O
.	O

Interventional	O
strategies	O
showed	O
that	O
existing	O
therapeutic	O
modalities	O
for	O
asthma	O
,	O
such	O
as	O
inhaled	O
corticosteroids	O
,	O
were	O
sufficient	O
to	O
block	O
the	O
enhanced	O
pulmonary	O
recruitment	O
of	O
cancer	O
cells	O
from	O
circulation	O
.	O

Additional	O
mechanistic	O
studies	O
further	O
suggested	O
that	O
the	O
ability	O
of	O
circulating	O
cancer	O
cells	O
to	O
extravasate	O
to	O
surrounding	O
lung	O
tissues	O
was	O
linked	O
to	O
the	O
activation	O
of	O
the	O
vascular	O
endothelium	O
via	O
one	O
or	O
more	O
Galpha	O
(	O
i	O
)	O
-	O
coupled	O
receptors	O
.	O

Interestingly	O
,	O
a	O
survey	O
of	O
a	O
clinical	O
breast	O
cancer	O
surgical	O
database	O
showed	O
that	O
the	O
incidence	O
of	O
asthma	O
was	O
higher	O
among	O
patients	O
with	O
lung	O
metastases	O
.	O

Thus	O
,	O
our	O
data	O
show	O
that	O
allergic	O
respiratory	O
inflammation	O
may	O
represent	O
a	O
risk	O
factor	O
for	O
the	O
development	O
of	O
lung	O
metastases	O
and	O
suggest	O
that	O
amelioration	O
of	O
the	O
pulmonary	O
inflammation	O
associated	O
with	O
asthma	O
will	O
have	O
a	O
direct	O
and	O
immediate	O
benefit	O
to	O
the	O
7	O
%	O
to	O
8	O
%	O
of	O
breast	O
cancer	O
patients	O
with	O
this	O
lung	O
disease	O
.	O

PI3	O
K	O
/	O
Akt	O
-	O
dependent	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
by	O
NF	O
-	O
kappaB	O
in	O
metastatic	O
prostate	O
cancer	O
cells	O
.	O

BACKGROUND	O
:	O
Bone	O
morphogenetic	O
proteins	O
(	O
BMPs	O
)	O
exert	O
osteoinductive	O
effects	O
in	O
prostate	O
cancer	O
(	O
PC	O
)	O
via	O
uncharacterized	O
mechanisms	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
implicated	O
in	O
PC	O
metastasis	O
,	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
and	O
activation	O
of	O
BMP	O
-	O
2	O
or	O
BMP	O
-	O
4	O
/	O
Smad	O
signaling	O
in	O
PC	O
cells	O
.	O

METHODS	O
:	O
NF	O
-	O
kappaB	O
inhibition	O
was	O
achieved	O
by	O
IkappaBalpha	O
super	O
-	O
repressor	O
adenoviral	O
vector	O
and	O
activation	O
was	O
monitored	O
by	O
EMSA	O
and	O
reporter	O
assays	O
.	O

BMP	O
expression	O
and	O
activation	O
was	O
measured	O
by	O
PCR	O
and	O
reporter	O
assays	O
.	O

Promoter	O
binding	O
assay	O
was	O
performed	O
by	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assay	O
.	O

Smad1	O
/	O
5	O
/	O
8	O
phosphorylation	O
was	O
measured	O
by	O
Western	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
PCR	O
and	O
chimeric	O
BMP	O
-	O
2	O
and	O
BMP	O
-	O
4	O
luciferase	O
assays	O
demonstrate	O
that	O
NF	O
-	O
kappaB	O
confers	O
robust	O
and	O
selective	O
activation	O
of	O
BMP	O
-	O
2	O
in	O
p65	O
overexpressing	O
or	O
rhTNF	O
-	O
alpha	O
-	O
stimulated	O
PC	O
cells	O
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
significantly	O
reduced	O
transcript	O
levels	O
and	O
autocrine	O
production	O
of	O
BMP	O
-	O
2	O
by	O
rhTNF	O
-	O
alpha	O
stimulated	O
C4	B
-	I
2B	I
cells	O
and	O
to	O
a	O
lesser	O
extent	O
by	O
the	O
parental	O
LNCaP	B
cells	O
.	O

Selective	O
inhibition	O
of	O
PI3	O
K	O
/	O
Akt	O
suppressed	O
the	O
NF	O
-	O
kappaB	O
-	O
induced	O
BMP	O
-	O
2	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreased	O
the	O
transcript	O
levels	O
and	O
BMP	O
-	O
2	O
-	O
induced	O
phosphorylation	O
of	O
Smad1	O
/	O
5	O
/	O
8	O
,	O
critical	O
downstream	O
targets	O
of	O
BMP	O
-	O
2	O
signaling	O
in	O
PC	O
cells	O
.	O

Notably	O
,	O
the	O
activation	O
of	O
BMPRII	O
by	O
BMP	O
-	O
2	O
is	O
required	O
for	O
modulation	O
of	O
Smad	O
activation	O
by	O
NF	O
-	O
kappaB	O
in	O
PC	O
cells	O
.	O

Based	O
on	O
ChIP	O
analysis	O
,	O
the	O
transcriptional	O
regulation	O
of	O
BMP	O
-	O
2	O
gene	O
by	O
NF	O
-	O
kappaB	O
may	O
be	O
partially	O
attributed	O
to	O
binding	O
to	O
kappab	O
site	O
on	O
the	O
BMP	O
-	O
2	O
promoter	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
PI3	O
K	O
/	O
Akt	O
-	O
NF	O
-	O
kappaB	O
axis	O
may	O
promote	O
PC	O
bone	O
metastasis	O
in	O
part	O
by	O
regulating	O
transcription	O
and	O
activation	O
of	O
the	O
BMP	O
-	O
2	O
-	O
Smad	O
signaling	O
cascade	O
in	O
osteotropic	O
PC	O
cells	O
.	O

Inhibition	O
of	O
energy	O
-	O
producing	O
pathways	O
of	O
HepG2	B
cells	O
by	O
3	O
-	O
bromopyruvate	O
.	O

3	O
-	O
BrPA	O
(	O
3	O
-	O
bromopyruvate	O
)	O
is	O
an	O
alkylating	O
agent	O
with	O
anti	O
-	O
tumoral	O
activity	O
on	O
hepatocellular	O
carcinoma	O
.	O

This	O
compound	O
inhibits	O
cellular	O
ATP	O
production	O
owing	O
to	O
its	O
action	O
on	O
glycolysis	O
and	O
oxidative	O
phosphorylation	O
;	O
however	O
,	O
the	O
specific	O
metabolic	O
steps	O
and	O
mechanisms	O
of	O
3	O
-	O
BrPA	O
action	O
in	O
human	O
hepatocellular	O
carcinomas	O
,	O
particularly	O
its	O
effects	O
on	O
mitochondrial	O
energetics	O
,	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
it	O
was	O
found	O
that	O
incubation	O
of	O
HepG2	B
cells	O
with	O
a	O
low	O
concentration	O
of	O
3	O
-	O
BrPA	O
for	O
a	O
short	O
period	O
(	O
150	O
microM	O
for	O
30	O
min	O
)	O
significantly	O
affected	O
both	O
glycolysis	O
and	O
mitochondrial	O
respiratory	O
functions	O
.	O

The	O
activity	O
of	O
mitochondrial	O
hexokinase	O
was	O
not	O
inhibited	O
by	O
150	O
microM	O
3	O
-	O
BrPA	O
,	O
but	O
this	O
concentration	O
caused	O
more	O
than	O
70	O
%	O
inhibition	O
of	O
GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
and	O
3	O
-	O
phosphoglycerate	O
kinase	O
activities	O
.	O

Additionally	O
,	O
3	O
-	O
BrPA	O
treatment	O
significantly	O
impaired	O
lactate	O
production	O
by	O
HepG2	B
cells	O
,	O
even	O
when	O
glucose	O
was	O
withdrawn	O
from	O
the	O
incubation	O
medium	O
.	O

Oxygen	O
consumption	O
of	O
HepG2	B
cells	O
supported	O
by	O
either	O
pyruvate	O
/	O
malate	O
or	O
succinate	O
was	O
inhibited	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
3	O
-	O
BrPA	O
in	O
glucose	O
-	O
free	O
medium	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
cells	O
were	O
pre	O
-	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
oxygen	O
consumption	O
was	O
affected	O
only	O
when	O
succinate	O
was	O
used	O
as	O
the	O
oxidizable	O
substrate	O
.	O

An	O
increase	O
in	O
oligomycin	O
-	O
independent	O
respiration	O
was	O
observed	O
in	O
HepG2	B
cells	O
treated	O
with	O
3	O
-	O
BrPA	O
only	O
when	O
incubated	O
in	O
glucose	O
-	O
supplemented	O
medium	O
,	O
indicating	O
that	O
3	O
-	O
BrPA	O
induces	O
mitochondrial	O
proton	O
leakage	O
as	O
well	O
as	O
blocking	O
the	O
electron	O
transport	O
system	O
.	O

The	O
activity	O
of	O
succinate	O
dehydrogenase	O
was	O
inhibited	O
by	O
70	O
%	O
by	O
3	O
-	O
BrPA	O
treatment	O
.	O

These	O
results	O
suggest	O
that	O
the	O
combined	O
action	O
of	O
3	O
-	O
BrPA	O
on	O
succinate	O
dehydrogenase	O
and	O
on	O
glycolysis	O
,	O
inhibiting	O
steps	O
downstream	O
of	O
the	O
phosphorylation	O
of	O
glucose	O
,	O
play	O
an	O
important	O
role	O
in	O
HepG2	B
cell	O
death	O
.	O

[	O
Retinochoroidopathy	O
after	O
intravitreal	O
anti	O
-	O
VEGF	O
treatment	O
]	O

A	O
74	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
persistent	O
metamorphopsias	O
of	O
the	O
right	O
eye	O
2	O
weeks	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	O
to	O
treat	O
choroidal	O
neovascularization	O
due	O
to	O
exudative	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

The	O
diagnosis	O
reached	O
was	O
retinochoroiditis	O
as	O
an	O
occult	O
manifestation	O
of	O
sarcoidosis	O
,	O
possibly	O
resulting	O
from	O
an	O
intravitreal	O
injection	O
of	O
bevacizumab	O
.	O

The	O
patient	O
received	O
a	O
prescription	O
for	O
100	O
mg	O
Ultralan	O
to	O
be	O
taken	O
daily	O
for	O
3	O
days	O
and	O
then	O
tapered	O
in	O
3	O
day	O
steps	O
.	O

During	O
the	O
further	O
course	O
no	O
deterioration	O
of	O
the	O
condition	O
was	O
observed	O
.	O

[	O
The	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
:	O
an	O
analysis	O
of	O
513	O
cases	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
investigate	O
the	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

METHODS	O
:	O

513	O
APL	O
patients	O
in	O
the	O
last	O
two	O
decades	O
were	O
retrospectively	O
analyzed	O
in	O
this	O
research	O
.	O

We	O
investigated	O
the	O
clinical	O
features	O
including	O
age	O
,	O
sex	O
,	O
abnormality	O
of	O
peripheral	O
hemogram	O
before	O
treatment	O
,	O
therapeutic	O
effect	O
and	O
follow	O
-	O
up	O
and	O
laboratory	O
data	O
such	O
as	O
morphology	O
,	O
immunology	O
,	O
cytogenetics	O
and	O
molecular	O
biology	O
(	O
MICM	O
)	O
.	O

RESULTS	O
:	O

The	O
median	O
age	O
of	O
the	O
APL	O
patients	O
was	O
33	O
years	O
old	O
and	O
the	O
ratio	O
of	O
male	O
and	O
female	O
was	O
1	O
.	O
21	O
:	O
1	O
.	O

Before	O
treatment	O
,	O
the	O
median	O
level	O
of	O
WBC	O
was	O
4	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
the	O
detection	O
rate	O
of	O
abnormal	O
promyelocyte	O
on	O
blood	O
film	O
was	O
85	O
.	O
8	O
%	O
;	O
with	O
immunophenotypic	O
detection	O
,	O
the	O
expression	O
levels	O
of	O
CD117	O
,	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD7	O
,	O
CD14	O
and	O
CD19	O
in	O
APL	O
were	O
found	O
to	O
be	O
lower	O
and	O
the	O
expression	O
levels	O
of	O
CD2	O
,	O
CD33	O
and	O
MPO	O
higher	O
than	O
those	O
in	O
other	O
subtypes	O
of	O
acute	O
myelocytic	O
leukemia	O
(	O
AML	O
)	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Specific	O
abnormal	O
chromosome	O
t	O
(	O
15	O
;	O
17	O
)	O
was	O
detected	O
in	O
91	O
.	O
7	O
%	O
of	O
the	O
patients	O
,	O
of	O
whom	O
75	O
.	O
9	O
%	O
had	O
standard	O
translocation	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
being	O
the	O
most	O
common	O
one	O
and	O
15	O
.	O
8	O
%	O
of	O
the	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
additional	O
abnormal	O
chromosome	O
.	O

There	O
was	O
only	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
with	O
normal	O
karyotype	O
.	O

However	O
,	O
the	O
presence	O
of	O
both	O
simple	O
translocation	O
and	O
complex	O
translocation	O
was	O
seldom	O
seen	O
.	O

With	O
molecular	O
biological	O
detection	O
,	O
PML	O
/	O
RARalpha	O
fusion	O
gene	O
positive	O
rate	O
was	O
99	O
.	O
6	O
%	O
.	O

In	O
a	O
relatively	O
long	O
clinical	O
follow	O
-	O
up	O
,	O
we	O
found	O
that	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
in	O
APL	O
patients	O
was	O
84	O
.	O
7	O
%	O
,	O
incidence	O
of	O
DIC	O
was	O
13	O
.	O
4	O
%	O
and	O
five	O
-	O
year	O
survival	O
rate	O
was	O
30	O
.	O
7	O
%	O
.	O

The	O
median	O
count	O
of	O
WBC	O
in	O
CR	O
group	O
was	O
lower	O
than	O
that	O
non	O
-	O
remission	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
on	O
expressions	O
of	O
CD34	O
and	O
CD2	O
and	O
changes	O
of	O
cytogenetics	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

Comprehensive	O
evaluation	O
of	O
MICM	O
could	O
be	O
of	O
important	O
significance	O
in	O
the	O
diagnosis	O
and	O
prognosis	O
judgment	O
for	O
APL	O
patients	O
.	O

The	O
CR	O
rate	O
in	O
these	O
patients	O
with	O
high	O
WBC	O
count	O
was	O
considerable	O
low	O
.	O

The	O
detection	O
of	O
macrosomia	O
at	O
a	O
teaching	O
hospital	O
.	O

We	O
sought	O
to	O
determine	O
the	O
detection	O
(	O
clinical	O
or	O
sonographic	O
)	O
rate	O
of	O
macrosomic	O
newborns	O
(	O
at	O
least	O
4000	O
g	O
)	O
and	O
the	O
peripartum	O
factors	O
among	O
those	O
who	O
were	O
or	O
were	O
not	O
identified	O
accurately	O
.	O

We	O
retrospectively	O
reviewed	O
all	O
deliveries	O
over	O
1	O
year	O
and	O
all	O
maternal	O
and	O
neonatal	O
charts	O
of	O
macrosomic	O
newborns	O
delivered	O
during	O
that	O
year	O
.	O

Odds	O
ratio	O
(	O
ORs	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
.	O

Over	O
a	O
12	O
-	O
month	O
period	O
,	O
the	O
rate	O
of	O
macrosomia	O
was	O
10	O
%	O
(	O
421	O
/	O
4194	O
)	O
and	O
of	O
those	O
,	O
only	O
11	O
%	O
(	O
95	O
%	O
CI	O
8	O
to	O
14	O
%	O
)	O
were	O
suspected	O
clinically	O
or	O
sonographically	O
.	O

None	O
of	O
the	O
newborns	O
weighing	O
4500	O
g	O
or	O
more	O
were	O
recognized	O
before	O
birth	O
(	O
0	O
/	O
57	O
;	O
95	O
%	O
CI	O
0	O
to	O
6	O
%	O
)	O
.	O

The	O
rate	O
of	O
cesarean	O
delivery	O
was	O
significantly	O
higher	O
among	O
newborns	O
correctly	O
identified	O
as	O
macrosomic	O
(	O
58	O
%	O
)	O
versus	O
those	O
missed	O
(	O
36	O
%	O
;	O
OR	O
2	O
.	O
76	O
,	O
95	O
%	O
CI	O
1	O
.	O
46	O
,	O
5	O
.	O
16	O
)	O
.	O

The	O
incidence	O
of	O
newborns	O
weighing	O
in	O
excess	O
of	O
4000	O
g	O
is	O
10	O
%	O
,	O
and	O
approximately	O
90	O
%	O
of	O
these	O
macrosomic	O
newborns	O
were	O
unsuspected	O
before	O
birth	O
.	O

Silencing	O
of	O
directional	O
migration	O
in	O
roundabout4	O
knockdown	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Roundabouts	O
are	O
axon	O
guidance	O
molecules	O
that	O
have	O
recently	O
been	O
identified	O
to	O
play	O
a	O
role	O
in	O
vascular	O
guidance	O
as	O
well	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
gene	O
knockdown	O
analysis	O
of	O
endothelial	O
Robos	O
,	O
in	O
particular	O
roundabout	O
4	O
(	O
robo4	O
)	O
,	O
the	O
predominant	O
Robo	O
in	O
endothelial	O
cells	O
using	O
small	O
interfering	O
RNA	O
technology	O
in	O
vitro	O
.	O

RESULTS	O
:	O
Robo1	O
and	O
Robo4	O
knockdown	O
cells	O
display	O
distinct	O
activity	O
in	O
endothelial	O
cell	O
migration	O
assay	O
.	O

The	O
knockdown	O
of	O
robo4	O
abrogated	O
the	O
chemotactic	O
response	O
of	O
endothelial	O
cells	O
to	O
serum	O
but	O
enhanced	O
a	O
chemokinetic	O
response	O
to	O
Slit2	O
,	O
while	O
robo1	O
knockdown	O
cells	O
do	O
not	O
display	O
chemotactic	O
response	O
to	O
serum	O
or	O
VEGF	O
.	O

Robo4	O
knockdown	O
endothelial	O
cells	O
unexpectedly	O
show	O
up	O
regulation	O
of	O
Rho	O
GTPases	O
.	O

Zebrafish	O
Robo4	O
rescues	O
both	O
Rho	O
GTPase	O
homeostasis	O
and	O
serum	O
reduced	O
chemotaxis	O
in	O
robo4	O
knockdown	O
cells	O
.	O

Robo1	O
and	O
Robo4	O
interact	O
and	O
share	O
molecules	O
such	O
as	O
Slit2	O
,	O
Mena	O
and	O
Vilse	O
,	O
a	O
Cdc42	O
-	O
GAP	O
.	O

In	O
addition	O
,	O
this	O
study	O
mechanistically	O
implicates	O
IRSp53	O
in	O
the	O
signaling	O
nexus	O
between	O
activated	O
Cdc42	O
and	O
Mena	O
,	O
both	O
of	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
involved	O
with	O
Robo4	O
signaling	O
in	O
endothelial	O
cells	O
.	O

CONCLUSION	O
:	O
This	O
study	O
identifies	O
specific	O
components	O
of	O
the	O
Robo	O
signaling	O
apparatus	O
that	O
work	O
together	O
to	O
guide	O
directional	O
migration	O
of	O
endothelial	O
cells	O
.	O

Atypical	O
mycobacteriosis	O
of	O
the	O
larynx	O
:	O
an	O
unusual	O
clinical	O
presentation	O
secondary	O
to	O
steroids	O
inhalation	O
.	O

Vocal	O
cords	O
stiffness	O
can	O
be	O
associated	O
with	O
a	O
variety	O
of	O
etiologic	O
agents	O
,	O
but	O
it	O
is	O
rarely	O
seen	O
with	O
atypical	O
mycobacteria	O
,	O
for	O
example	O
,	O
Mycobacterium	O
avium	O
complex	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
white	O
woman	O
who	O
is	O
and	O
was	O
maintained	O
on	O
inhaled	O
steroids	O
.	O

She	O
presented	O
with	O
hoarseness	O
and	O
low	O
-	O
grade	O
fever	O
,	O
but	O
her	O
medical	O
history	O
was	O
otherwise	O
unremarkable	O
.	O

Laryngoscopy	O
revealed	O
bilateral	O
scarring	O
of	O
the	O
vocal	O
cords	O
.	O

Vocal	O
cord	O
biopsies	O
were	O
performed	O
.	O

Histologic	O
examination	O
revealed	O
unremarkable	O
laryngeal	O
mucosa	O
,	O
except	O
for	O
abundant	O
subepithelial	O
non	O
-	O
necrotizing	O
granulomata	O
.	O

The	O
differential	O
diagnosis	O
included	O
sarcoid	O
,	O
Klebsiella	O
scleroma	O
,	O
and	O
tuberculosis	O
.	O

Special	O
stains	O
reviewed	O
abundant	O
acid	O
-	O
fast	O
bacilli	O
,	O
later	O
confirmed	O
by	O
a	O
DNA	O
assay	O
on	O
induced	O
deep	O
sputum	O
,	O
consistent	O
with	O
M	O
avium	O
complex	O
.	O

Subsequently	O
,	O
steroids	O
were	O
withdrawn	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
a	O
multiple	O
-	O
drug	O
antituberculous	O
regimen	O
and	O
had	O
a	O
full	O
recovery	O
.	O

This	O
unusual	O
clinical	O
presentation	O
of	O
the	O
atypical	O
mycobacteriosis	O
may	O
be	O
encountered	O
by	O
otolaryngologists	O
and	O
pathologists	O
,	O
and	O
it	O
is	O
critical	O
to	O
recognize	O
it	O
in	O
patients	O
immunocompromised	O
because	O
of	O
steroids	O
.	O

A	O
novel	O
integrin	O
alpha5beta1	O
antagonistic	O
peptide	O
,	O
A5	O
-	O
1	O
,	O
screened	O
by	O
Protein	O
Chip	O
system	O
as	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

Integrin	O
alpha5beta1	O
immobilized	O
on	O
a	O
ProteoChip	O
was	O
used	O
to	O
screen	O
new	O
antagonistic	O
peptides	O
from	O
multiple	O
hexapeptide	O
sub	O
-	O
libraries	O
of	O
the	O
positional	O
scanning	O
synthetic	O
peptide	O
combinatorial	O
library	O
(	O
PS	O
-	O
SPCL	O
)	O
.	O

The	O
integrin	O
alpha5beta1	O
-	O
Fibronectin	O
interaction	O
was	O
demonstrated	O
on	O
the	O
chip	O
.	O

A	O
novel	O
peptide	O
ligand	O
,	O
A5	O
-	O
1	O
(	O
VILVLF	O
)	O
,	O
with	O
high	O
affinity	O
to	O
integrin	O
alpha5beta1	O
was	O
identified	O
from	O
the	O
hexapeptide	O
libraries	O
with	O
this	O
chip	O
-	O
based	O
screening	O
method	O
on	O
the	O
basis	O
of	O
a	O
competitive	O
inhibition	O
assay	O
.	O

A5	O
-	O
1	O
inhibits	O
the	O
integrin	O
-	O
fibronectin	O
interaction	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC	O
(	O
50	O
)	O
;	O
1	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
28	O
microM	O
.	O

In	O
addition	O
,	O
it	O
inhibits	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
,	O
tubular	O
network	O
formation	O
,	O
and	O
bFGF	O
-	O
induced	O
neovascularization	O
in	O
a	O
chick	O
chorioallantoic	O
membrane	O
.	O

These	O
results	O
suggest	O
that	O
A5	O
-	O
1	O
will	O
be	O
a	O
potent	O
inhibitor	O
of	O
neovascularization	O
.	O

Are	O
former	O
female	O
elite	O
athletes	O
more	O
likely	O
to	O
experience	O
urinary	O
incontinence	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
?	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
former	O
female	O
elite	O
athletes	O
are	O
more	O
likely	O
to	O
experience	O
urinary	O
incontinence	O
(	O
UI	O
)	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
and	O
to	O
assess	O
possible	O
risk	O
factors	O
for	O
UI	O
in	O
athletes	O
.	O

Three	O
hundred	O
and	O
thirty	O
-	O
one	O
former	O
elite	O
athletes	O
(	O
response	O
rate	O
81	O
%	O
)	O
and	O
640	O
controls	O
replied	O
to	O
a	O
postal	O
questionnaire	O
including	O
validated	O
questions	O
on	O
UI	O
.	O

While	O
competing	O
in	O
sport	O
,	O
10	O
.	O
9	O
%	O
and	O
2	O
.	O
7	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
reported	O
stress	O
urinary	O
incontinence	O
(	O
SUI	O
)	O
and	O
urge	O
incontinence	O
,	O
respectively	O
.	O

Presently	O
,	O
36	O
.	O
5	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
and	O
36	O
.	O
9	O
%	O
of	O
the	O
controls	O
reported	O
SUI	O
.	O

9	O
.	O
1	O
%	O
and	O
9	O
.	O
4	O
%	O
reported	O
urge	O
incontinence	O
.	O

Among	O
former	O
elite	O
athletes	O
,	O
those	O
with	O
two	O
or	O
three	O
children	O
were	O
more	O
likely	O
than	O
nulliparous	O
women	O
to	O
have	O
UI	O
now	O
.	O

Also	O
,	O
among	O
former	O
athletes	O
,	O
UI	O
was	O
more	O
common	O
in	O
women	O
with	O
vs	O
those	O
without	O
UI	O
while	O
competing	O
(	O
odds	O
ratio	O
8	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
55	O
-	O
20	O
.	O
71	O
)	O
.	O

Age	O
,	O
menopause	O
and	O
being	O
regularly	O
physically	O
active	O
now	O
were	O
not	O
associated	O
with	O
UI	O
in	O
either	O
group	O
.	O

Based	O
on	O
this	O
study	O
,	O
the	O
prevalence	O
of	O
UI	O
does	O
not	O
seem	O
to	O
be	O
higher	O
in	O
former	O
athletes	O
than	O
in	O
controls	O
.	O

However	O
,	O
the	O
results	O
indicate	O
that	O
UI	O
early	O
in	O
life	O
,	O
as	O
reported	O
during	O
elite	O
sport	O
,	O
is	O
a	O
strong	O
predictor	O
of	O
UI	O
later	O
in	O
life	O
.	O

Evaluation	O
of	O
electrical	O
stimulation	O
for	O
ischemic	O
wound	O
therapy	O
:	O
a	O
feasibility	O
study	O
using	O
the	O
lapine	O
wound	O
model	O
.	O

Chronic	O
wounds	O
are	O
a	O
major	O
secondary	O
complication	O
for	O
many	O
people	O
with	O
impaired	O
mobility	O
.	O

Electrical	O
stimulation	O
(	O
ES	O
)	O
has	O
been	O
recommended	O
as	O
a	O
adjunctive	O
therapy	O
,	O
however	O
optimal	O
treatment	O
paradigms	O
have	O
not	O
been	O
established	O
.	O

Our	O
group	O
seeks	O
to	O
determine	O
the	O
basic	O
mechanisms	O
underlying	O
ES	O
wound	O
therapy	O
,	O
an	O
area	O
where	O
understanding	O
is	O
currently	O
limited	O
.	O

A	O
feasibility	O
study	O
was	O
carried	O
out	O
to	O
develop	O
the	O
Ahn	O
/	O
Mustoe	O
lapine	O
wound	O
model	O
for	O
systematic	O
investigation	O
of	O
the	O
effects	O
of	O
electrical	O
stimulation	O
on	O
ischemic	O
wound	O
therapy	O
.	O

A	O
standardized	O
surgical	O
procedure	O
incorporated	O
a	O
hybrid	O
stimulation	O
system	O
comprising	O
an	O
implantable	O
mini	O
-	O
stimulator	O
and	O
surface	O
electrodes	O
,	O
with	O
creation	O
of	O
repeatable	O
ischemic	O
wounds	O
.	O

Twenty	O
mature	O
male	O
New	O
Zealand	O
white	O
rabbits	O
(	O
3	O
kg	O
weight	O
)	O
were	O
employed	O
to	O
evaluate	O
the	O
effects	O
of	O
two	O
empirically	O
selected	O
stimulation	O
paradigms	O
applied	O
continuously	O
for	O
7	O
-	O
21	O
days	O
,	O
using	O
each	O
animal	O
as	O
its	O
own	O
control	O
.	O

Outcomes	O
measures	O
included	O
transcutaneous	O
blood	O
gas	O
levels	O
,	O
histology	O
,	O
total	O
RNA	O
content	O
and	O
analysis	O
of	O
alpha2	O
(	O
I	O
)	O
collagen	O
(	O
COL	O
-	O
I	O
)	O
,	O
type	O
IV	O
collagen	O
(	O
COL	O
-	O
IV	O
)	O
,	O
alpha1	O
(	O
V	O
)	O
collagen	O
(	O
COL	O
-	O
V	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
.	O

All	O
markers	O
for	O
stimulated	O
wounds	O
showed	O
increased	O
activity	O
relative	O
to	O
non	O
-	O
stimulated	O
control	O
wounds	O
between	O
7	O
and	O
14	O
days	O
following	O
injury	O
,	O
with	O
peak	O
activity	O
at	O
14	O
days	O
.	O

By	O
21	O
days	O
post	O
-	O
injury	O
,	O
all	O
activity	O
had	O
returned	O
to	O
near	O
baseline	O
level	O
.	O

VEGF	O
and	O
COL	O
-	O
IV	O
levels	O
were	O
found	O
to	O
be	O
significantly	O
higher	O
for	O
pattern	O
A	O
(	O
110	O
mus	O
pulse	O
width	O
)	O
compared	O
to	O
pattern	O
B	O
(	O
5	O
mus	O
pulse	O
width	O
)	O
at	O
14	O
days	O
,	O
implying	O
that	O
pattern	O
A	O
may	O
be	O
more	O
effective	O
at	O
promoting	O
angiogenesis	O
.	O

All	O
wounds	O
were	O
fully	O
re	O
-	O
epithelialized	O
by	O
10	O
days	O
post	O
-	O
injury	O
.	O

Both	O
COL	O
-	O
I	O
and	O
COL	O
-	O
V	O
showed	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
increased	O
activity	O
between	O
day	O
7	O
and	O
day	O
14	O
for	O
pattern	O
A	O
,	O
potentially	O
indicating	O
a	O
continued	O
effect	O
on	O
matrix	O
remodeling	O
.	O

The	O
early	O
closure	O
of	O
all	O
wounds	O
implies	O
that	O
the	O
rabbit	O
ear	O
model	O
may	O
not	O
be	O
valid	O
for	O
chronic	O
wound	O
studies	O
.	O

VEGF	O
,	O
angiopoietin	O
-	O
1	O
and	O
-	O
2	O
in	O
bronchial	O
asthma	O
:	O
new	O
molecular	O
targets	O
in	O
airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
.	O

Airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
are	O
known	O
features	O
of	O
bronchial	O
asthma	O
,	O
but	O
the	O
mechanisms	O
of	O
these	O
structural	O
alterations	O
are	O
just	O
beginning	O
to	O
be	O
elucidated	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
angiogenic	O
factors	O
,	O
stimulates	O
endothelial	O
cell	O
proliferation	O
and	O
induces	O
the	O
angiogenesis	O
.	O

Recently	O
,	O
considerable	O
attentions	O
have	O
been	O
devoted	O
to	O
the	O
physiological	O
roles	O
of	O
angiopoietin	O
(	O
Ang	O
)	O
-	O
1	O
and	O
-	O
2	O
as	O
regulatory	O
factors	O
of	O
VEGF	O
.	O

Ang	O
-	O
1	O
has	O
been	O
shown	O
to	O
induce	O
the	O
migration	O
and	O
sprouting	O
of	O
endothelial	O
cells	O
,	O
and	O
coexpression	O
of	O
Ang	O
-	O
1	O
and	O
VEGF	O
enhanced	O
angiogenesis	O
.	O

In	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
,	O
Ang	O
-	O
2	O
also	O
promotes	O
rapid	O
increase	O
in	O
capillary	O
diameter	O
,	O
remodeling	O
of	O
the	O
basal	O
lamina	O
,	O
proliferation	O
and	O
migration	O
of	O
endothelial	O
cells	O
,	O
and	O
stimulates	O
sprouting	O
of	O
new	O
blood	O
vessels	O
.	O

Thus	O
,	O
VEGF	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
may	O
play	O
complementary	O
and	O
coordinated	O
roles	O
in	O
airway	O
angiogenesis	O
and	O
microvascular	O
remodeling	O
,	O
and	O
these	O
structural	O
changes	O
are	O
potentially	O
reversible	O
by	O
therapeutic	O
intervention	O
.	O

The	O
scope	O
of	O
the	O
present	O
review	O
is	O
to	O
discuss	O
from	O
a	O
clinical	O
point	O
of	O
view	O
the	O
potential	O
interactions	O
between	O
VEGF	O
and	O
angiopoietins	O
in	O
the	O
asthmatic	O
airways	O
,	O
and	O
focus	O
on	O
the	O
therapeutic	O
implications	O
targeting	O
for	O
these	O
angiogenic	O
factors	O
.	O

Recently	O
,	O
there	O
is	O
an	O
increasing	O
number	O
of	O
patents	O
which	O
have	O
been	O
focused	O
on	O
the	O
inhibitors	O
of	O
VEGF	O
action	O
.	O

These	O
inhibitors	O
are	O
directed	O
towards	O
the	O
receptors	O
of	O
VEGF	O
or	O
intracellular	O
substrates	O
for	O
the	O
receptors	O
.	O

We	O
will	O
also	O
discuss	O
several	O
patents	O
regarding	O
inhibitors	O
of	O
VEGF	O
action	O
in	O
the	O
present	O
review	O
.	O

Effect	O
of	O
transplanted	O
mesenchymal	O
stem	O
cells	O
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	O
function	O
after	O
acute	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
transplantation	O
is	O
of	O
therapeutic	O
potential	O
after	O
ischemic	O
injury	O
in	O
both	O
experimental	O
and	O
clinical	O
studies	O
.	O

Clinically	O
,	O
elderly	O
patients	O
are	O
more	O
vulnerable	O
to	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
.	O

But	O
little	O
is	O
known	O
about	O
the	O
characteristics	O
of	O
young	O
donor	O
-	O
derived	O
MSCs	O
transplanted	O
to	O
old	O
patients	O
with	O
AMI	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
transplanted	O
MSCs	O
from	O
rats	O
of	O
different	O
ages	O
on	O
the	O
improvement	O
of	O
heart	O
function	O
after	O
AMI	O
.	O

METHODS	O
:	O
MSCs	O
from	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
isolated	O
and	O
cultured	O
in	O
vitro	O
.	O

The	O
apoptosis	O
characteristics	O
of	O
MSCs	O
were	O
observed	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
.	O

SD	O
rats	O
underwent	O
MI	O
received	O
intramyocardial	O
injection	O
of	O
MSCs	O
from	O
young	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
old	O
donor	O
rats	O
(	O
n	O
=	O
8	O
)	O
,	O
respectively	O
.	O

AMI	O
control	O
group	O
received	O
equal	O
volume	O
physiological	O
saline	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
observe	O
the	O
differentiation	O
of	O
the	O
grafted	O
cells	O
into	O
cardiomyocytes	O
.	O

Four	O
weeks	O
after	O
cell	O
transplantation	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
immunohistochemistry	O
for	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
VIII	O
-	O
factor	O
immunohistochemistry	O
for	O
vessel	O
density	O
,	O
TUNEL	O
,	O
caspase	O
-	O
3	O
for	O
cardiomyocyte	O
apoptosis	O
,	O
echocardiography	O
and	O
hemodynamic	O
detection	O
for	O
heart	O
function	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
apoptosis	O
rate	O
of	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	O
group	O
under	O
conditions	O
of	O
ischemia	O
and	O
anoxia	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Engrafted	O
MSCs	O
survived	O
,	O
proliferated	O
and	O
differentiated	O
into	O
myocardium	O
-	O
like	O
cells	O
.	O

VEGF	O
gene	O
expression	O
and	O
capillary	O
density	O
in	O
the	O
old	O
donor	O
-	O
derived	O
group	O
were	O
lower	O
than	O
those	O
in	O
the	O
young	O
donor	O
-	O
derived	O
group	O
but	O
higher	O
than	O
those	O
in	O
the	O
control	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
transplantation	O
of	O
old	O
donor	O
-	O
derived	O
MSCs	O
attenuated	O
apoptosis	O
of	O
cardiomyocytes	O
in	O
the	O
peri	O
-	O
infarct	O
region	O
compared	O
with	O
the	O
control	O
group	O
and	O
the	O
effect	O
was	O
elevated	O
in	O
young	O
donor	O
-	O
derived	O
MSCs	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
heart	O
functions	O
(	O
left	O
ventricle	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
left	O
ventricle	O
fractional	O
shortening	O
(	O
LVFS	O
)	O
)	O
were	O
improved	O
more	O
significantly	O
in	O
the	O
old	O
donor	O
-	O
derived	O
MSCs	O
group	O
than	O
in	O
the	O
control	O
group	O
and	O
the	O
heart	O
function	O
in	O
the	O
young	O
donor	O
-	O
derived	O
MSCs	O
group	O
further	O
improved	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
Young	O
donor	O
-	O
derived	O
MSCs	O
can	O
improve	O
heart	O
function	O
significantly	O
through	O
angiogenesis	O
and	O
decreasing	O
cardiomyocyte	O
apoptosis	O
when	O
transplanted	O
to	O
the	O
infarcted	O
area	O
.	O

Clinical	O
significance	O
of	O
chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
expression	O
in	O
human	O
colorectal	O
cancer	O
.	O

Chicken	O
ovalbumin	O
upstream	O
promoter	O
-	O
transcription	O
factor	O
II	O
(	O
COUP	O
-	O
TFII	O
)	O
plays	O
an	O
essential	O
role	O
in	O
angiogenesis	O
and	O
development	O
.	O

A	O
previous	O
study	O
showed	O
that	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
enhanced	O
invasiveness	O
of	O
human	O
lung	O
carcinoma	O
cells	O
.	O

However	O
,	O
no	O
published	O
data	O
are	O
available	O
concerning	O
the	O
biological	O
and	O
clinical	O
significance	O
of	O
COUP	O
-	O
TFII	O
expression	O
in	O
colorectal	O
cancer	O
.	O

Thus	O
,	O
our	O
objective	O
was	O
to	O
explore	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
in	O
colorectal	O
cancer	O
as	O
well	O
as	O
its	O
association	O
with	O
clinicopathological	O
features	O
,	O
and	O
to	O
evaluate	O
the	O
role	O
of	O
COUP	O
-	O
TFII	O
as	O
a	O
prognostic	O
indicator	O
in	O
colorectal	O
cancer	O
.	O

We	O
investigated	O
the	O
presence	O
of	O
COUP	O
-	O
TFII	O
in	O
human	O
colorectal	O
cancer	O
tissues	O
and	O
adjacent	O
normal	O
tissues	O
from	O
95	O
primary	O
colorectal	O
cancer	O
patients	O
by	O
immunohistochemistry	O
.	O

The	O
correlation	O
between	O
the	O
expression	O
of	O
COUP	O
-	O
TFII	O
and	O
clinicopathologic	O
features	O
was	O
investigated	O
.	O

The	O
3	O
-	O
year	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
tumors	O
expressing	O
different	O
levels	O
of	O
COUP	O
-	O
TFII	O
were	O
evaluated	O
by	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
COUP	O
-	O
TFII	O
expression	O
and	O
age	O
at	O
surgery	O
,	O
gender	O
,	O
histopathologic	O
differentiation	O
,	O
vessel	O
invasion	O
,	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
,	O
or	O
nodal	O
involvement	O
.	O

However	O
,	O
survival	O
analysis	O
showed	O
that	O
the	O
COUP	O
-	O
TFII	O
-	O
positive	O
group	O
had	O
a	O
significantly	O
better	O
OS	O
compared	O
to	O
COUP	O
-	O
TFII	O
-	O
negative	O
group	O
(	O
80	O
.	O
4	O
%	O
vs	O
.	O
57	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
0491	O
)	O
.	O

Based	O
on	O
our	O
results	O
,	O
COUP	O
-	O
TFII	O
may	O
represent	O
a	O
biomarker	O
for	O
good	O
prognosis	O
in	O
colorectal	O
cancer	O
.	O

p53	O
hot	O
-	O
spot	O
mutants	O
increase	O
tumor	O
vascularization	O
via	O
ROS	O
-	O
mediated	O
activation	O
of	O
the	O
HIF1	O
/	O
VEGF	O
-	O
A	O
pathway	O
.	O

The	O
function	O
of	O
p53	O
tumor	O
suppressor	O
is	O
often	O
altered	O
in	O
various	O
human	O
tumors	O
predominantly	O
through	O
missense	O
-	O
mutations	O
resulting	O
in	O
accumulation	O
of	O
mutant	O
proteins	O
.	O

We	O
revealed	O
that	O
expression	O
of	O
p53	O
proteins	O
with	O
amino	O
-	O
acid	O
substitutions	O
at	O
codons	O
175	O
(	O
R175H	O
)	O
,	O
248	O
(	O
R248W	O
)	O
,	O
and	O
273	O
(	O
R273H	O
)	O
,	O
representing	O
the	O
hot	O
-	O
spots	O
of	O
mutations	O
in	O
various	O
human	O
tumors	O
,	O
increased	O
the	O
number	O
of	O
vessels	O
in	O
HCT116	B
human	O
colon	O
carcinoma	O
xenografts	O
and	O
,	O
as	O
a	O
result	O
,	O
accelerated	O
their	O
growth	O
.	O

Stimulation	O
of	O
tumor	O
angiogenesis	O
was	O
connected	O
with	O
about	O
2	O
-	O
fold	O
increase	O
in	O
intracellular	O
level	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

Antioxidant	O
N	O
-	O
acetyl	O
-	O
l	O
-	O
aspartate	O
(	O
NAC	O
)	O
decreased	O
vessels	O
number	O
in	O
tumors	O
formed	O
by	O
cells	O
with	O
inactivated	O
p53	O
and	O
inhibited	O
their	O
growth	O
.	O

Effect	O
of	O
ROS	O
on	O
angiogenesis	O
in	O
tumors	O
expressing	O
hot	O
-	O
spot	O
p53	O
mutants	O
was	O
correlated	O
with	O
their	O
ability	O
to	O
increase	O
a	O
content	O
of	O
HIF1	O
transcriptional	O
factor	O
responsible	O
for	O
up	O
-	O
regulation	O
of	O
VEGF	O
-	O
A	O
mRNAs	O
.	O

The	O
Akt	O
/	O
mTOR	O
pathway	O
assures	O
the	O
synthesis	O
of	O
HIF	O
-	O
1alpha	O
protein	O
in	O
a	O
glucose	O
-	O
and	O
reoxygenation	O
-	O
dependent	O
manner	O
in	O
irradiated	O
tumors	O
.	O

Transcriptional	O
activity	O
of	O
HIF	O
-	O
1	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
)	O
has	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
solid	O
tumors	O
after	O
ionizing	O
radiation	O
;	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
response	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
series	O
of	O
molecular	O
imaging	O
experiments	O
using	O
a	O
HIF	O
-	O
1	O
-	O
dependent	O
reporter	O
gene	O
,	O
5HREp	O
-	O
ODD	O
-	O
luc	O
,	O
and	O
found	O
an	O
essential	O
role	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
.	O

Hypoxic	O
tumor	O
cells	O
distant	O
from	O
blood	O
vessels	O
were	O
dramatically	O
reoxygenated	O
at	O
24	O
h	O
postirradiation	O
,	O
and	O
HIF	O
-	O
1	O
activity	O
increased	O
as	O
HIF	O
-	O
1alpha	O
accumulated	O
in	O
the	O
reoxygenated	O
regions	O
.	O

The	O
accumulation	O
was	O
inhibited	O
with	O
a	O
nonmetabolizable	O
glucose	O
analog	O
,	O
2	O
-	O
deoxy	O
-	O
d	O
-	O
glucose	O
,	O
through	O
the	O
suppression	O
of	O
radiation	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
in	O
the	O
reoxygenated	O
regions	O
.	O

Akt	O
knockdown	O
and	O
an	O
mTOR	O
inhibitor	O
revealed	O
the	O
importance	O
of	O
the	O
Akt	O
/	O
mTOR	O
pathway	O
in	O
the	O
postirradiation	O
accumulation	O
of	O
HIF	O
-	O
1alpha	O
.	O

In	O
vitro	O
experiments	O
confirmed	O
that	O
an	O
increase	O
in	O
glucose	O
availability	O
induced	O
Akt	O
phosphorylation	O
under	O
reoxygenated	O
conditions	O
and	O
consequently	O
up	O
-	O
regulated	O
HIF	O
-	O
1alpha	O
translation	O
.	O

Moreover	O
,	O
both	O
the	O
accelerated	O
translation	O
and	O
the	O
previously	O
reported	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
stabilization	O
of	O
HIF	O
-	O
1alpha	O
protein	O
were	O
essential	O
to	O
the	O
activation	O
of	O
HIF	O
-	O
1	O
.	O

All	O
of	O
these	O
results	O
indicate	O
that	O
Akt	O
/	O
mTOR	O
-	O
dependent	O
translation	O
of	O
HIF	O
-	O
1alpha	O
plays	O
a	O
critical	O
role	O
in	O
the	O
postirradiation	O
up	O
-	O
regulation	O
of	O
intratumoral	O
HIF	O
-	O
1	O
activity	O
in	O
response	O
to	O
radiation	O
-	O
induced	O
alterations	O
of	O
glucose	O
and	O
oxygen	O
availability	O
in	O
a	O
solid	O
tumor	O
.	O

Homeostatic	O
functions	O
of	O
the	O
p53	O
tumor	O
suppressor	O
:	O
regulation	O
of	O
energy	O
metabolism	O
and	O
antioxidant	O
defense	O
.	O

The	O
p53	O
tumor	O
suppressor	O
plays	O
pivotal	O
role	O
in	O
the	O
organism	O
by	O
supervising	O
strict	O
compliance	O
of	O
individual	O
cells	O
to	O
needs	O
of	O
the	O
whole	O
organisms	O
.	O

It	O
has	O
been	O
widely	O
accepted	O
that	O
p53	O
acts	O
in	O
response	O
to	O
stresses	O
and	O
abnormalities	O
in	O
cell	O
physiology	O
by	O
mobilizing	O
the	O
repair	O
processes	O
or	O
by	O
removing	O
the	O
diseased	O
cells	O
through	O
initiating	O
the	O
cell	O
death	O
programs	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
indicate	O
that	O
even	O
under	O
normal	O
physiological	O
conditions	O
certain	O
activities	O
of	O
p53	O
participate	O
in	O
homeostatic	O
regulation	O
of	O
metabolic	O
processes	O
and	O
that	O
these	O
activities	O
are	O
important	O
for	O
prevention	O
of	O
cancer	O
.	O

These	O
novel	O
functions	O
of	O
p53	O
help	O
to	O
align	O
metabolic	O
processes	O
with	O
the	O
proliferation	O
and	O
energy	O
status	O
,	O
to	O
maintain	O
optimal	O
mode	O
of	O
glucose	O
metabolism	O
and	O
to	O
boost	O
the	O
energy	O
efficient	O
mitochondrial	O
respiration	O
in	O
response	O
to	O
ATP	O
deficiency	O
.	O

Additional	O
activities	O
of	O
p53	O
in	O
non	O
-	O
stressed	O
cells	O
tune	O
up	O
the	O
antioxidant	O
defense	O
mechanisms	O
reducing	O
the	O
probability	O
of	O
mutations	O
caused	O
by	O
DNA	O
oxidation	O
under	O
conditions	O
of	O
daily	O
stresses	O
.	O

The	O
deficiency	O
in	O
the	O
p53	O
-	O
mediated	O
regulation	O
of	O
glycolysis	O
and	O
mitochondrial	O
respiration	O
greatly	O
accounts	O
for	O
the	O
deficient	O
respiration	O
of	O
the	O
predominance	O
of	O
aerobic	O
glycolysis	O
in	O
cancer	O
cells	O
(	O
the	O
Warburg	O
effect	O
)	O
,	O
while	O
the	O
deficiency	O
in	O
the	O
p53	O
-	O
modulated	O
antioxidant	O
defense	O
mechanisms	O
contributes	O
to	O
mutagenesis	O
and	O
additionally	O
boosts	O
the	O
carcinogenesis	O
process	O
.	O

Estradiol	O
increases	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
human	O
breast	O
tissue	O
and	O
breast	O
cancer	O
in	O
vivo	O
.	O

IL	O
-	O
8	O
or	O
CXCL8	O
has	O
been	O
associated	O
with	O
tumor	O
angiogenesis	O
,	O
metastasis	O
,	O
and	O
poor	O
prognosis	O
in	O
breast	O
cancer	O
.	O

Estrogen	O
is	O
crucial	O
in	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O

Whether	O
sex	O
steroids	O
affect	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
breast	O
tissue	O
or	O
breast	O
cancer	O
is	O
not	O
known	O
.	O

Several	O
cell	O
types	O
in	O
a	O
tissue	O
secrete	O
IL	O
-	O
8	O
.	O

Hence	O
,	O
regulatory	O
mechanisms	O
of	O
IL	O
-	O
8	O
need	O
to	O
be	O
investigated	O
in	O
whole	O
tissue	O
.	O

We	O
used	O
microdialysis	O
to	O
sample	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	O
tissue	O
in	O
situ	O
in	O
pre	O
-	O
and	O
postmenopausal	O
women	O
,	O
preoperatively	O
in	O
breast	O
cancers	O
of	O
women	O
,	O
and	O
in	O
experimental	O
breast	O
cancer	O
in	O
mice	O
.	O

We	O
found	O
a	O
significant	O
positive	O
correlation	O
between	O
IL	O
-	O
8	O
and	O
estradiol	O
in	O
normal	O
breast	O
tissue	O
and	O
hormone	O
-	O
dependent	O
breast	O
cancer	O
in	O
vivo	O
.	O

Ex	O
vivo	O
,	O
estradiol	O
exposure	O
increased	O
the	O
IL	O
-	O
8	O
secretion	O
of	O
normal	O
whole	O
breast	O
tissue	O
in	O
culture	O
.	O

In	O
experimental	O
breast	O
cancer	O
,	O
estradiol	O
increased	O
IL	O
-	O
8	O
whereas	O
the	O
anti	O
-	O
estrogen	O
tamoxifen	O
inhibited	O
the	O
secretion	O
of	O
IL	O
-	O
8	O
both	O
in	O
vitro	O
and	O
extracellularly	O
in	O
vivo	O
in	O
tumors	O
of	O
nude	O
mice	O
.	O

An	O
anti	O
-	O
IL	O
-	O
8	O
Ab	O
inhibited	O
endothelial	O
cell	O
proliferation	O
induced	O
by	O
cancer	O
cell	O
produced	O
IL	O
-	O
8	O
and	O
tumors	O
with	O
low	O
IL	O
-	O
8	O
levels	O
exhibited	O
decreased	O
angiogenesis	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
estradiol	O
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
IL	O
-	O
8	O
in	O
normal	O
human	O
breast	O
tissue	O
and	O
human	O
breast	O
cancer	O
.	O

IL	O
-	O
8	O
may	O
present	O
a	O
novel	O
therapeutic	O
target	O
for	O
estrogen	O
driven	O
breast	O
carcinogenesis	O
and	O
tumor	O
progression	O
.	O

Involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
cerebral	O
cavernous	O
malformations	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	O
cavernous	O
malformations	O
(	O
CCMs	O
)	O
are	O
prevalent	O
cerebral	O
vascular	O
lesions	O
involving	O
aberrant	O
angiogenesis	O
.	O

However	O
,	O
the	O
underlying	O
mechanism	O
is	O
poorly	O
understood	O
.	O

Phosphatase	O
and	O
tension	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
,	O
a	O
tumor	O
suppressor	O
,	O
is	O
frequently	O
deficient	O
in	O
various	O
pathologies	O
due	O
to	O
mutation	O
or	O
epigenetic	O
alterations	O
.	O

PTEN	O
promoter	O
hypermethylation	O
is	O
a	O
major	O
epigenetic	O
silencing	O
mechanism	O
leading	O
to	O
activation	O
of	O
angiogenesis	O
in	O
tumors	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
PTEN	O
promoter	O
methylation	O
was	O
involved	O
in	O
CCMs	O
.	O

METHODS	O
:	O
PTEN	O
promoter	O
methylation	O
was	O
detected	O
in	O
surgical	O
specimens	O
of	O
CCMs	O
(	O
n	O
=	O
69	O
)	O
by	O
methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

The	O
methylation	O
status	O
was	O
correlated	O
to	O
the	O
clinical	O
manifestations	O
and	O
to	O
PTEN	O
expression	O
,	O
which	O
was	O
analyzed	O
by	O
both	O
Western	O
blot	O
and	O
immunohistochemistry	O
.	O

To	O
investigate	O
the	O
endothelial	O
proliferation	O
and	O
the	O
potential	O
signaling	O
pathways	O
affected	O
by	O
PTEN	O
methylation	O
,	O
proliferating	O
cell	O
nuclear	O
antigen	O
as	O
well	O
as	O
phosphor	O
-	O
Akt	O
and	O
phosphor	O
-	O
Erk1	O
,	O
2	O
were	O
detected	O
by	O
immunofluorescence	O
and	O
Western	O
blot	O
,	O
respectively	O
,	O
in	O
CCM	O
specimens	O
.	O

RESULTS	O
:	O
Methylation	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
revealed	O
PTEN	O
promoter	O
methylation	O
in	O
15	O
.	O
9	O
%	O
CCMs	O
.	O

Strikingly	O
,	O
5	O
of	O
6	O
familial	O
CCMs	O
showed	O
PTEN	O
promoter	O
methylation	O
(	O
83	O
.	O
3	O
%	O
)	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
in	O
sporadic	O
cases	O
(	O
9	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
addition	O
,	O
PTEN	O
promoter	O
methylation	O
appeared	O
more	O
frequently	O
in	O
multiple	O
CCMs	O
,	O
including	O
familial	O
cases	O
(	O
46	O
.	O
7	O
%	O
)	O
,	O
than	O
that	O
in	O
single	O
-	O
lesioned	O
CCMs	O
(	O
11	O
.	O
8	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Immunostaining	O
and	O
Western	O
blot	O
revealed	O
a	O
more	O
significant	O
PTEN	O
downregulation	O
in	O
PTEN	O
-	O
methylated	O
CCMs	O
in	O
comparison	O
to	O
PTEN	O
-	O
unmethylated	O
CCMs	O
.	O

Reduced	O
PTEN	O
expression	O
was	O
inversely	O
correlated	O
to	O
the	O
expression	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
and	O
to	O
the	O
activation	O
of	O
Erk1	O
,	O
2	O
,	O
but	O
not	O
of	O
Akt	O
.	O

CONCLUSIONS	O
:	O
We	O
reported	O
here	O
for	O
the	O
first	O
time	O
the	O
involvement	O
of	O
PTEN	O
promoter	O
methylation	O
in	O
CCMs	O
,	O
particularly	O
in	O
familial	O
CCMs	O
,	O
suggesting	O
this	O
epigenetic	O
alteration	O
as	O
a	O
potential	O
pathomechanism	O
of	O
CCMs	O
.	O

The	O
identification	O
of	O
Erk1	O
,	O
2	O
as	O
triggered	O
signaling	O
in	O
the	O
lesions	O
may	O
be	O
valuable	O
for	O
the	O
development	O
of	O
effective	O
therapy	O
for	O
this	O
disease	O
.	O

Grape	O
seed	O
extract	O
inhibits	O
angiogenesis	O
via	O
suppression	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Blockade	O
of	O
angiogenesis	O
is	O
an	O
important	O
approach	O
for	O
cancer	O
treatment	O
and	O
prevention	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
one	O
of	O
the	O
most	O
critical	O
factors	O
that	O
induce	O
angiogenesis	O
and	O
has	O
thus	O
become	O
an	O
attractive	O
target	O
for	O
antiangiogenesis	O
treatment	O
.	O

However	O
,	O
most	O
current	O
anti	O
-	O
VEGF	O
agents	O
often	O
cause	O
some	O
side	O
effects	O
when	O
given	O
chronically	O
.	O

Identification	O
of	O
naturally	O
occurring	O
VEGF	O
inhibitors	O
derived	O
from	O
diet	O
would	O
be	O
one	O
alternative	O
approach	O
with	O
an	O
advantage	O
of	O
known	O
safety	O
.	O

Grape	O
seed	O
extract	O
(	O
GSE	O
)	O
,	O
a	O
widely	O
used	O
dietary	O
supplement	O
,	O
is	O
known	O
to	O
have	O
antitumor	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
activity	O
of	O
GSE	O
on	O
VEGF	O
receptor	O
and	O
angiogenesis	O
.	O

We	O
found	O
that	O
GSE	O
could	O
directly	O
inhibit	O
the	O
kinase	O
activity	O
of	O
purified	O
VEGF	O
receptor	O
2	O
,	O
a	O
novel	O
activity	O
of	O
GSE	O
that	O
has	O
not	O
been	O
characterized	O
.	O

GSE	O
could	O
also	O
inhibit	O
the	O
VEGF	O
receptor	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
-	O
mediated	O
signaling	O
pathway	O
in	O
endothelial	O
cells	O
.	O

As	O
a	O
result	O
,	O
GSE	O
could	O
inhibit	O
VEGF	O
-	O
induced	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
as	O
well	O
as	O
sprout	O
formation	O
from	O
aorta	O
ring	O
.	O

In	O
vivo	O
assay	O
further	O
showed	O
that	O
GSE	O
could	O
inhibit	O
tumor	O
growth	O
and	O
tumor	O
angiogenesis	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
breast	O
cancer	O
cells	O
in	O
mice	O
.	O

Consistent	O
with	O
the	O
in	O
vitro	O
data	O
,	O
GSE	O
treatment	O
of	O
tumor	O
-	O
bearing	O
mice	O
led	O
to	O
concomitant	O
reduction	O
of	O
blood	O
vessel	O
density	O
and	O
phosphorylation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

Depletion	O
of	O
polyphenol	O
with	O
polyvinylpyrrolidone	O
abolished	O
the	O
antiangiogenic	O
activity	O
of	O
GSE	O
,	O
suggesting	O
a	O
water	O
-	O
soluble	O
fraction	O
of	O
polyphenol	O
in	O
GSE	O
is	O
responsible	O
for	O
the	O
antiangiogenic	O
activity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
GSE	O
is	O
a	O
well	O
-	O
tolerated	O
and	O
inexpensive	O
natural	O
VEGF	O
inhibitor	O
and	O
could	O
potentially	O
be	O
useful	O
in	O
cancer	O
prevention	O
or	O
treatment	O
.	O

Chemokine	O
receptor	O
CXCR4	O
expression	O
,	O
function	O
,	O
and	O
clinical	O
implications	O
in	O
gastric	O
cancer	O
.	O

The	O
chemokine	O
receptor	O
CXCR4	O
is	O
associated	O
with	O
the	O
biological	O
behavior	O
of	O
cancer	O
,	O
but	O
few	O
studies	O
have	O
addressed	O
the	O
expression	O
and	O
function	O
of	O
CXCR4	O
in	O
human	O
gastric	O
cancer	O
and	O
its	O
impact	O
on	O
disease	O
prognosis	O
.	O

We	O
studied	O
the	O
expression	O
of	O
CXCR4	O
using	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
,	O
flow	O
cytometry	O
,	O
and	O
confocal	O
microscopy	O
in	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O

We	O
also	O
examined	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
anti	O
-	O
apoptotic	O
activity	O
in	O
response	O
to	O
stromal	O
cell	O
-	O
derived	O
factor	O
(	O
SDF	O
)	O
-	O
1alpha	O
and	O
evaluated	O
SDF	O
-	O
1alpha	O
/	O
CXCR4	O
signaling	O
pathways	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
correlation	O
between	O
CXCR4	O
expression	O
and	O
the	O
clinical	O
features	O
of	O
221	O
gastric	O
cancer	O
tissue	O
samples	O
.	O

CXCR4	O
transcripts	O
and	O
proteins	O
were	O
detectable	O
in	O
all	O
five	O
gastric	O
cancer	O
cell	O
lines	O
.	O

However	O
,	O
MKN	B
-	I
28	I
,	O
MKN	B
-	I
45	I
,	O
MKN	B
-	I
74	I
,	O
and	O
SNU16	B
cells	O
did	O
not	O
express	O
membrane	O
CXCR4	O
.	O

In	O
contrast	O
,	O
KATO	B
III	I
cells	O
expressed	O
membrane	O
CXCR4	O
.	O

In	O
these	O
cells	O
,	O
SDF	O
-	O
1alpha	O
-	O
induced	O
migration	O
was	O
observed	O
and	O
was	O
blocked	O
by	O
AMD3100	O
,	O
a	O
specific	O
inhibitor	O
of	O
CXCR4	O
.	O

SDF	O
-	O
1alpha	O
induced	O
rapid	O
phosphorylation	O
of	O
Erk1	O
/	O
2	O
MAPK	O
but	O
did	O
not	O
promote	O
phosphorylation	O
of	O
Stat3	O
or	O
Akt	O
.	O

Gastric	O
cancer	O
tissue	O
samples	O
expressed	O
CXCR4	O
with	O
variable	O
intensities	O
.	O

Strong	O
CXCR4	O
expression	O
was	O
significantly	O
associated	O
with	O
lymph	O
node	O
metastases	O
(	O
P	O
=	O
0	O
.	O
028	O
)	O
and	O
higher	O
stages	O
III	O
/	O
IV	O
(	O
P	O
=	O
0	O
.	O
047	O
)	O
,	O
and	O
further	O
tended	O
to	O
be	O
correlated	O
with	O
a	O
reduced	O
5	O
-	O
year	O
survival	O
rate	O
(	O
42	O
.	O
6	O
%	O
vs	O
.	O
53	O
.	O
9	O
%	O
;	O
P	O
=	O
0	O
.	O
1	O
)	O
.	O

In	O
conclusion	O
,	O
CXCR4	O
expression	O
is	O
associated	O
with	O
gastric	O
cancer	O
cell	O
migration	O
in	O
vitro	O
,	O
and	O
strong	O
expression	O
of	O
CXCR4	O
by	O
gastric	O
cancer	O
cells	O
is	O
significantly	O
associated	O
with	O
lymphatic	O
metastasis	O
in	O
patients	O
with	O
gastric	O
cancer	O
,	O
suggesting	O
that	O
CXCR4	O
plays	O
an	O
important	O
role	O
during	O
gastric	O
cancer	O
progression	O
.	O

Effect	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
wound	O
healing	O
.	O

Age	O
-	O
related	O
impaired	O
wound	O
healing	O
leads	O
to	O
substantial	O
morbidity	O
and	O
mortality	O
along	O
with	O
a	O
large	O
financial	O
burden	O
to	O
health	O
services	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
the	O
tissue	O
damage	O
associated	O
with	O
chronic	O
wounds	O
is	O
initiated	O
and	O
propagated	O
by	O
an	O
inappropriately	O
excessive	O
inflammatory	O
response	O
.	O

Research	O
on	O
age	O
-	O
related	O
impaired	O
wound	O
healing	O
suggests	O
that	O
the	O
decline	O
in	O
sex	O
steroid	O
hormones	O
with	O
age	O
may	O
have	O
a	O
substantial	O
influence	O
on	O
the	O
inflammatory	O
response	O
in	O
vivo	O
.	O

Topical	O
and	O
systemic	O
estrogen	O
treatments	O
have	O
shown	O
an	O
increased	O
rate	O
of	O
healing	O
by	O
reducing	O
inflammation	O
,	O
however	O
the	O
underlying	O
mechanisms	O
are	O
little	O
understood	O
.	O

In	O
vitro	O
studies	O
also	O
suggest	O
progesterone	O
may	O
play	O
a	O
role	O
in	O
modulating	O
inflammation	O
.	O

Macrophages	O
are	O
essential	O
mediators	O
of	O
inflammation	O
and	O
wound	O
healing	O
.	O

Macrophages	O
can	O
be	O
activated	O
in	O
a	O
classical	O
or	O
alternative	O
manner	O
in	O
parallel	O
with	O
the	O
T	O
(	O
H	O
)	O
1	O
/	O
T	O
(	O
H	O
)	O
2	O
dichotomy	O
,	O
respectively	O
.	O

Using	O
a	O
murine	O
incisional	O
wound	O
healing	O
model	O
this	O
study	O
was	O
carried	O
out	O
to	O
investigate	O
the	O
roles	O
of	O
estrogen	O
and	O
progesterone	O
on	O
macrophage	O
activation	O
during	O
the	O
wound	O
healing	O
response	O
.	O

Our	O
findings	O
suggest	O
with	O
a	O
reduction	O
of	O
steroid	O
hormones	O
following	O
ovariectomy	O
,	O
alternatively	O
activated	O
macrophage	O
markers	O
(	O
Fizz1	O
and	O
Ym1	O
)	O
were	O
reduced	O
,	O
with	O
this	O
effect	O
being	O
reversed	O
with	O
the	O
administration	O
of	O
estrogen	O
or	O
progesterone	O
;	O
suggesting	O
that	O
with	O
the	O
reduction	O
of	O
steroid	O
hormones	O
macrophages	O
are	O
activated	O
in	O
a	O
classical	O
manner	O
,	O
promoting	O
inflammation	O
,	O
whereas	O
estrogen	O
or	O
progesterone	O
are	O
contributing	O
toward	O
macrophage	O
activation	O
in	O
an	O
alternative	O
manner	O
,	O
driving	O
wound	O
repair	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O

Heart	O
sound	O
and	O
electrocardiogram	O
recording	O
devices	O
for	O
telemedicine	O
environments	O
.	O

There	O
is	O
currently	O
a	O
worldwide	O
trend	O
to	O
bring	O
healthcare	O
services	O
as	O
close	O
as	O
possible	O
to	O
the	O
patient	O
,	O
either	O
through	O
home	O
healthcare	O
systems	O
,	O
or	O
telemedicine	O
.	O

There	O
is	O
thus	O
a	O
general	O
need	O
for	O
equipment	O
that	O
can	O
capture	O
patient	O
data	O
electronically	O
for	O
automated	O
review	O
or	O
analysis	O
by	O
a	O
medical	O
practitioner	O
.	O

This	O
paper	O
presents	O
prototype	O
systems	O
that	O
were	O
developed	O
with	O
the	O
ultimate	O
aim	O
for	O
use	O
in	O
telemedicine	O
settings	O
in	O
rural	O
Africa	O
.	O

These	O
devices	O
can	O
be	O
used	O
to	O
electronically	O
capture	O
data	O
on	O
patients	O
from	O
several	O
sensors	O
in	O
a	O
quick	O
an	O
easy	O
manner	O
.	O

In	O
our	O
presented	O
cases	O
we	O
focus	O
on	O
cardiovascular	O
information	O
.	O

One	O
of	O
the	O
main	O
advantages	O
of	O
the	O
proposed	O
systems	O
is	O
that	O
the	O
data	O
are	O
captured	O
simultaneously	O
from	O
multiple	O
sensors	O
.	O

The	O
data	O
can	O
be	O
stored	O
and	O
sent	O
electronically	O
for	O
review	O
and	O
analysis	O
,	O
and	O
knowledge	O
-	O
based	O
systems	O
or	O
neural	O
network	O
type	O
models	O
can	O
be	O
used	O
in	O
the	O
future	O
for	O
semi	O
-	O
autonomous	O
screening	O
of	O
the	O
recordings	O
,	O
before	O
a	O
patient	O
is	O
referred	O
to	O
a	O
specialist	O
.	O

Effect	O
of	O
platelet	O
-	O
rich	O
plasma	O
and	O
fibrin	O
glue	O
on	O
healing	O
of	O
critical	O
-	O
size	O
calvarial	O
bone	O
defects	O
.	O

Despite	O
the	O
insufficient	O
number	O
of	O
experimental	O
studies	O
,	O
platelet	O
-	O
rich	O
plasma	O
(	O
PRP	O
)	O
including	O
high	O
amounts	O
of	O
growth	O
factors	O
is	O
introduced	O
to	O
clinical	O
use	O
rapidly	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effects	O
of	O
PRP	O
and	O
platelet	O
-	O
poor	O
plasma	O
(	O
PPP	O
)	O
on	O
healing	O
of	O
critical	O
-	O
size	O
bone	O
defects	O
.	O
Bilateral	O
full	O
-	O
thickness	O
,	O
critical	O
-	O
size	O
bone	O
defects	O
were	O
created	O
in	O
the	O
parietal	O
bones	O
of	O
32	O
rabbits	O
,	O
which	O
had	O
been	O
studied	O
in	O
4	O
groups	O
.	O

Saline	O
,	O
thrombin	O
solution	O
,	O
PPP	O
,	O
and	O
PRP	O
were	O
applied	O
to	O
the	O
created	O
defects	O
before	O
closure	O
.	O

Radiologic	O
defect	O
area	O
measurement	O
results	O
at	O
0	O
,	O
4	O
,	O
and	O
16	O
weeks	O
were	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
densities	O
of	O
the	O
newly	O
formed	O
bones	O
at	O
16th	O
week	O
were	O
studied	O
.	O

Histologic	O
parameters	O
(	O
primary	O
and	O
secondary	O
bone	O
trabecula	O
,	O
neovascularization	O
,	O
and	O
bone	O
marrow	O
and	O
connective	O
tissue	O
formation	O
)	O
were	O
compared	O
between	O
4	O
-	O
and	O
16	O
-	O
week	O
groups	O
.	O
More	O
rapid	O
decrease	O
in	O
defect	O
size	O
was	O
observed	O
in	O
groups	O
3	O
and	O
4	O
than	O
in	O
groups	O
1	O
and	O
2	O
,	O
both	O
in	O
the	O
4th	O
and	O
16th	O
weeks	O
.	O

Newly	O
formed	O
bone	O
densities	O
were	O
also	O
found	O
to	O
be	O
higher	O
in	O
these	O
2	O
groups	O
.	O

New	O
bone	O
formation	O
was	O
detected	O
to	O
be	O
more	O
rapid	O
considering	O
histologic	O
parameters	O
,	O
in	O
groups	O
3	O
and	O
4	O
at	O
4th	O
and	O
16th	O
weeks	O
.	O
Study	O
demonstrates	O
that	O
PRP	O
and	O
PPP	O
might	O
have	O
favorable	O
effects	O
on	O
bone	O
healing	O
.	O

Although	O
we	O
can	O
not	O
reveal	O
any	O
statistical	O
difference	O
between	O
these	O
2	O
substances	O
considering	O
osteoinductive	O
potential	O
,	O
PRP	O
group	O
has	O
demonstrated	O
superior	O
results	O
compared	O
with	O
fibrin	O
glue	O
group	O
.	O

Higher	O
platelet	O
concentrations	O
may	O
expose	O
beneficial	O
effects	O
of	O
PRP	O
.	O

Host	O
-	O
derived	O
angiopoietin	O
-	O
2	O
affects	O
early	O
stages	O
of	O
tumor	O
development	O
and	O
vessel	O
maturation	O
but	O
is	O
dispensable	O
for	O
later	O
stages	O
of	O
tumor	O
growth	O
.	O

The	O
angiopoietin	O
/	O
Tie2	O
system	O
has	O
been	O
identified	O
as	O
the	O
second	O
vascular	O
-	O
specific	O
receptor	O
tyrosine	O
kinase	O
system	O
controlling	O
vessel	O
assembly	O
,	O
maturation	O
,	O
and	O
quiescence	O
.	O

Angiopoietin	O
-	O
2	O
(	O
Ang	O
-	O
2	O
)	O
is	O
prominently	O
up	O
-	O
regulated	O
in	O
the	O
host	O
-	O
derived	O
vasculature	O
of	O
most	O
tumors	O
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
antiangiogenic	O
intervention	O
.	O

Yet	O
,	O
the	O
net	O
outcome	O
of	O
Ang	O
-	O
2	O
functions	O
on	O
tumor	O
angiogenesis	O
is	O
believed	O
to	O
be	O
contextual	O
depending	O
on	O
the	O
local	O
cytokine	O
milieu	O
.	O

Correspondingly	O
,	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
have	O
been	O
shown	O
to	O
exert	O
protumorigenic	O
as	O
well	O
as	O
antitumorigenic	O
effects	O
.	O

To	O
clarify	O
the	O
role	O
of	O
Ang	O
-	O
2	O
for	O
angiogenesis	O
and	O
tumor	O
growth	O
in	O
a	O
definite	O
genetic	O
experimental	O
setting	O
,	O
the	O
present	O
study	O
was	O
aimed	O
at	O
comparatively	O
studying	O
the	O
growth	O
of	O
different	O
tumors	O
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O

Lewis	O
lung	O
carcinomas	O
,	O
MT	O
-	O
ret	O
melanomas	O
,	O
and	O
B16F10	B
melanomas	O
all	O
grew	O
slower	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
.	O

Yet	O
,	O
tumor	O
growth	O
in	O
wild	O
-	O
type	O
and	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
dissociated	O
during	O
early	O
stages	O
of	O
tumor	O
development	O
,	O
whereas	O
tumor	O
growth	O
rates	O
during	O
later	O
stages	O
of	O
primary	O
tumor	O
progression	O
were	O
similar	O
.	O

Analysis	O
of	O
the	O
intratumoral	O
vascular	O
architecture	O
revealed	O
no	O
major	O
differences	O
in	O
microvessel	O
density	O
and	O
perfusion	O
characteristics	O
.	O

However	O
,	O
diameters	O
of	O
intratumoral	O
microvessels	O
were	O
smaller	O
in	O
tumors	O
grown	O
in	O
Ang	O
-	O
2	O
-	O
deficient	O
mice	O
,	O
and	O
the	O
vasculature	O
had	O
an	O
altered	O
pattern	O
of	O
pericyte	O
recruitment	O
and	O
maturation	O
.	O

Ang	O
-	O
2	O
-	O
deficient	O
tumor	O
vessels	O
had	O
higher	O
pericyte	O
coverage	O
indices	O
.	O

Recruited	O
pericytes	O
were	O
desmin	O
and	O
NG2	O
positive	O
and	O
predominately	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
negative	O
,	O
indicative	O
of	O
a	O
more	O
mature	O
pericyte	O
phenotype	O
.	O

Collectively	O
,	O
the	O
experiments	O
define	O
the	O
role	O
of	O
Ang	O
-	O
2	O
during	O
tumor	O
angiogenesis	O
and	O
establish	O
a	O
better	O
rationale	O
for	O
combination	O
therapies	O
involving	O
Ang	O
-	O
2	O
manipulatory	O
therapies	O
.	O

Liposomal	O
honokiol	O
inhibits	O
VEGF	O
-	O
D	O
-	O
induced	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
xenograft	O
tumor	O
model	O
.	O

Lymph	O
nodes	O
metastasis	O
of	O
tumor	O
could	O
be	O
a	O
crucial	O
early	O
step	O
in	O
the	O
metastatic	O
process	O
.	O

Induction	O
of	O
tumor	O
lymphangiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
D	O
may	O
play	O
an	O
important	O
role	O
in	O
promoting	O
tumor	O
metastasis	O
to	O
regional	O
lymph	O
nodes	O
and	O
these	O
processes	O
can	O
be	O
inhibited	O
by	O
inactivation	O
of	O
the	O
VEGFR	O
-	O
3	O
signaling	O
pathway	O
.	O

Honokiol	O
has	O
been	O
reported	O
to	O
possess	O
potent	O
antiangiogenesis	O
and	O
antitumor	O
properties	O
in	O
several	O
cell	O
lines	O
and	O
xenograft	O
tumor	O
models	O
.	O

However	O
,	O
its	O
role	O
in	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
lymphatic	O
metastasis	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
established	O
lymph	O
node	O
metastasis	O
models	O
by	O
injecting	O
overexpressing	O
VEGF	O
-	O
D	O
Lewis	O
lung	O
carcinoma	O
cells	O
into	O
C57BL	O
/	O
6	O
mice	O
to	O
explore	O
the	O
effect	O
of	O
honokiol	O
on	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
related	O
lymph	O
node	O
metastasis	O
.	O

The	O
underlying	O
mechanisms	O
were	O
systematically	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
in	O
vivo	O
study	O
,	O
liposomal	O
honokiol	O
significantly	O
inhibited	O
the	O
tumor	O
-	O
associated	O
lymphangiogenesis	O
and	O
metastasis	O
in	O
Lewis	O
lung	O
carcinoma	O
model	O
.	O

A	O
remarkable	O
delay	O
of	O
tumor	O
growth	O
and	O
prolonged	O
life	O
span	O
were	O
also	O
observed	O
.	O

In	O
in	O
vitro	O
study	O
,	O
honokiol	O
inhibited	O
VEGF	O
-	O
D	O
-	O
induced	O
survival	O
,	O
proliferation	O
and	O
tube	O
-	O
formation	O
of	O
both	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
lymphatic	O
vascular	O
endothelial	O
cells	O
(	O
HLECs	B
)	O
.	O

Western	O
blotting	O
analysis	O
showed	O
that	O
liposomal	O
honokiol	O
-	O
inhibited	O
Akt	O
and	O
MAPK	O
phosphorylation	O
in	O
2	O
endothelial	O
cells	O
,	O
and	O
downregulated	O
expressions	O
of	O
VEGFR	O
-	O
2	O
of	O
human	O
vascular	O
endothelial	O
cells	O
and	O
VEGFR	O
-	O
3	O
of	O
lymphatic	O
endothelial	O
cells	O
.	O

Thus	O
,	O
we	O
identified	O
for	O
the	O
first	O
time	O
that	O
honokiol	O
provided	O
therapeutic	O
benefit	O
not	O
only	O
by	O
direct	O
effects	O
on	O
tumor	O
cells	O
and	O
antiangiogenesis	O
but	O
also	O
by	O
inhibiting	O
lymphangiogenesis	O
and	O
metastasis	O
via	O
the	O
VEGFR	O
-	O
3	O
pathway	O
.	O

The	O
present	O
findings	O
may	O
be	O
of	O
importance	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
spread	O
of	O
cancer	O
via	O
the	O
lymphatics	O
and	O
explore	O
the	O
therapeutical	O
strategy	O
of	O
honokiol	O
on	O
antilymphangiogenesis	O
and	O
antimetastasis	O
.	O

Short	O
pigment	O
epithelial	O
-	O
derived	O
factor	O
-	O
derived	O
peptide	O
inhibits	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

PURPOSE	O
:	O
Pigment	O
epithelial	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
with	O
multiple	O
other	O
functions	O
,	O
some	O
of	O
which	O
enhance	O
tumor	O
growth	O
.	O

Our	O
previous	O
studies	O
mapped	O
PEDF	O
antiangiogenic	O
and	O
prosurvival	O
activities	O
to	O
distinct	O
epitopes	O
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
minimal	O
fragment	O
of	O
PEDF	O
,	O
which	O
maintains	O
antiangiogenic	O
and	O
antitumor	O
efficacy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
analyzed	O
antigenicity	O
,	O
hydrophilicity	O
,	O
and	O
charge	O
distribution	O
of	O
the	O
angioinhibitory	O
epitope	O
(	O
the	O
34	O
-	O
mer	O
)	O
and	O
designed	O
three	O
peptides	O
covering	O
its	O
COOH	O
terminus	O
,	O
P14	O
,	O
P18	O
,	O
and	O
P23	O
.	O

We	O
analyzed	O
their	O
ability	O
to	O
block	O
endothelial	O
cell	O
chemotaxis	O
and	O
induce	O
apoptosis	O
in	O
vitro	O
and	O
their	O
antiangiogenic	O
activity	O
in	O
vivo	O
.	O

The	O
selected	O
peptide	O
was	O
tested	O
for	O
the	O
antitumor	O
activity	O
against	O
mildly	O
aggressive	O
xenografted	O
prostate	O
carcinoma	O
and	O
highly	O
aggressive	O
renal	O
cell	O
carcinoma	O
.	O

To	O
verify	O
that	O
P18	O
acts	O
in	O
the	O
same	O
manner	O
as	O
PEDF	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
measure	O
PEDF	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
and	O
CD95	O
ligand	O
expression	O
in	O
P18	O
-	O
treated	O
vasculature	O
.	O

RESULTS	O
:	O
P14	O
and	O
P18	O
blocked	O
endothelial	O
cell	O
chemotaxis	O
;	O
P18	O
and	O
P23	O
induced	O
apoptosis	O
.	O

P18	O
showed	O
the	O
highest	O
IC50	O
and	O
blocked	O
angiogenesis	O
in	O
vivo	O
:	O
P23	O
was	O
inactive	O
and	O
P14	O
was	O
proangiogenic	O
.	O

P18	O
increased	O
the	O
production	O
of	O
CD95	O
ligand	O
and	O
reduced	O
the	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
by	O
the	O
endothelial	O
cells	O
in	O
vivo	O
.	O

In	O
tumor	O
studies	O
,	O
P18	O
was	O
more	O
effective	O
in	O
blocking	O
the	O
angiogenesis	O
and	O
growth	O
of	O
the	O
prostate	O
cancer	O
than	O
parental	O
34	O
-	O
mer	O
;	O
in	O
the	O
renal	O
cell	O
carcinoma	O
,	O
P18	O
strongly	O
decreased	O
angiogenesis	O
and	O
halted	O
the	O
progression	O
of	O
established	O
tumors	O
.	O

CONCLUSIONS	O
:	O
P18	O
is	O
a	O
novel	O
and	O
potent	O
antiangiogenic	O
biotherapeutic	O
agent	O
that	O
has	O
potential	O
to	O
be	O
developed	O
for	O
the	O
treatment	O
of	O
prostate	O
and	O
renal	O
cancer	O
.	O

An	O
introduction	O
to	O
evidence	O
-	O
based	O
practice	O
for	O
hand	O
surgeons	O
and	O
therapists	O
.	O

Evidence	O
-	O
based	O
practice	O
is	O
a	O
methodical	O
approach	O
to	O
clinical	O
practice	O
where	O
experience	O
,	O
best	O
research	O
evidence	O
,	O
and	O
patient	O
goals	O
and	O
values	O
are	O
integrated	O
to	O
make	O
optimal	O
decisions	O
when	O
making	O
a	O
diagnosis	O
,	O
selecting	O
a	O
diagnostic	O
test	O
,	O
picking	O
an	O
intervention	O
or	O
determining	O
prognosis	O
.	O

There	O
are	O
five	O
steps	O
in	O
this	O
process	O
.	O

Hand	O
surgeons	O
and	O
therapists	O
can	O
use	O
the	O
evidence	O
-	O
based	O
process	O
to	O
attain	O
optimal	O
management	O
of	O
individual	O
patients	O
,	O
manage	O
their	O
overall	O
practice	O
,	O
guide	O
the	O
ongoing	O
professional	O
development	O
,	O
and	O
deal	O
with	O
funding	O
and	O
policy	O
makers	O
.	O

Aflibercept	O
(	O
AVE0005	O
)	O
:	O
an	O
alternative	O
strategy	O
for	O
inhibiting	O
tumour	O
angiogenesis	O
by	O
vascular	O
endothelial	O
growth	O
factors	O
.	O

BACKGROUND	O
:	O
Aberrant	O
angiogenesis	O
is	O
a	O
landmark	O
feature	O
in	O
cancer	O
,	O
which	O
is	O
important	O
for	O
proliferation	O
,	O
growth	O
and	O
metastasis	O
,	O
and	O
is	O
mediated	O
by	O
various	O
pro	O
-	O
angiogenic	O
factors	O
.	O

The	O
VEGF	O
pathway	O
is	O
one	O
of	O
the	O
most	O
important	O
and	O
best	O
-	O
studied	O
angiogenic	O
pathways	O
.	O

Inhibition	O
of	O
this	O
pathway	O
may	O
provide	O
clinical	O
benefits	O
to	O
cancer	O
patients	O
.	O

OBJECTIVES	O
:	O
Strategies	O
to	O
inhibit	O
the	O
VEGF	O
pathway	O
,	O
including	O
antibodies	O
to	O
VEGF	O
,	O
antibodies	O
to	O
the	O
extracellular	O
domain	O
of	O
VEGFR	O
-	O
1	O
or	O
VEGFR	O
-	O
2	O
,	O
decoy	O
receptors	O
for	O
VEGF	O
and	O
tyrosine	O
kinase	O
inhibitors	O
of	O
VEGFRs	O
,	O
are	O
summarized	O
.	O

METHODS	O
:	O
This	O
review	O
outlines	O
and	O
compares	O
the	O
latest	O
development	O
of	O
these	O
strategies	O
,	O
with	O
emphasis	O
on	O
aflibercept	O
,	O
a	O
novel	O
decoy	O
fusion	O
protein	O
of	O
domain	O
2	O
of	O
VEGFR	O
-	O
1	O
and	O
domain	O
3	O
of	O
VEGFR	O
-	O
2	O
with	O
the	O
Fc	O
fragment	O
of	O
IgG1	O
.	O

RESULTS	O
:	O
Aflibercept	O
was	O
shown	O
to	O
have	O
early	O
clinical	O
activity	O
.	O

Multiple	O
studies	O
are	O
ongoing	O
to	O
determine	O
the	O
clinical	O
benefits	O
of	O
aflibercept	O
in	O
cancer	O
patients	O
.	O

Prolonged	O
control	O
of	O
patterned	O
biofilm	O
formation	O
by	O
bio	O
-	O
inert	O
surface	O
chemistry	O
.	O

A	O
bio	O
-	O
inert	O
surface	O
chemistry	O
was	O
developed	O
that	O
can	O
confine	O
biofilm	O
formation	O
in	O
designed	O
patterns	O
for	O
at	O
least	O
26	O
days	O
.	O

Handling	O
within	O
run	O
retention	O
time	O
shifts	O
in	O
two	O
-	O
dimensional	O
chromatography	O
data	O
using	O
shift	O
correction	O
and	O
modeling	O
.	O

The	O
use	O
of	O
PARAFAC	O
for	O
modeling	O
GC	O
x	O
GC	O
-	O
TOFMS	O
peaks	O
is	O
well	O
documented	O
.	O

This	O
success	O
is	O
due	O
to	O
the	O
trilinear	O
structure	O
of	O
these	O
data	O
under	O
ideal	O
,	O
or	O
sufficiently	O
close	O
to	O
ideal	O
,	O
chromatographic	O
conditions	O
.	O

However	O
,	O
using	O
temperature	O
programming	O
to	O
cope	O
with	O
the	O
general	O
elution	O
problem	O
,	O
deviations	O
from	O
trilinearity	O
within	O
a	O
run	O
are	O
more	O
likely	O
to	O
be	O
seen	O
for	O
the	O
following	O
three	O
cases	O
:	O
(	O
1	O
)	O
compounds	O
(	O
i	O
.	O
e	O
.	O
,	O
analytes	O
)	O
severely	O
broadened	O
on	O
the	O
first	O
column	O
hence	O
defined	O
by	O
many	O
modulation	O
periods	O
,	O
(	O
2	O
)	O
analytes	O
with	O
a	O
very	O
high	O
retention	O
factor	O
on	O
the	O
second	O
column	O
and	O
likely	O
wrapped	O
around	O
in	O
that	O
dimension	O
,	O
or	O
(	O
3	O
)	O
with	O
fast	O
temperature	O
program	O
rates	O
.	O

This	O
deviation	O
from	O
trilinearity	O
is	O
seen	O
as	O
retention	O
time	O
-	O
shifted	O
peak	O
profiles	O
in	O
subsequent	O
modulation	O
periods	O
(	O
first	O
column	O
fractions	O
)	O
.	O

In	O
this	O
report	O
,	O
a	O
relaxed	O
yet	O
powerful	O
version	O
of	O
PARAFAC	O
,	O
known	O
as	O
PARAFAC2	O
has	O
been	O
applied	O
to	O
handle	O
this	O
shift	O
within	O
the	O
model	O
step	O
by	O
allowing	O
generation	O
of	O
individual	O
peak	O
profiles	O
in	O
subsequent	O
first	O
column	O
fractions	O
.	O

An	O
alternative	O
approach	O
was	O
also	O
studied	O
,	O
utilizing	O
a	O
standard	O
retention	O
time	O
shift	O
correction	O
to	O
restore	O
the	O
data	O
trilinearity	O
structure	O
followed	O
by	O
PARAFAC	O
.	O

These	O
two	O
approaches	O
are	O
compared	O
when	O
identifying	O
and	O
quantifying	O
a	O
known	O
analyte	O
over	O
a	O
large	O
concentration	O
series	O
where	O
a	O
certain	O
shift	O
is	O
simulated	O
in	O
the	O
successive	O
first	O
column	O
fractions	O
.	O

Finally	O
,	O
the	O
methods	O
are	O
applied	O
to	O
real	O
chromatographic	O
data	O
showing	O
severely	O
shifted	O
peak	O
profiles	O
.	O

The	O
pros	O
and	O
cons	O
of	O
the	O
presented	O
approaches	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
model	O
parameters	O
,	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
degree	O
of	O
shift	O
.	O

Women	O
'	O
s	O
attitudes	O
,	O
preferences	O
,	O
and	O
perceived	O
barriers	O
to	O
treatment	O
for	O
perinatal	O
depression	O
.	O

BACKGROUND	O
:	O

Perinatal	O
depression	O
is	O
associated	O
with	O
potential	O
negative	O
consequences	O
for	O
the	O
mother	O
and	O
infant	O
,	O
and	O
therefore	O
efforts	O
to	O
improve	O
treatment	O
access	O
and	O
efficacy	O
are	O
warranted	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
pregnant	O
women	O
'	O
s	O
preferences	O
and	O
attitudes	O
about	O
treatment	O
for	O
depression	O
,	O
and	O
perceived	O
potential	O
barriers	O
to	O
accessing	O
treatment	O
.	O

METHODS	O
:	O

Data	O
were	O
collected	O
by	O
means	O
of	O
a	O
questionnaire	O
from	O
a	O
convenience	O
sample	O
of	O
509	O
predominantly	O
well	O
-	O
educated	O
,	O
high	O
-	O
income	O
,	O
married	O
women	O
in	O
the	O
northeastern	O
United	O
States	O
during	O
the	O
last	O
trimester	O
of	O
pregnancy	O
.	O

Participants	O
were	O
queried	O
as	O
to	O
treatment	O
modalities	O
in	O
which	O
they	O
would	O
most	O
likely	O
participate	O
if	O
they	O
wanted	O
help	O
for	O
depression	O
,	O
their	O
attitudes	O
toward	O
psychotherapeutic	O
and	O
pharmacological	O
treatments	O
,	O
and	O
perceived	O
barriers	O
to	O
receiving	O
help	O
.	O

RESULTS	O
:	O

Most	O
women	O
(	O
92	O
%	O
)	O
indicated	O
that	O
would	O
likely	O
participate	O
in	O
individual	O
therapy	O
if	O
help	O
was	O
needed	O
.	O

Only	O
35	O
percent	O
stated	O
that	O
they	O
would	O
likely	O
take	O
medication	O
if	O
recommended	O
,	O
and	O
14	O
percent	O
indicated	O
that	O
they	O
would	O
participate	O
in	O
group	O
therapy	O
.	O

The	O
greatest	O
perceived	O
potential	O
barriers	O
to	O
treatment	O
were	O
lack	O
of	O
time	O
(	O
65	O
%	O
)	O
,	O
stigma	O
(	O
43	O
%	O
)	O
,	O
and	O
childcare	O
issues	O
(	O
33	O
%	O
)	O
.	O

Most	O
women	O
indicated	O
a	O
preference	O
to	O
receive	O
mental	O
health	O
care	O
at	O
the	O
obstetrics	O
clinic	O
,	O
either	O
from	O
their	O
obstetrics	O
practitioner	O
or	O
from	O
a	O
mental	O
health	O
practitioner	O
located	O
at	O
the	O
clinic	O
.	O

Factors	O
associated	O
with	O
acceptability	O
of	O
various	O
depression	O
treatments	O
are	O
presented	O
.	O

CONCLUSIONS	O
:	O

Understanding	O
what	O
prevents	O
women	O
from	O
seeking	O
or	O
obtaining	O
help	O
for	O
depression	O
and	O
determining	O
what	O
they	O
prefer	O
in	O
the	O
way	O
of	O
treatment	O
may	O
lead	O
to	O
improved	O
depression	O
treatment	O
rates	O
and	O
hold	O
promise	O
for	O
improving	O
the	O
overall	O
health	O
of	O
childbearing	O
women	O
.	O

The	O
effect	O
of	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carriers	O
on	O
tissue	O
-	O
engineered	O
trachea	O
.	O

The	O
biological	O
effect	O
of	O
the	O
perfluorocarbon	O
-	O
based	O
artificial	O
oxygen	O
carrier	O
(	O
Oxygent	O
)	O
was	O
investigated	O
in	O
tissue	O
-	O
engineered	O
trachea	O
(	O
TET	O
)	O
construction	O
.	O

Media	O
supplemented	O
with	O
and	O
without	O
10	O
%	O
Oxygent	O
were	O
compared	O
in	O
all	O
assessments	O
.	O

Partial	O
tissue	O
oxygen	O
tension	O
(	O
PtO	O
(	O
2	O
)	O
)	O
was	O
measured	O
with	O
polarographic	O
microprobes	O
;	O
epithelial	O
metabolism	O
was	O
monitored	O
by	O
microdialysis	O
inside	O
the	O
TET	O
epithelium	O
perfused	O
with	O
the	O
medium	O
underneath	O
.	O

Chondrocyte	O
-	O
DegraPol	O
constructs	O
were	O
cultured	O
for	O
1	O
month	O
with	O
the	O
medium	O
before	O
glycosaminoglycan	O
assessment	O
and	O
histology	O
.	O

Tissue	O
reaction	O
of	O
TET	O
epithelial	O
scaffolds	O
immersed	O
with	O
the	O
medium	O
was	O
evaluated	O
on	O
the	O
chick	O
embryo	O
chorioallantoic	O
membrane	O
.	O

Oxygent	O
perfusion	O
medium	O
increased	O
the	O
TET	O
epithelial	O
PtO	O
(	O
2	O
)	O
(	O
51	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
vs	O
.	O
33	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
3	O
mm	O
Hg	O
at	O
200	O
microm	O
thickness	O
;	O
12	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
vs	O
.	O
3	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
mm	O
Hg	O
at	O
400	O
microm	O
thickness	O
,	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
decreased	O
the	O
lactate	O
concentration	O
(	O
0	O
.	O
63	O
+	O
/	O
-	O
0	O
.	O
08	O
vs	O
.	O
0	O
.	O
80	O
+	O
/	O
-	O
0	O
.	O
06	O
mmol	O
/	O
L	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
lactate	O
/	O
pyruvate	O
(	O
1	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
26	O
vs	O
.	O
3	O
.	O
36	O
+	O
/	O
-	O
10	O
.	O
13	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
,	O
and	O
lactate	O
/	O
glucose	O
ratios	O
(	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
14	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
.	O

Chondrocyte	O
-	O
DegraPol	O
in	O
Oxygent	O
group	O
presented	O
lower	O
glycosaminoglycan	O
value	O
(	O
0	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
00	O
vs	O
.	O
0	O
.	O
13	O
+	O
/	O
-	O
0	O
.	O
00	O
,	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
;	O
histology	O
slides	O
showed	O
poor	O
acid	O
mucopolysaccharides	O
formation	O
.	O

Orthogonal	O
polarization	O
spectral	O
imaging	O
showed	O
no	O
difference	O
in	O
functional	O
capillary	O
density	O
between	O
the	O
scaffolds	O
cultured	O
on	O
chorioallantoic	O
membranes	O
.	O

The	O
foreign	O
body	O
reaction	O
was	O
similar	O
in	O
both	O
groups	O
.	O

We	O
conclude	O
that	O
Oxygent	O
increases	O
TET	O
epithelial	O
PtO	O
(	O
2	O
)	O
,	O
improves	O
epithelial	O
metabolism	O
,	O
does	O
not	O
impair	O
angiogenesis	O
,	O
and	O
tends	O
to	O
slow	O
cartilage	O
tissue	O
formation	O
.	O

Distinct	O
role	O
of	O
PLCbeta3	O
in	O
VEGF	O
-	O
mediated	O
directional	O
migration	O
and	O
vascular	O
sprouting	O
.	O

Endothelial	O
cell	O
proliferation	O
and	O
migration	O
is	O
essential	O
to	O
angiogenesis	O
.	O

Typically	O
,	O
proliferation	O
and	O
chemotaxis	O
of	O
endothelial	O
cells	O
is	O
driven	O
by	O
growth	O
factors	O
such	O
as	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
.	O

VEGF	O
activates	O
phospholipases	O
(	O
PLCs	O
)	O
-	O
specifically	O
PLCgamma1	O
-	O
that	O
are	O
important	O
for	O
tubulogenesis	O
,	O
differentiation	O
and	O
DNA	O
synthesis	O
.	O

However	O
,	O
we	O
show	O
here	O
that	O
VEGF	O
,	O
specifically	O
through	O
VEGFR2	O
,	O
induces	O
phosphorylation	O
of	O
two	O
serine	O
residues	O
on	O
PLCbeta3	O
,	O
and	O
this	O
was	O
confirmed	O
in	O
an	O
ex	O
vivo	O
embryoid	O
body	O
model	O
.	O

Knockdown	O
of	O
PLCbeta3	O
in	O
HUVEC	O
cells	O
affects	O
IP3	O
production	O
,	O
actin	O
reorganization	O
,	O
migration	O
and	O
proliferation	O
;	O
whereas	O
migration	O
is	O
inhibited	O
,	O
proliferation	O
is	O
enhanced	O
.	O

Our	O
data	O
suggest	O
that	O
enhanced	O
proliferation	O
is	O
precipitated	O
by	O
an	O
accelerated	O
cell	O
cycle	O
,	O
and	O
decreased	O
migration	O
by	O
an	O
inability	O
to	O
activate	O
CDC42	O
.	O

Given	O
that	O
PLCbeta3	O
is	O
typically	O
known	O
as	O
an	O
effector	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
,	O
our	O
data	O
demonstrate	O
a	O
unique	O
crosstalk	O
between	O
the	O
G	O
-	O
protein	O
and	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
axes	O
and	O
reveal	O
a	O
novel	O
molecular	O
mechanism	O
of	O
VEGF	O
signaling	O
and	O
,	O
thus	O
,	O
angiogenesis	O
.	O

The	O
semaphorin	O
7A	O
receptor	O
Plexin	O
C1	O
is	O
lost	O
during	O
melanoma	O
metastasis	O
.	O

The	O
transformation	O
of	O
normal	O
melanocytes	O
,	O
or	O
melanocyte	O
stem	O
cells	O
,	O
to	O
melanoma	O
,	O
is	O
a	O
complex	O
process	O
involving	O
multiple	O
mechanisms	O
.	O

Loss	O
of	O
tumor	O
suppressor	O
proteins	O
,	O
which	O
function	O
as	O
brakes	O
on	O
cell	O
growth	O
,	O
migration	O
,	O
or	O
cell	O
survival	O
,	O
was	O
recognized	O
early	O
on	O
as	O
an	O
important	O
mechanism	O
for	O
initiation	O
and	O
progression	O
of	O
melanoma	O
.	O

Semaphorins	O
and	O
their	O
cognate	O
receptors	O
,	O
Plexins	O
and	O
neuropilins	O
,	O
are	O
involved	O
in	O
neuronal	O
pathfinding	O
,	O
immune	O
function	O
,	O
and	O
tumor	O
progression	O
through	O
effects	O
on	O
blood	O
vessel	O
growth	O
and	O
cell	O
migration	O
.	O

Semaphorin	O
7A	O
(	O
Sema7A	O
)	O
is	O
a	O
membrane	O
-	O
linked	O
semaphorin	O
that	O
is	O
expressed	O
by	O
human	O
keratinocytes	O
,	O
and	O
we	O
have	O
shown	O
that	O
Sema7A	O
binds	O
to	O
human	O
melanocytes	O
through	O
beta1	O
-	O
integrins	O
and	O
the	O
Plexin	O
C1	O
receptor	O
.	O

Functional	O
studies	O
showed	O
that	O
Sema7A	O
stimulates	O
cytoskeletal	O
reorganization	O
in	O
human	O
melanocytes	O
,	O
resulting	O
in	O
adhesion	O
and	O
dendrite	O
formation	O
.	O

Downstream	O
targets	O
of	O
Plexin	O
C1	O
signaling	O
in	O
human	O
melanocytes	O
include	O
cofilin	O
and	O
LIM	O
kinase	O
II	O
,	O
both	O
of	O
which	O
are	O
critical	O
mediators	O
of	O
cell	O
adhesion	O
and	O
migration	O
.	O

In	O
this	O
report	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
Plexin	O
C1	O
using	O
immunohistochemistry	O
on	O
sections	O
of	O
primary	O
and	O
matched	O
metastatic	O
lesions	O
from	O
19	O
subjects	O
and	O
in	O
a	O
large	O
melanoma	O
tumor	O
microarray	O
.	O

Our	O
data	O
show	O
a	O
significant	O
loss	O
of	O
Plexin	O
C1	O
in	O
metastatic	O
melanoma	O
compared	O
with	O
primary	O
melanoma	O
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
Plexin	O
C1	O
receptor	O
is	O
a	O
tumor	O
suppressor	O
protein	O
for	O
melanoma	O
.	O

Coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
.	O

BACKGROUND	O
:	O
The	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
is	O
abnormal	O
and	O
the	O
reason	O
is	O
not	O
very	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
coagulation	O
function	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
.	O

METHODS	O
:	O
From	O
June	O
2004	O
to	O
December	O
2007	O
,	O
132	O
patients	O
received	O
diagnosis	O
and	O
treatment	O
in	O
our	O
hospital	O
.	O

The	O
coagulative	O
parameters	O
including	O
the	O
prothrombin	O
time	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
,	O
and	O
fibrinogen	O
levels	O
were	O
collected	O
and	O
studied	O
retrospectively	O
.	O

RESULTS	O
:	O
The	O
average	O
fibrinogen	O
levels	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
,	O
(	O
476	O
.	O
21	O
+	O
/	O
-	O
142	O
.	O
05	O
)	O
mg	O
/	O
dl	O
,	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
with	O
cholangiolithiasis	O
,	O
(	O
403	O
.	O
28	O
+	O
/	O
-	O
126	O
.	O
41	O
)	O
mg	O
/	O
dl	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	O
with	O
pancreatic	O
carcinoma	O
,	O
the	O
levels	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
jaundice	O
were	O
significantly	O
higher	O
than	O
in	O
patients	O
without	O
jaundice	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	O
who	O
received	O
Pancreaticoduodenectomy	O
,	O
Whipple	O
'	O
s	O
operation	O
,	O
the	O
level	O
of	O
fibrinogen	O
in	O
the	O
group	O
with	O
local	O
invasiveness	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
group	O
without	O
invasiveness	O
.	O

The	O
group	O
with	O
lymphatic	O
metastasis	O
had	O
higher	O
levels	O
than	O
the	O
group	O
without	O
lymphatic	O
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
of	O
intraoperative	O
blood	O
loss	O
between	O
patients	O
with	O
vitamin	O
K	O
,	O
(	O
748	O
.	O
27	O
+	O
/	O
-	O
448	O
.	O
51	O
)	O
ml	O
,	O
and	O
those	O
without	O
vitamin	O
K	O
,	O
(	O
767	O
.	O
31	O
+	O
/	O
-	O
547	O
.	O
89	O
)	O
ml	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
level	O
of	O
fibrinogen	O
in	O
patients	O
with	O
pancreatic	O
carcinoma	O
was	O
elevated	O
.	O

The	O
elevated	O
fibrinogen	O
level	O
may	O
be	O
associated	O
with	O
invasiveness	O
and	O
lymphatic	O
metastasis	O
.	O

Using	O
vitamin	O
K	O
in	O
perioperation	O
management	O
did	O
not	O
reduce	O
intraoperative	O
blood	O
loss	O
.	O

Role	O
of	O
the	O
interferon	O
-	O
inducible	O
IFI16	O
gene	O
in	O
the	O
induction	O
of	O
ICAM	O
-	O
1	O
by	O
TNF	O
-	O
alpha	O
.	O

The	O
Interferon	O
-	O
inducible	O
gene	O
IFI16	O
,	O
a	O
member	O
of	O
the	O
HIN200	O
family	O
,	O
is	O
activated	O
by	O
oxidative	O
stress	O
and	O
cell	O
density	O
,	O
in	O
addition	O
to	O
Interferons	O
,	O
and	O
it	O
is	O
implicated	O
in	O
the	O
regulation	O
of	O
endothelial	O
cell	O
proliferation	O
and	O
vessel	O
formation	O
in	O
vitro	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IFI16	O
is	O
required	O
for	O
proinflammatory	O
gene	O
stimulation	O
by	O
IFN	O
-	O
gamma	O
through	O
the	O
NF	O
-	O
kappaB	O
complex	O
.	O

To	O
examine	O
whether	O
IFI16	O
induction	O
might	O
be	O
extended	O
to	O
other	O
proinflammatory	O
cytokines	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
we	O
used	O
the	O
strategy	O
of	O
the	O
RNA	O
interference	O
to	O
knock	O
down	O
IFI16	O
expression	O
,	O
and	O
analyze	O
the	O
capability	O
of	O
TNF	O
-	O
alpha	O
to	O
stimulate	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
or	O
CD54	O
)	O
expression	O
in	O
the	O
absence	O
of	O
functional	O
IFI16	O
.	O

Our	O
studies	O
demonstrate	O
that	O
IFI16	O
mediates	O
ICAM	O
-	O
1	O
stimulation	O
by	O
TNF	O
-	O
alpha	O
through	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
thus	O
reinforcing	O
the	O
role	O
of	O
the	O
IFI16	O
molecule	O
in	O
the	O
inflammation	O
process	O
.	O

Molecular	O
analysis	O
of	O
genetic	O
instability	O
caused	O
by	O
chronic	O
inflammation	O
.	O

Genetic	O
instability	O
is	O
a	O
hallmark	O
of	O
human	O
cancers	O
.	O

It	O
is	O
the	O
driving	O
force	O
for	O
tumor	O
development	O
as	O
it	O
facilitates	O
the	O
accumulation	O
of	O
mutations	O
in	O
genes	O
that	O
regulate	O
cell	O
death	O
and	O
proliferation	O
and	O
therefore	O
promotes	O
malignant	O
transformation	O
.	O

Chronic	O
inflammation	O
is	O
a	O
common	O
underlying	O
condition	O
for	O
human	O
tumor	O
development	O
,	O
accounting	O
for	O
approximately	O
20	O
%	O
of	O
human	O
cancers	O
.	O

TNFalpha	O
is	O
an	O
important	O
inflammation	O
cytokine	O
and	O
is	O
crucial	O
to	O
the	O
development	O
of	O
inflammation	O
-	O
associated	O
cancers	O
.	O

We	O
have	O
shown	O
that	O
TNFalpha	O
can	O
cause	O
DNA	O
damages	O
through	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
.	O

TNFalpha	O
treatment	O
in	O
cultured	O
cells	O
resulted	O
in	O
increased	O
gene	O
mutations	O
,	O
gene	O
amplification	O
,	O
micronuclei	O
formation	O
and	O
chromosomal	O
instability	O
.	O

Antioxidants	O
significantly	O
reduced	O
TNFalpha	O
-	O
induced	O
genetic	O
damage	O
.	O

In	O
addition	O
,	O
TNFalpha	O
treatment	O
alone	O
led	O
to	O
increased	O
malignant	O
transformation	O
of	O
mouse	O
embryo	O
fibroblasts	O
,	O
which	O
could	O
be	O
partially	O
suppressed	O
by	O
antioxidants	O
.	O

Therefore	O
,	O
genetic	O
instability	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
-	O
associated	O
cancers	O
.	O

The	O
impact	O
of	O
tracheal	O
intubation	O
on	O
host	O
defenses	O
and	O
risks	O
for	O
nosocomial	O
pneumonia	O
.	O

Nosocomial	O
pneumonia	O
remains	O
a	O
common	O
complication	O
in	O
patients	O
treated	O
with	O
endotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
and	O
continues	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
mortality	O
rate	O
of	O
these	O
patients	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
that	O
the	O
risk	O
of	O
pneumonia	O
increases	O
with	O
the	O
duration	O
of	O
intubation	O
but	O
that	O
the	O
period	O
of	O
highest	O
risk	O
is	O
the	O
first	O
2	O
weeks	O
of	O
therapy	O
.	O

Gram	O
-	O
negative	O
bacteria	O
account	O
for	O
most	O
nosocomial	O
pneumonias	O
in	O
intubated	O
patients	O
,	O
but	O
Staphylococcus	O
aureus	O
may	O
also	O
play	O
a	O
role	O
in	O
what	O
may	O
be	O
a	O
polymicrobial	O
infection	O
.	O

In	O
the	O
most	O
seriously	O
ill	O
individuals	O
,	O
and	O
in	O
those	O
treated	O
with	O
long	O
-	O
term	O
mechanical	O
ventilation	O
,	O
Pseudomonas	O
aeruginosa	O
is	O
a	O
common	O
pathogen	O
.	O

Endotracheal	O
intubation	O
and	O
mechanical	O
ventilation	O
predispose	O
to	O
pneumonia	O
for	O
a	O
variety	O
of	O
reasons	O
(	O
see	O
Fig	O
.	O
1	O
)	O
.	O

The	O
endotracheal	O
tube	O
can	O
have	O
direct	O
effects	O
on	O
the	O
airway	O
that	O
result	O
in	O
a	O
reduction	O
in	O
local	O
host	O
defenses	O
.	O

Thus	O
,	O
mucosal	O
injury	O
can	O
reduce	O
mucociliary	O
function	O
,	O
while	O
upper	O
airway	O
defenses	O
are	O
bypassed	O
and	O
the	O
effectiveness	O
of	O
cough	O
is	O
reduced	O
.	O

Indirectly	O
,	O
intubation	O
can	O
result	O
in	O
an	O
enhanced	O
capacity	O
of	O
tracheobronchial	O
cells	O
to	O
bind	O
gram	O
-	O
negative	O
bacteria	O
,	O
an	O
effect	O
that	O
favors	O
airway	O
colonization	O
and	O
pneumonia	O
.	O

The	O
injury	O
to	O
the	O
airway	O
can	O
create	O
binding	O
sites	O
for	O
bacteria	O
in	O
the	O
basement	O
membrane	O
of	O
the	O
bronchial	O
tree	O
and	O
the	O
stimulation	O
of	O
the	O
secretion	O
of	O
mucus	O
,	O
which	O
then	O
stagnates	O
and	O
can	O
create	O
potential	O
sites	O
for	O
bacterial	O
adherence	O
.	O

The	O
endotracheal	O
tube	O
also	O
enhances	O
bacterial	O
entry	O
to	O
the	O
lung	O
by	O
serving	O
as	O
a	O
reservoir	O
for	O
bacteria	O
to	O
remain	O
sequestered	O
,	O
safe	O
from	O
host	O
defenses	O
.	O

Respiratory	O
therapy	O
devices	O
can	O
allow	O
bacteria	O
to	O
proliferate	O
and	O
can	O
then	O
introduce	O
them	O
into	O
the	O
patient	O
if	O
not	O
handled	O
properly	O
.	O

Finally	O
,	O
patients	O
who	O
are	O
ill	O
enough	O
to	O
require	O
intubation	O
also	O
have	O
disease	O
-	O
associated	O
impairments	O
in	O
systemic	O
host	O
defense	O
,	O
which	O
add	O
to	O
the	O
impairments	O
caused	O
by	O
the	O
use	O
of	O
an	O
artificial	O
airway	O
.	O

The	O
host	O
defense	O
impairments	O
that	O
occur	O
in	O
mechanically	O
ventilated	O
patients	O
can	O
lead	O
to	O
respiratory	O
tract	O
infection	O
in	O
the	O
form	O
of	O
either	O
febrile	O
tracheobronchitis	O
or	O
pneumonia	O
.	O

The	O
diagnosis	O
of	O
pneumonia	O
in	O
intubated	O
patients	O
is	O
difficult	O
and	O
controversial	O
.	O

It	O
can	O
be	O
made	O
by	O
either	O
clinical	O
criteria	O
or	O
microbiologic	O
criteria	O
,	O
the	O
latter	O
by	O
using	O
a	O
bronchoscopically	O
directed	O
protected	O
specimen	O
brush	O
.	O

Therapy	O
of	O
pneumonia	O
in	O
mechanically	O
ventilated	O
patients	O
is	O
not	O
always	O
successful	O
,	O
and	O
systemic	O
antibiotics	O
may	O
need	O
to	O
be	O
supplemented	O
by	O
topical	O
antimicrobials	O
.	O

No	O
clearly	O
effective	O
prophylactic	O
strategy	O
currently	O
exists	O
,	O
but	O
our	O
understanding	O
of	O
pneumonia	O
pathogenesis	O
has	O
led	O
to	O
some	O
promising	O
directions	O
.	O

As	O
more	O
data	O
are	O
collected	O
,	O
inhaled	O
antibiotics	O
,	O
selective	O
digestive	O
decontamination	O
,	O
and	O
enhancement	O
of	O
host	O
defenses	O
by	O
cytokines	O
and	O
pre	O
-	O
formed	O
antibodies	O
may	O
emerge	O
as	O
useful	O
approaches	O
.	O

Antivascular	O
actions	O
of	O
microtubule	O
-	O
binding	O
drugs	O
.	O

Microtubule	O
-	O
binding	O
drugs	O
(	O
MBD	O
)	O
are	O
widely	O
used	O
in	O
cancer	O
chemotherapy	O
and	O
also	O
have	O
clinically	O
relevant	O
antiangiogenic	O
and	O
vascular	O
-	O
disrupting	O
properties	O
.	O

These	O
antivascular	O
actions	O
are	O
due	O
in	O
part	O
to	O
direct	O
effects	O
on	O
endothelial	O
cells	O
,	O
and	O
all	O
MBDs	O
(	O
both	O
microtubule	O
-	O
stabilizing	O
and	O
microtubule	O
-	O
destabilizing	O
)	O
inhibit	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
tube	O
formation	O
in	O
vitro	O
,	O
actions	O
that	O
are	O
thought	O
to	O
correspond	O
to	O
therapeutic	O
antiangiogenic	O
actions	O
.	O

In	O
addition	O
,	O
the	O
microtubule	O
-	O
destabilizing	O
agents	O
cause	O
prominent	O
changes	O
in	O
endothelial	O
cell	O
morphology	O
,	O
an	O
action	O
associated	O
with	O
rapid	O
vascular	O
collapse	O
in	O
vivo	O
.	O

The	O
effects	O
on	O
endothelial	O
cells	O
occur	O
in	O
vitro	O
at	O
low	O
drug	O
concentrations	O
,	O
which	O
do	O
not	O
affect	O
microtubule	O
gross	O
morphology	O
,	O
do	O
not	O
cause	O
microtubule	O
bundling	O
or	O
microtubule	O
loss	O
and	O
do	O
not	O
induce	O
cell	O
cycle	O
arrest	O
,	O
apoptosis	O
,	O
or	O
cell	O
death	O
.	O

Rather	O
,	O
it	O
has	O
been	O
hypothesized	O
that	O
,	O
at	O
low	O
concentrations	O
,	O
MBDs	O
produce	O
more	O
subtle	O
effects	O
on	O
microtubule	O
dynamics	O
,	O
block	O
critical	O
cell	O
signaling	O
pathways	O
,	O
and	O
prevent	O
the	O
microtubules	O
from	O
properly	O
interacting	O
with	O
transient	O
subcellular	O
assemblies	O
(	O
focal	O
adhesions	O
and	O
adherens	O
junctions	O
)	O
whose	O
subsequent	O
stabilization	O
and	O
/	O
or	O
maturation	O
are	O
required	O
for	O
cell	O
motility	O
and	O
cell	O
-	O
cell	O
interactions	O
.	O

This	O
review	O
will	O
focus	O
on	O
recent	O
studies	O
to	O
define	O
the	O
molecular	O
mechanisms	O
for	O
the	O
antivascular	O
actions	O
of	O
the	O
MBDs	O
,	O
information	O
that	O
could	O
be	O
useful	O
in	O
the	O
identification	O
or	O
design	O
of	O
agents	O
whose	O
actions	O
more	O
selectively	O
target	O
the	O
tumor	O
vasculature	O
.	O

PTTG	O
overexpression	O
promotes	O
lymph	O
node	O
metastasis	O
in	O
human	O
esophageal	O
squamous	O
cell	O
carcinoma	O
.	O

Human	O
pituitary	O
tumor	O
transforming	O
gene	O
(	O
PTTG	O
)	O
overexpression	O
correlates	O
with	O
metastasis	O
in	O
multiple	O
tumors	O
,	O
and	O
yet	O
its	O
molecular	O
mechanisms	O
of	O
action	O
remain	O
elusive	O
.	O

We	O
detected	O
PTTG	O
overexpression	O
in	O
66	O
%	O
(	O
111	O
of	O
169	O
)	O
of	O
primary	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
tumor	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

PTTG	O
overexpression	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Ectopic	O
PTTG	O
overexpression	O
in	O
a	O
representative	O
ESCC	O
cell	O
line	O
,	O
EC9706	B
,	O
increased	O
in	O
vitro	O
cell	O
migration	O
and	O
invasion	O
and	O
promoted	O
in	O
vivo	O
lymph	O
node	O
metastasis	O
.	O

Suppressing	O
PTTG	O
expression	O
by	O
siRNA	O
decreased	O
cell	O
motility	O
in	O
both	O
PTTG	O
-	O
HA	O
/	O
EC9706	B
and	O
KYSE150	B
cells	O
.	O

By	O
using	O
mass	O
spectrometric	O
analysis	O
,	O
we	O
identified	O
that	O
PTTG	O
up	O
-	O
regulated	O
S100A4	O
and	O
galectin	O
-	O
1	O
secretion	O
and	O
down	O
-	O
regulated	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
2	O
secretion	O
to	O
the	O
culture	O
media	O
.	O

PTTG	O
induced	O
S100A4	O
and	O
galectin	O
-	O
1	O
mRNA	O
and	O
protein	O
expression	O
as	O
assessed	O
by	O
Western	O
blot	O
and	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Attenuating	O
galectin	O
-	O
1	O
expression	O
by	O
siRNA	O
constrained	O
PTTG	O
-	O
HA	O
/	O
EC9706	B
cell	O
motility	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

PTTG	O
activated	O
E	O
-	O
box	O
transcription	O
and	O
induced	O
c	O
-	O
Myc	O
protein	O
expression	O
in	O
EC9706	B
cells	O
,	O
which	O
in	O
turn	O
may	O
act	O
on	O
an	O
E	O
-	O
box	O
motif	O
within	O
the	O
galectin	O
-	O
1	O
promoter	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
further	O
confirmed	O
specific	O
c	O
-	O
Myc	O
binding	O
to	O
galectin	O
-	O
1	O
promoter	O
.	O

PTTG	O
-	O
induced	O
galectin	O
-	O
1	O
transactivation	O
and	O
expression	O
were	O
mediated	O
by	O
c	O
-	O
Myc	O
,	O
and	O
both	O
inductions	O
were	O
suppressed	O
by	O
c	O
-	O
Myc	O
RNAi	O
cotranfection	O
.	O

These	O
findings	O
elucidate	O
the	O
molecular	O
mechanisms	O
of	O
PTTG	O
overexpression	O
in	O
promoting	O
tumor	O
metastasis	O
,	O
whereby	O
up	O
-	O
regulated	O
PTTG	O
modulates	O
expression	O
and	O
secretion	O
of	O
metastasis	O
-	O
related	O
factors	O
to	O
facilitate	O
cell	O
motility	O
.	O

Neurovascular	O
effects	O
of	O
CD47	O
signaling	O
:	O
promotion	O
of	O
cell	O
death	O
,	O
inflammation	O
,	O
and	O
suppression	O
of	O
angiogenesis	O
in	O
brain	O
endothelial	O
cells	O
in	O
vitro	O
.	O

The	O
concept	O
of	O
the	O
neurovascular	O
unit	O
emphasizes	O
that	O
common	O
signals	O
and	O
substrates	O
underlie	O
the	O
physiology	O
and	O
pathophysiology	O
of	O
neuronal	O
and	O
endothelial	O
compartments	O
in	O
brain	O
.	O

Recent	O
data	O
suggest	O
that	O
activation	O
of	O
the	O
integrin	O
-	O
associated	O
protein	O
CD47	O
promotes	O
neuronal	O
cell	O
death	O
.	O

Is	O
it	O
possible	O
that	O
CD47	O
may	O
also	O
negatively	O
affect	O
cerebral	O
endothelial	O
cells	O
?	O

Exposure	O
of	O
wild	O
-	O
type	O
primary	O
mouse	O
cerebral	O
endothelial	O
cells	O
to	O
the	O
CD47	O
ligand	O
thrombospondin	O
1	O
(	O
TSP	O
-	O
1	O
)	O
induced	O
an	O
increasing	O
amount	O
of	O
cell	O
death	O
,	O
whereas	O
cytotoxicity	O
was	O
significantly	O
decreased	O
in	O
cerebral	O
endothelial	O
cells	O
derived	O
from	O
CD47	O
knockout	O
mice	O
.	O

The	O
specific	O
CD47	O
-	O
activating	O
peptide	O
,	O
4N1	O
K	O
,	O
similarly	O
induced	O
cell	O
death	O
in	O
human	O
brain	O
microvascular	O
endothelial	O
cells	O
.	O

Promotion	O
of	O
inflammation	O
was	O
also	O
involved	O
because	O
lower	O
TSP	O
-	O
1	O
was	O
able	O
to	O
up	O
-	O
regulate	O
the	O
adhesion	O
molecules	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
.	O

Finally	O
,	O
CD47	O
signaling	O
may	O
suppress	O
angiogenesis	O
because	O
4N1	O
K	O
significantly	O
inhibited	O
endothelial	O
cell	O
migration	O
and	O
tube	O
formation	O
in	O
vitro	O
.	O

We	O
conclude	O
that	O
CD47	O
signaling	O
can	O
negatively	O
affect	O
the	O
viability	O
and	O
function	O
of	O
cerebral	O
endothelial	O
cells	O
,	O
further	O
supporting	O
the	O
notion	O
that	O
CD47	O
may	O
be	O
a	O
potential	O
neurovascular	O
target	O
for	O
stroke	O
and	O
brain	O
injury	O
.	O

Characterization	O
of	O
the	O
metabolic	O
changes	O
underlying	O
growth	O
factor	O
angiogenic	O
activation	O
:	O
identification	O
of	O
new	O
potential	O
therapeutic	O
targets	O
.	O

Angiogenesis	O
is	O
a	O
fundamental	O
process	O
to	O
normal	O
and	O
abnormal	O
tissue	O
growth	O
and	O
repair	O
,	O
which	O
consists	O
of	O
recruiting	O
endothelial	O
cells	O
toward	O
an	O
angiogenic	O
stimulus	O
.	O

The	O
cells	O
subsequently	O
proliferate	O
and	O
differentiate	O
to	O
form	O
endothelial	O
tubes	O
and	O
capillary	O
-	O
like	O
structures	O
.	O

Little	O
is	O
known	O
about	O
the	O
metabolic	O
adaptation	O
of	O
endothelial	O
cells	O
through	O
such	O
a	O
transformation	O
.	O

We	O
studied	O
the	O
metabolic	O
changes	O
of	O
endothelial	O
cell	O
activation	O
by	O
growth	O
factors	O
using	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
and	O
mass	O
isotopomer	O
distribution	O
analysis	O
.	O

The	O
metabolism	O
of	O
[	O
1	O
,	O
2	O
-	O
(	O
13	O
)	O
C	O
(	O
2	O
)	O
]	O
-	O
glucose	O
by	O
HUVEC	O
allows	O
us	O
to	O
trace	O
many	O
of	O
the	O
main	O
glucose	O
metabolic	O
pathways	O
,	O
including	O
glycogen	O
synthesis	O
,	O
the	O
pentose	O
cycle	O
and	O
the	O
glycolytic	O
pathways	O
.	O

So	O
we	O
established	O
that	O
these	O
pathways	O
were	O
crucial	O
to	O
endothelial	O
cell	O
proliferation	O
under	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
stimulation	O
.	O

A	O
specific	O
VEGF	O
receptor	O
-	O
2	O
inhibitor	O
demonstrated	O
the	O
importance	O
of	O
glycogen	O
metabolism	O
and	O
pentose	O
cycle	O
pathway	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
glycogen	O
was	O
depleted	O
in	O
a	O
low	O
glucose	O
medium	O
,	O
but	O
conserved	O
under	O
hypoxic	O
conditions	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
direct	O
inhibition	O
of	O
key	O
enzymes	O
to	O
glycogen	O
metabolism	O
and	O
pentose	O
phosphate	O
pathways	O
reduced	O
HUVEC	O
viability	O
and	O
migration	O
.	O

In	O
this	O
regard	O
,	O
inhibitors	O
of	O
these	O
pathways	O
have	O
been	O
shown	O
to	O
be	O
effective	O
antitumoral	O
agents	O
.	O

To	O
sum	O
up	O
,	O
our	O
data	O
suggest	O
that	O
the	O
inhibition	O
of	O
metabolic	O
pathways	O
offers	O
a	O
novel	O
and	O
powerful	O
therapeutic	O
approach	O
,	O
which	O
simultaneously	O
inhibits	O
tumor	O
cell	O
proliferation	O
and	O
tumor	O
-	O
induced	O
angiogenesis	O
.	O

Rab	O
GTPase	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
in	O
endothelial	O
cells	O
.	O

OBJECTIVE	O
:	O
Vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
VEGFR2	O
)	O
is	O
a	O
receptor	O
tyrosine	O
kinase	O
that	O
regulates	O
vascular	O
physiology	O
.	O

However	O
,	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
VEGFR2	O
signaling	O
and	O
trafficking	O
is	O
coordinated	O
are	O
not	O
clear	O
.	O

Here	O
,	O
we	O
have	O
tested	O
endocytic	O
Rab	O
GTPases	O
for	O
regulation	O
of	O
VEGFR2	O
trafficking	O
and	O
signaling	O
linked	O
to	O
endothelial	O
cell	O
migration	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Quiescent	O
VEGFR2	O
displays	O
endosomal	O
localization	O
and	O
colocalization	O
with	O
the	O
Rab5a	O
GTPase	O
,	O
an	O
early	O
endosome	O
fusion	O
regulator	O
.	O

Expression	O
of	O
GTP	O
or	O
GDP	O
-	O
bound	O
Rab5a	O
mutants	O
block	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O

Manipulation	O
of	O
Rab7a	O
GTPase	O
activity	O
associated	O
with	O
late	O
endosomes	O
using	O
overexpression	O
of	O
wild	O
-	O
type	O
or	O
mutant	O
proteins	O
blocks	O
activated	O
VEGFR2	O
trafficking	O
and	O
degradation	O
.	O

Depletion	O
of	O
Rab7a	O
decreased	O
VEGFR2	O
Y1175	O
phosphorylation	O
but	O
increased	O
p42	O
/	O
44	O
(	O
pERK1	O
/	O
2	O
)	O
MAPK	O
phosphorylation	O
.	O

Endothelial	O
cell	O
migration	O
was	O
increased	O
by	O
Rab5a	O
depletion	O
but	O
decreased	O
by	O
Rab7a	O
depletion	O
.	O

CONCLUSIONS	O
:	O
Rab5a	O
and	O
Rab7a	O
regulate	O
VEGFR2	O
trafficking	O
toward	O
early	O
and	O
late	O
endosomes	O
.	O

Our	O
data	O
suggest	O
that	O
VEGFR2	O
-	O
mediated	O
regulation	O
of	O
endothelial	O
function	O
is	O
dependent	O
on	O
different	O
but	O
specific	O
Rab	O
-	O
mediated	O
GTP	O
hydrolysis	O
activity	O
required	O
for	O
endosomal	O
trafficking	O
.	O

FOXO3a	O
elicits	O
a	O
pro	O
-	O
apoptotic	O
transcription	O
program	O
and	O
cellular	O
response	O
to	O
human	O
lung	O
carcinogen	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
.	O

Long	O
-	O
term	O
carcinogen	O
exposure	O
exerts	O
continuous	O
pressure	O
on	O
key	O
mechanisms	O
that	O
repair	O
or	O
eliminate	O
carcinogen	O
-	O
damaged	O
cells	O
giving	O
rise	O
to	O
selective	O
failures	O
that	O
contribute	O
to	O
lung	O
cancer	O
.	O

FOXO3a	O
is	O
a	O
transcription	O
factor	O
that	O
elicits	O
a	O
protective	O
response	O
to	O
diverse	O
cellular	O
stresses	O
.	O

Although	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
,	O
its	O
role	O
in	O
sporadic	O
cancer	O
is	O
uncertain	O
.	O

We	O
recently	O
observed	O
that	O
FOXO3a	O
gene	O
inactivation	O
occurs	O
frequently	O
in	O
carcinogen	O
-	O
induced	O
lung	O
adenocarcinoma	O
(	O
LAC	O
)	O
.	O

This	O
suggests	O
that	O
FOXO3a	O
may	O
play	O
a	O
role	O
in	O
LAC	O
suppression	O
by	O
eliciting	O
a	O
protective	O
response	O
to	O
carcinogenic	O
stress	O
.	O

Here	O
we	O
investigated	O
this	O
possibility	O
by	O
examining	O
the	O
role	O
of	O
FOXO3a	O
in	O
the	O
cellular	O
response	O
to	O
nicotine	O
-	O
derived	O
nitrosaminoketone	O
(	O
NNK	O
)	O
,	O
a	O
lung	O
carcinogen	O
implicated	O
as	O
a	O
cause	O
of	O
human	O
LAC	O
.	O

We	O
show	O
that	O
restoration	O
of	O
FOXO3a	O
in	O
FOXO3a	O
-	O
deficient	O
LAC	O
cells	O
increases	O
sensitivity	O
to	O
apoptosis	O
caused	O
by	O
a	O
DNA	O
-	O
damaging	O
intermediate	O
of	O
NNK	O
.	O

Prior	O
to	O
this	O
cellular	O
outcome	O
,	O
FOXO3a	O
is	O
functionally	O
activated	O
and	O
mediates	O
a	O
large	O
-	O
scale	O
transcription	O
program	O
in	O
response	O
to	O
this	O
damage	O
involving	O
a	O
significant	O
modulation	O
of	O
440	O
genes	O
.	O

Genes	O
most	O
significantly	O
represented	O
in	O
this	O
program	O
are	O
those	O
with	O
roles	O
in	O
cell	O
growth	O
and	O
proliferation	O
>	O
protein	O
synthesis	O
>	O
gene	O
expression	O
>	O
cell	O
death	O
>	O
cell	O
cycle	O
.	O

The	O
results	O
of	O
this	O
study	O
show	O
that	O
FOXO3a	O
directs	O
an	O
anti	O
-	O
carcinogenic	O
transcription	O
program	O
that	O
culminates	O
in	O
the	O
elimination	O
of	O
carcinogen	O
-	O
damaged	O
cells	O
.	O

This	O
suggests	O
that	O
FOXO3a	O
is	O
a	O
potential	O
suppressor	O
of	O
carcinogenic	O
damage	O
in	O
LAC	O
.	O

Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
neural	O
stem	O
/	O
progenitor	O
cells	O
increases	O
proliferation	O
and	O
neurogenesis	O
in	O
culture	O
but	O
has	O
little	O
effect	O
on	O
these	O
functions	O
in	O
vivo	O
.	O

The	O
polycomb	O
gene	O
Bmi	O
-	O
1	O
is	O
required	O
for	O
the	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
from	O
diverse	O
tissues	O
,	O
including	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Bmi	O
-	O
1	O
expression	O
is	O
elevated	O
in	O
most	O
human	O
gliomas	O
,	O
irrespective	O
of	O
grade	O
,	O
raising	O
the	O
question	O
of	O
whether	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
is	O
sufficient	O
to	O
promote	O
self	O
-	O
renewal	O
or	O
tumorigenesis	O
by	O
CNS	O
stem	O
/	O
progenitor	O
cells	O
.	O

To	O
test	O
this	O
we	O
generated	O
Nestin	O
-	O
Bmi	O
-	O
1	O
-	O
GFP	O
transgenic	O
mice	O
.	O

Analysis	O
of	O
two	O
independent	O
lines	O
with	O
expression	O
in	O
the	O
fetal	O
and	O
adult	O
CNS	O
demonstrated	O
that	O
transgenic	O
neural	O
stem	O
cells	O
formed	O
larger	O
colonies	O
,	O
more	O
self	O
-	O
renewing	O
divisions	O
,	O
and	O
more	O
neurons	O
in	O
culture	O
.	O

However	O
,	O
in	O
vivo	O
,	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
had	O
little	O
effect	O
on	O
CNS	O
stem	O
cell	O
frequency	O
,	O
subventricular	O
zone	O
proliferation	O
,	O
olfactory	O
bulb	O
neurogenesis	O
,	O
or	O
neurogenesis	O
/	O
gliogenesis	O
during	O
development	O
.	O

Bmi	O
-	O
1	O
transgenic	O
mice	O
were	O
born	O
with	O
enlarged	O
lateral	O
ventricles	O
and	O
a	O
minority	O
developed	O
idiopathic	O
hydrocephalus	O
as	O
adults	O
,	O
but	O
none	O
of	O
the	O
transgenic	O
mice	O
formed	O
detectable	O
CNS	O
tumors	O
,	O
even	O
when	O
aged	O
.	O

The	O
more	O
pronounced	O
effects	O
of	O
Bmi	O
-	O
1	O
over	O
-	O
expression	O
in	O
culture	O
were	O
largely	O
attributable	O
to	O
the	O
attenuated	O
induction	O
of	O
p16	O
(	O
Ink4a	O
)	O
and	O
p19	O
(	O
Arf	O
)	O
in	O
culture	O
,	O
proteins	O
that	O
are	O
generally	O
not	O
expressed	O
by	O
neural	O
stem	O
/	O
progenitor	O
cells	O
in	O
young	O
mice	O
in	O
vivo	O
.	O

Bmi	O
-	O
1	O
over	O
-	O
expression	O
therefore	O
has	O
more	O
pronounced	O
effects	O
in	O
culture	O
and	O
does	O
not	O
appear	O
to	O
be	O
sufficient	O
to	O
induce	O
tumorigenesis	O
in	O
vivo	O
.	O

Erbb2	O
suppresses	O
DNA	O
damage	O
-	O
induced	O
checkpoint	O
activation	O
and	O
UV	O
-	O
induced	O
mouse	O
skin	O
tumorigenesis	O
.	O

The	O
Erbb2	O
receptor	O
is	O
activated	O
by	O
UV	O
irradiation	O
,	O
the	O
primary	O
cause	O
of	O
non	O
-	O
melanoma	O
skin	O
cancer	O
.	O

We	O
hypothesized	O
that	O
Erbb2	O
activation	O
contributes	O
to	O
UV	O
-	O
induced	O
skin	O
tumorigenesis	O
by	O
suppressing	O
cell	O
cycle	O
arrest	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
inhibition	O
of	O
Erbb2	O
in	O
v	O
-	O
ras	O
(	O
Ha	O
)	O
transgenic	O
mice	O
before	O
UV	O
exposure	O
resulted	O
in	O
both	O
56	O
%	O
fewer	O
skin	O
tumors	O
and	O
tumors	O
that	O
were	O
70	O
%	O
smaller	O
.	O

Inhibition	O
of	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
Erbb2	O
also	O
resulted	O
in	O
milder	O
epidermal	O
hyperplasia	O
,	O
S	O
-	O
phase	O
accumulation	O
,	O
and	O
decreased	O
levels	O
of	O
the	O
cell	O
cycle	O
regulator	O
Cdc25a	O
,	O
suggesting	O
altered	O
cell	O
cycle	O
regulation	O
on	O
inhibition	O
of	O
Erbb2	O
.	O

Further	O
investigation	O
using	O
inhibition	O
or	O
genetic	O
deletion	O
of	O
Erbb2	O
in	O
vitro	O
revealed	O
reduced	O
Cdc25a	O
levels	O
and	O
increased	O
S	O
-	O
phase	O
arrest	O
in	O
UV	O
-	O
irradiated	O
cells	O
lacking	O
Erbb2	O
activity	O
.	O

Ectopic	O
expression	O
of	O
Cdc25a	O
prevented	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
in	O
keratinocytes	O
lacking	O
Erbb2	O
activity	O
,	O
demonstrating	O
that	O
maintenance	O
of	O
Cdc25a	O
by	O
Erbb2	O
suppresses	O
cell	O
cycle	O
arrest	O
.	O

Examination	O
of	O
checkpoint	O
pathway	O
activation	O
upstream	O
of	O
Cdc25a	O
revealed	O
Erbb2	O
activation	O
did	O
not	O
alter	O
Ataxia	O
Telangiectasia	O
and	O
Rad3	O
-	O
related	O
/	O
Ataxia	O
Telangiectasia	O
Mutated	O
activity	O
but	O
increased	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
.	O

Since	O
Akt	O
phosphorylates	O
Chk1	O
-	O
Ser	O
(	O
280	O
)	O
,	O
the	O
effect	O
of	O
Erbb2	O
on	O
phosphatidyl	O
inositol	O
-	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
/	O
Akt	O
signaling	O
during	O
UV	O
-	O
induced	O
cell	O
cycle	O
arrest	O
was	O
determined	O
.	O

Erbb2	O
ablation	O
reduced	O
the	O
UV	O
-	O
induced	O
activation	O
of	O
PI3	O
K	O
while	O
inhibition	O
of	O
PI3	O
K	O
/	O
Akt	O
increased	O
UV	O
-	O
induced	O
S	O
-	O
phase	O
arrest	O
.	O

Thus	O
,	O
UV	O
-	O
induced	O
Erbb2	O
activation	O
increases	O
skin	O
tumorigenesis	O
through	O
inhibitory	O
phosphorylation	O
of	O
Chk1	O
,	O
Cdc25a	O
maintenance	O
,	O
and	O
suppression	O
of	O
S	O
-	O
phase	O
arrest	O
via	O
a	O
PI3	O
K	O
/	O
Akt	O
-	O
dependent	O
mechanism	O
.	O

The	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
signaling	O
pathway	O
specific	O
to	O
breast	O
cancer	O
invasion	O
and	O
metastasis	O
.	O

Tumors	O
are	O
tissue	O
-	O
specific	O
diseases	O
,	O
and	O
their	O
mechanisms	O
of	O
invasion	O
and	O
metastasis	O
are	O
highly	O
diverse	O
.	O

In	O
breast	O
cancer	O
,	O
biomarkers	O
that	O
specifically	O
correlate	O
with	O
the	O
invasive	O
phenotypes	O
have	O
not	O
been	O
clearly	O
identified	O
.	O

A	O
small	O
GTPase	O
Arf6	O
primarily	O
regulates	O
recycling	O
of	O
plasma	O
membrane	O
components	O
.	O

We	O
have	O
shown	O
that	O
Arf6	O
and	O
its	O
effector	O
AMAP1	O
(	O
DDEF1	O
,	O
DEF1	O
,	O
ASAP1	O
and	O
centaurin	O
beta4	O
)	O
are	O
abnormally	O
overexpressed	O
in	O
some	O
breast	O
cancers	O
and	O
used	O
for	O
their	O
invasion	O
and	O
metastasis	O
.	O

Overexpression	O
of	O
these	O
proteins	O
is	O
independent	O
of	O
the	O
transcriptional	O
upregulation	O
of	O
their	O
genes	O
,	O
and	O
occurs	O
only	O
in	O
highly	O
malignant	O
breast	O
cancer	O
cells	O
.	O

We	O
recently	O
identified	O
GEP100	O
(	O
BRAG2	O
)	O
to	O
be	O
responsible	O
for	O
the	O
Arf6	O
activation	O
to	O
induce	O
invasion	O
and	O
metastasis	O
,	O
by	O
directly	O
binding	O
to	O
ligand	O
-	O
activated	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

A	O
series	O
of	O
our	O
studies	O
revealed	O
that	O
for	O
activation	O
of	O
the	O
invasion	O
pathway	O
of	O
EGFR	O
,	O
it	O
is	O
prerequisite	O
that	O
Arf6	O
and	O
AMAP1	O
both	O
are	O
highly	O
overexpressed	O
,	O
and	O
that	O
EGFR	O
is	O
activated	O
by	O
ligands	O
.	O

Pathological	O
analyses	O
indicate	O
that	O
a	O
significant	O
large	O
population	O
of	O
human	O
ductal	O
cancers	O
may	O
utilize	O
the	O
EGFR	O
-	O
GEP100	O
-	O
Arf6	O
-	O
AMAP1	O
pathway	O
for	O
their	O
malignancy	O
.	O

Microenvironments	O
have	O
been	O
highly	O
implicated	O
in	O
the	O
malignancy	O
of	O
mammary	O
tumors	O
.	O

Our	O
results	O
reveal	O
an	O
aspect	O
of	O
the	O
precise	O
molecular	O
mechanisms	O
of	O
some	O
breast	O
cancers	O
,	O
in	O
which	O
full	O
invasiveness	O
is	O
not	O
acquired	O
just	O
by	O
intracellular	O
alterations	O
of	O
cancer	O
cells	O
,	O
but	O
extracellular	O
factors	O
from	O
microenvironments	O
may	O
also	O
be	O
necessary	O
.	O

Possible	O
translation	O
of	O
our	O
knowledge	O
to	O
cancer	O
therapeutics	O
will	O
also	O
be	O
discussed	O
.	O

Met	O
amplification	O
and	O
tumor	O
progression	O
in	O
Cdkn2a	O
-	O
deficient	O
melanocytes	O
.	O

While	O
many	O
genetic	O
alterations	O
have	O
been	O
identified	O
in	O
melanoma	O
,	O
the	O
relevant	O
molecular	O
events	O
that	O
contribute	O
to	O
disease	O
progression	O
are	O
poorly	O
understood	O
.	O

Most	O
primary	O
human	O
melanomas	O
exhibit	O
loss	O
of	O
expression	O
of	O
the	O
CDKN2A	O
locus	O
in	O
addition	O
to	O
activation	O
of	O
the	O
canonical	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
signaling	O
pathway	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
Cdkn2a	O
-	O
deficient	O
mouse	O
melanocyte	O
cell	O
line	O
to	O
screen	O
for	O
secondary	O
genetic	O
events	O
in	O
melanoma	O
tumor	O
progression	O
.	O

Upon	O
investigation	O
,	O
intrachromosomal	O
gene	O
amplification	O
of	O
Met	O
,	O
a	O
receptor	O
tyrosine	O
kinase	O
implicated	O
in	O
melanoma	O
progression	O
,	O
was	O
identified	O
in	O
Cdkn2a	O
-	O
deficient	O
tumors	O
.	O

RNA	O
interference	O
targeting	O
Met	O
in	O
these	O
tumor	O
cells	O
resulted	O
in	O
a	O
significant	O
delay	O
in	O
tumor	O
growth	O
in	O
vivo	O
compared	O
with	O
the	O
control	O
cells	O
.	O

MET	O
expression	O
is	O
rarely	O
detected	O
in	O
primary	O
human	O
melanoma	O
but	O
is	O
frequently	O
observed	O
in	O
metastatic	O
disease	O
.	O

This	O
study	O
validates	O
a	O
role	O
for	O
Met	O
activation	O
in	O
melanoma	O
tumor	O
progression	O
in	O
the	O
context	O
of	O
Cdkn2a	O
deficiency	O
.	O

Activated	O
platelets	O
enhance	O
ovarian	O
cancer	O
cell	O
invasion	O
in	O
a	O
cellular	O
model	O
of	O
metastasis	O
.	O

Increased	O
platelet	O
counts	O
and	O
systemic	O
coagulation	O
activation	O
are	O
associated	O
with	O
ovarian	O
cancer	O
progression	O
.	O

Platelet	O
activation	O
occurs	O
in	O
the	O
tumor	O
microenvironment	O
and	O
may	O
influence	O
local	O
invasion	O
and	O
metastasis	O
.	O

We	O
used	O
a	O
cellular	O
model	O
of	O
tumor	O
invasion	O
to	O
investigate	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
the	O
human	O
ovarian	O
cancer	O
cell	O
line	O
,	O
SKOV3	B
.	O

SKOV3	B
cells	O
were	O
exposed	O
to	O
washed	O
,	O
thrombin	O
receptor	O
activating	O
peptide	O
(	O
TRAP	O
)	O
-	O
activated	O
or	O
TRAP	O
-	O
naive	O
platelets	O
under	O
various	O
experimental	O
conditions	O
,	O
and	O
tumor	O
cell	O
invasion	O
was	O
assayed	O
in	O
Matrigel	O
chambers	O
.	O

The	O
effect	O
of	O
platelets	O
on	O
the	O
content	O
of	O
urokinase	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
and	O
VEGF	O
in	O
SKOV3	B
cell	O
conditioned	O
medium	O
was	O
measured	O
using	O
an	O
ELISA	O
assay	O
.	O

TRAP	O
-	O
activated	O
platelets	O
stimulated	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
SKOV3	B
cell	O
invasion	O
.	O

Exposure	O
to	O
activated	O
platelet	O
membranes	O
and	O
to	O
soluble	O
proteins	O
contained	O
in	O
activated	O
platelet	O
releasate	O
both	O
contributed	O
to	O
the	O
observed	O
increase	O
in	O
invasion	O
.	O

The	O
inhibition	O
of	O
platelet	O
activation	O
with	O
prostaglandin	O
E1	O
(	O
PGE	O
(	O
1	O
)	O
)	O
attenuated	O
the	O
invasive	O
capacity	O
of	O
SKOV3	B
cells	O
.	O

Exposure	O
to	O
platelets	O
resulted	O
in	O
significantly	O
increased	O
uPA	O
and	O
VEGF	O
content	O
of	O
SKOV3	B
cell	O
conditioned	O
medium	O
.	O

Activated	O
platelets	O
enhance	O
SKOV3	B
human	O
ovarian	O
cancer	O
cell	O
invasion	O
through	O
Matrigel	O
and	O
increase	O
the	O
amount	O
of	O
uPA	O
and	O
VEGF	O
secreted	O
into	O
SKOV3	B
cell	O
conditioned	O
medium	O
.	O

If	O
generalizable	O
to	O
additional	O
cell	O
lines	O
and	O
human	O
disease	O
,	O
this	O
observation	O
may	O
partially	O
explain	O
the	O
adverse	O
prognosis	O
associated	O
with	O
thrombocytosis	O
in	O
ovarian	O
cancer	O
.	O

Platelets	O
,	O
therefore	O
,	O
may	O
represent	O
a	O
potential	O
target	O
for	O
therapeutic	O
intervention	O
in	O
human	O
ovarian	O
cancer	O
.	O

AngiomiRs	O
-	O
-	O
key	O
regulators	O
of	O
angiogenesis	O
.	O

The	O
formation	O
of	O
new	O
blood	O
vessels	O
through	O
the	O
process	O
of	O
angiogenesis	O
is	O
critical	O
in	O
vascular	O
development	O
and	O
homeostasis	O
.	O

Aberrant	O
angiogenesis	O
leads	O
to	O
a	O
variety	O
of	O
diseases	O
,	O
such	O
as	O
ischemia	O
and	O
cancer	O
.	O

Recent	O
studies	O
have	O
revealed	O
important	O
roles	O
for	O
miRNAs	O
in	O
regulating	O
endothelial	O
cell	O
(	O
EC	O
)	O
function	O
,	O
especially	O
angiogenesis	O
.	O

Mice	O
with	O
EC	O
-	O
specific	O
deletion	O
of	O
Dicer	O
,	O
a	O
key	O
enzyme	O
for	O
generating	O
miRNAs	O
,	O
display	O
defective	O
postnatal	O
angiogenesis	O
.	O

Specific	O
miRNAs	O
(	O
angiomiRs	O
)	O
have	O
recently	O
been	O
shown	O
to	O
regulate	O
angiogenesis	O
in	O
vivo	O
.	O

miRNA	O
-	O
126	O
,	O
an	O
EC	O
-	O
restricted	O
miRNA	O
,	O
regulates	O
vascular	O
integrity	O
and	O
developmental	O
angiogenesis	O
.	O

miR	O
-	O
378	O
,	O
miR	O
-	O
296	O
,	O
and	O
the	O
miR	O
-	O
17	O
-	O
92	O
cluster	O
contribute	O
to	O
tumor	O
angiogenesis	O
.	O

Manipulating	O
angiomiRs	O
in	O
the	O
settings	O
of	O
pathological	O
vascularization	O
represents	O
a	O
new	O
therapeutic	O
approach	O
.	O

[	O
Incidence	O
of	O
fungal	O
infection	O
in	O
surgical	O
diseases	O
of	O
the	O
pancreas	O
]	O
.	O

Recently	O
the	O
number	O
of	O
mycotic	O
infections	O
has	O
increased	O
significantly	O
.	O

Authors	O
have	O
observed	O
13	O
mycotic	O
infections	O
on	O
operated	O
patients	O
suffering	O
pancreatic	O
diseases	O
between	O
1984	O
and	O
1990	O
.	O

9	O
of	O
13	O
patients	O
had	O
pancreatic	O
abscesses	O
as	O
well	O
.	O

The	O
risk	O
factors	O
of	O
fungal	O
infections	O
are	O
analysed	O
.	O

It	O
is	O
important	O
to	O
take	O
differentiation	O
between	O
fungal	O
colonisation	O
and	O
septicaemia	O
caused	O
by	O
yeasts	O
.	O

Repeated	O
microbiological	O
examinations	O
can	O
promote	O
recognising	O
of	O
the	O
fungal	O
invasion	O
.	O

The	O
base	O
of	O
the	O
therapy	O
is	O
to	O
avoid	O
risk	O
factors	O
of	O
infections	O
and	O
to	O
use	O
antifungal	O
medication	O
in	O
time	O
.	O

Cisplatin	O
reduces	O
endothelial	O
cell	O
migration	O
via	O
regulation	O
of	O
type	O
2	O
-	O
matrix	O
metalloproteinase	O
activity	O
.	O

AIMS	O
:	O
In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	O
on	O
endothelial	O
cell	O
migration	O
,	O
an	O
essential	O
process	O
for	O
vascular	O
remodeling	O
and	O
regeneration	O
in	O
several	O
physiological	O
and	O
pathological	O
situations	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
were	O
treated	O
with	O
cisplatin	O
and	O
endothelial	O
cell	O
migration	O
analyzed	O
by	O
fluorescence	O
and	O
scratch	O
-	O
wound	O
migration	O
assay	O
.	O

MMP2	O
and	O
MMP9	O
activity	O
were	O
determined	O
by	O
zymographic	O
assay	O
,	O
and	O
MAPK	O
activation	O
by	O
Western	O
blotting	O
analysis	O
.	O

RESULTS	O
:	O
We	O
demonstrated	O
that	O
cisplatin	O
provoked	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
decrease	O
of	O
HUVEC	O
migration	O
;	O
this	O
effect	O
was	O
clearly	O
independent	O
from	O
its	O
well	O
known	O
cytotoxic	O
activity	O
.	O

In	O
addition	O
,	O
cisplatin	O
markedly	O
reduced	O
MMP2	O
activity	O
in	O
both	O
conditioned	O
media	O
and	O
cell	O
lysates	O
,	O
increased	O
p38	O
MAPK	O
and	O
JNK	O
phosphorylation	O
,	O
but	O
did	O
not	O
affect	O
ERK	O
phosphorylation	O
.	O

Endothelial	O
cell	O
migration	O
was	O
attenuated	O
by	O
treatment	O
of	O
cells	O
with	O
GM6001	O
,	O
a	O
non	O
-	O
specific	O
inhibitor	O
of	O
MMPs	O
,	O
or	O
by	O
a	O
selective	O
anti	O
-	O
MMP2	O
antibody	O
.	O

However	O
,	O
treatment	O
of	O
cells	O
with	O
SB202190	O
or	O
SP600125	O
,	O
inhibitors	O
of	O
p38	O
MAPK	O
and	O
JNK	O
respectively	O
,	O
did	O
not	O
affect	O
HUVEC	O
migration	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggested	O
that	O
cisplatin	O
induced	O
a	O
reduction	O
of	O
endothelial	O
cell	O
migration	O
through	O
an	O
inhibition	O
of	O
MMP2	O
activity	O
by	O
downstream	O
signal	O
transduction	O
pathways	O
independent	O
of	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
.	O

Promoting	O
angiogenesis	O
via	O
manipulation	O
of	O
VEGF	O
responsiveness	O
with	O
notch	O
signaling	O
.	O

Promoting	O
angiogenesis	O
via	O
delivery	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
other	O
angiogenic	O
factors	O
is	O
both	O
a	O
potential	O
therapy	O
for	O
cardiovascular	O
diseases	O
and	O
a	O
critical	O
aspect	O
for	O
tissue	O
regeneration	O
.	O

The	O
recent	O
demonstration	O
that	O
VEGF	O
signaling	O
is	O
modulated	O
by	O
the	O
Notch	O
signaling	O
pathway	O
,	O
however	O
,	O
suggests	O
that	O
inhibiting	O
Notch	O
signaling	O
may	O
enhance	O
regional	O
neovascularization	O
,	O
by	O
altering	O
the	O
responsiveness	O
of	O
local	O
endothelial	O
cells	O
to	O
angiogenic	O
stimuli	O
.	O

We	O
tested	O
this	O
possibility	O
with	O
in	O
vitro	O
assays	O
using	O
human	O
endothelial	O
cells	O
,	O
as	O
well	O
as	O
in	O
a	O
rodent	O
hindlimb	O
ischemia	O
model	O
.	O

Treatment	O
of	O
cultured	O
human	O
endothelial	O
cells	O
with	O
DAPT	O
,	O
a	O
gamma	O
secretase	O
inhibitor	O
,	O
increased	O
cell	O
migration	O
and	O
sprout	O
formation	O
in	O
response	O
to	O
VEGF	O
stimulation	O
with	O
a	O
biphasic	O
dependence	O
on	O
DAPT	O
concentration	O
.	O

Further	O
,	O
delivery	O
of	O
an	O
appropriate	O
combination	O
of	O
DAPT	O
and	O
VEGF	O
from	O
an	O
injectable	O
alginate	O
hydrogel	O
system	O
into	O
ischemic	O
hindlimbs	O
led	O
to	O
a	O
faster	O
recovery	O
of	O
blood	O
flow	O
than	O
VEGF	O
or	O
DAPT	O
alone	O
;	O
perfusion	O
levels	O
reached	O
80	O
%	O
of	O
the	O
normal	O
level	O
by	O
week	O
4	O
with	O
combined	O
DAPT	O
and	O
VEGF	O
delivery	O
.	O

Direct	O
intramuscular	O
or	O
intraperitoneal	O
injection	O
of	O
DAPT	O
did	O
not	O
result	O
in	O
the	O
same	O
level	O
of	O
improvement	O
,	O
suggesting	O
that	O
appropriate	O
presentation	O
of	O
DAPT	O
(	O
gel	O
delivery	O
)	O
is	O
important	O
for	O
its	O
activity	O
.	O

DAPT	O
delivery	O
from	O
the	O
hydrogels	O
also	O
did	O
not	O
lead	O
to	O
any	O
adverse	O
side	O
effects	O
,	O
in	O
contrast	O
to	O
systemic	O
introduction	O
of	O
DAPT	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
a	O
new	O
approach	O
to	O
promote	O
angiogenesis	O
by	O
controlling	O
Notch	O
signaling	O
,	O
and	O
may	O
provide	O
new	O
options	O
to	O
treat	O
patients	O
with	O
diseases	O
that	O
diminish	O
angiogenic	O
responsiveness	O
.	O

[	O
Activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
and	O
its	O
involvement	O
in	O
endothelial	O
cell	O
migration	O
]	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
activation	O
of	O
sterol	O
regulatory	O
element	O
binding	O
protein	O
(	O
SREBP	O
)	O
and	O
its	O
critical	O
role	O
in	O
endothelial	O
cell	O
migration	O
.	O

METHODS	O
:	O
Bovine	O
aortic	O
endothelial	O
cells	O
(	O
ECs	O
)	O
were	O
cultured	O
.	O

The	O
expression	O
of	O
SREBP	O
and	O
Cdc42	O
were	O
determined	O
by	O
Western	O
blot	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Moreover	O
,	O
outward	O
growth	O
migration	O
model	O
and	O
transwell	O
chamber	O
assay	O
were	O
used	O
to	O
detect	O
ECs	O
migration	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
SREBP	O
was	O
activated	O
during	O
ECs	O
migration	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
increased	O
active	O
form	O
SREBP	O
in	O
migrating	O
as	O
compared	O
to	O
non	O
-	O
migrating	O
ECs	O
population	O
.	O

SREBP	O
activation	O
decreased	O
as	O
ECs	O
migration	O
slowed	O
;	O
(	O
2	O
)	O
Coincidental	O
with	O
SREBP	O
activation	O
,	O
mRNA	O
expression	O
of	O
its	O
target	O
genes	O
such	O
as	O
low	O
density	O
lipoprotein	O
receptor	O
,	O
HMG	O
-	O
CoA	O
reductase	O
,	O
and	O
fatty	O
acid	O
synthase	O
also	O
increased	O
in	O
migrating	O
ECs	O
population	O
as	O
detected	O
by	O
real	O
-	O
time	O
PCR	O
;	O
(	O
3	O
)	O
Migration	O
induced	O
SREBP	O
activation	O
in	O
ECs	O
was	O
inhibited	O
by	O
SREBP	O
-	O
acting	O
protein	O
RNAi	O
and	O
pharmacologically	O
by	O
25	O
-	O
hydroxycholesterol	O
;	O
(	O
4	O
)	O
Inhibition	O
of	O
SREBP	O
led	O
to	O
decreased	O
ECs	O
migration	O
in	O
various	O
models	O
;	O
(	O
5	O
)	O
Cells	O
genetically	O
deficient	O
in	O
SREBP	O
-	O
acting	O
protein	O
,	O
S1P	O
,	O
or	O
S2P	O
,	O
phenotypically	O
exhibited	O
impaired	O
migration	O
;	O
(	O
6	O
)	O
SREBP	O
inhibition	O
in	O
ECs	O
suppressed	O
the	O
activity	O
of	O
small	O
GTPase	O
Cdc42	O
,	O
a	O
key	O
molecule	O
for	O
ECs	O
motility	O
.	O

CONCLUSIONS	O
:	O
SREBP	O
is	O
activated	O
during	O
and	O
plays	O
a	O
critical	O
role	O
in	O
ECs	O
migration	O
.	O

Targeting	O
SREBP	O
could	O
become	O
a	O
novel	O
approach	O
in	O
fighting	O
diseases	O
involving	O
abnormal	O
ECs	O
migration	O
.	O

Fibroblast	O
growth	O
factor	O
receptor	O
2	O
-	O
positive	O
fibroblasts	O
provide	O
a	O
suitable	O
microenvironment	O
for	O
tumor	O
development	O
and	O
progression	O
in	O
esophageal	O
carcinoma	O
.	O

PURPOSE	O
:	O
Tumor	O
fibroblasts	O
(	O
TF	O
)	O
have	O
been	O
suggested	O
to	O
play	O
an	O
essential	O
role	O
in	O
the	O
complex	O
process	O
of	O
tumor	O
-	O
stroma	O
interactions	O
and	O
tumorigenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
specific	O
role	O
of	O
TF	O
in	O
the	O
esophageal	O
cancer	O
microenvironment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
An	O
Affymetrix	O
expression	O
microarray	O
was	O
used	O
to	O
compare	O
gene	O
expression	O
profiles	O
between	O
six	O
pairs	O
of	O
TFs	O
and	O
normal	O
fibroblasts	O
from	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
ESCC	O
)	O
.	O

Differentially	O
expressed	O
genes	O
were	O
identified	O
,	O
and	O
a	O
subset	O
was	O
evaluated	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
About	O
43	O
%	O
(	O
126	O
of	O
292	O
)	O
of	O
known	O
deregulated	O
genes	O
in	O
TFs	O
were	O
associated	O
with	O
cell	O
proliferation	O
,	O
extracellular	O
matrix	O
remodeling	O
,	O
and	O
immune	O
response	O
.	O

Up	O
-	O
regulation	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
FGFR2	O
)	O
,	O
which	O
showed	O
the	O
most	O
significant	O
change	O
,	O
was	O
detected	O
in	O
all	O
six	O
tested	O
TFs	O
compared	O
with	O
their	O
paired	O
normal	O
fibroblasts	O
.	O

A	O
further	O
study	O
found	O
that	O
FGFR2	O
-	O
positive	O
fibroblasts	O
were	O
only	O
observed	O
inside	O
the	O
tumor	O
tissues	O
and	O
not	O
in	O
tumor	O
-	O
surrounding	O
stromal	O
tissues	O
,	O
suggesting	O
that	O
FGFR2	O
could	O
be	O
used	O
as	O
a	O
TF	O
-	O
specific	O
marker	O
in	O
ESCC	O
.	O

Moreover	O
,	O
the	O
conditioned	O
medium	O
from	O
TFs	O
was	O
found	O
to	O
be	O
able	O
to	O
promote	O
ESCC	O
tumor	O
cell	O
growth	O
,	O
migration	O
,	O
and	O
invasion	O
in	O
vitro	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
provides	O
new	O
candidate	O
genes	O
for	O
the	O
esophageal	O
cancer	O
microenvironment	O
.	O

Based	O
on	O
our	O
results	O
,	O
we	O
hypothesize	O
that	O
FGFR2	O
(	O
+	O
)	O
-	O
TFs	O
might	O
provide	O
cancer	O
cells	O
with	O
a	O
suitable	O
microenvironment	O
via	O
secretion	O
of	O
proteins	O
that	O
could	O
promote	O
cancer	O
development	O
and	O
progression	O
through	O
stimulation	O
of	O
cancer	O
cell	O
proliferation	O
,	O
induction	O
of	O
angiogenesis	O
,	O
inhibition	O
of	O
cell	O
adhesion	O
,	O
enhancement	O
of	O
cell	O
mobility	O
,	O
and	O
promotion	O
of	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
.	O

[	O
Role	O
of	O
the	O
tumor	O
suppressor	O
ARF	O
in	O
oncogenesis	O
]	O

The	O
paper	O
reviews	O
the	O
data	O
available	O
in	O
the	O
literature	O
on	O
a	O
role	O
of	O
the	O
tumor	O
suppressor	O
ARF	O
in	O
oncogenesis	O
and	O
considers	O
the	O
structure	O
of	O
a	O
gene	O
encoding	O
ARF	O
protein	O
.	O

The	O
p53	O
-	O
dependent	O
and	O
p	O
-	O
53	O
-	O
independent	O
functions	O
of	O
this	O
protein	O
are	O
under	O
many	O
studies	O
.	O

There	O
is	O
evidence	O
for	O
the	O
implication	O
of	O
ARF	O
in	O
angiogenesis	O
.	O

There	O
is	O
more	O
and	O
more	O
information	O
on	O
the	O
role	O
of	O
ARF	O
in	O
the	O
regulation	O
of	O
a	O
cell	O
cycle	O
,	O
apoptosis	O
,	O
and	O
autophagy	O
.	O

The	O
importance	O
of	O
this	O
tumor	O
suppressor	O
in	O
the	O
mechanisms	O
of	O
carcinogenesis	O
is	O
beyond	O
question	O
as	O
the	O
inactivation	O
of	O
ARF	O
suppressor	O
activity	O
leads	O
to	O
the	O
rapid	O
growth	O
of	O
neoplasia	O
.	O

However	O
,	O
the	O
exact	O
mechanisms	O
of	O
ARF	O
action	O
yet	O
remain	O
unclear	O
and	O
require	O
further	O
studies	O
by	O
different	O
specialists	O
at	O
both	O
the	O
molecular	O
genetic	O
and	O
other	O
levels	O
of	O
investigation	O
.	O

Impact	O
of	O
tumor	O
cell	O
VEGF	O
expression	O
on	O
the	O
in	O
vivo	O
efficacy	O
of	O
vandetanib	O
(	O
ZACTIMA	O
;	O
ZD6474	O
)	O
.	O

VEGF	O
is	O
the	O
key	O
player	O
in	O
tumor	O
angiogenesis	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
impact	O
of	O
VEGF	O
expression	O
on	O
the	O
response	O
of	O
tumors	O
to	O
the	O
VEGFR2	O
associated	O
tyrosine	O
kinase	O
inhibitor	O
vandetanib	O
was	O
evaluated	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
colon	O
carcinoma	O
(	O
HT29	B
)	O
and	O
murine	O
squamous	O
carcinoma	O
(	O
SCCVII	B
)	O
clonal	O
cell	O
lines	O
expressing	O
varying	O
levels	O
of	O
VEGF	O
were	O
established	O
and	O
their	O
response	O
to	O
vandetanib	O
was	O
assessed	O
in	O
tissue	O
culture	O
and	O
as	O
solid	O
tumors	O
.	O

RESULTS	O
:	O
Vandetanib	O
treatment	O
had	O
no	O
effect	O
on	O
tumor	O
cell	O
clonogenic	O
cell	O
survival	O
in	O
vitro	O
but	O
doses	O
>	O
or	O
=	O
10	O
nM	O
significantly	O
reduced	O
endothelial	O
cell	O
migration	O
.	O

In	O
vivo	O
,	O
tumors	O
derived	O
from	O
cell	O
clones	O
expressing	O
high	O
levels	O
of	O
VEGF	O
displayed	O
significantly	O
enhanced	O
angiogenesis	O
and	O
more	O
aggressive	O
growth	O
.	O

An	O
intradermal	O
angiogenesis	O
assay	O
was	O
used	O
to	O
demonstrate	O
that	O
a	O
4	O
-	O
day	O
treatment	O
with	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
able	O
to	O
significantly	O
inhibit	O
blood	O
vessel	O
growth	O
induced	O
by	O
both	O
parental	O
and	O
high	O
VEGF	O
-	O
expressing	O
tumor	O
cell	O
clones	O
.	O

In	O
the	O
HT29	B
tumor	O
model	O
,	O
treatment	O
response	O
to	O
vandetanib	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
Monday	O
-	O
Friday	O
for	O
2	O
weeks	O
)	O
was	O
greatest	O
in	O
xenografts	O
derived	O
from	O
the	O
highest	O
VEGF	O
-	O
expressing	O
cell	O
clones	O
.	O

A	O
similar	O
trend	O
was	O
noted	O
in	O
the	O
SCCVII	B
tumor	O
model	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
vandetanib	O
therapy	O
effectively	O
counteracted	O
the	O
aggressive	O
feature	O
of	O
tumor	O
growth	O
resulting	O
from	O
VEGF	O
over	O
-	O
expressing	O
tumor	O
cells	O
and	O
suggest	O
that	O
such	O
tumors	O
may	O
be	O
particularly	O
well	O
suited	O
for	O
anti	O
-	O
VEGF	O
interventions	O
.	O

The	O
modulation	O
of	O
platelet	O
and	O
endothelial	O
cell	O
adhesion	O
to	O
vascular	O
graft	O
materials	O
by	O
perlecan	O
.	O

Controlled	O
neo	O
-	O
endothelialisation	O
is	O
critical	O
to	O
the	O
patency	O
of	O
small	O
diameter	O
vascular	O
grafts	O
.	O

Endothelialisation	O
and	O
platelet	O
adhesion	O
to	O
purified	O
endothelial	O
cell	O
-	O
derived	O
perlecan	O
,	O
the	O
major	O
heparan	O
sulfate	O
(	O
HS	O
)	O
proteoglycan	O
in	O
basement	O
membranes	O
,	O
were	O
investigated	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
assays	O
.	O

Expanded	O
polytetrafluoroethylene	O
(	O
ePTFE	O
)	O
vascular	O
grafts	O
were	O
coated	O
with	O
perlecan	O
and	O
tested	O
in	O
an	O
ovine	O
carotid	O
interposition	O
model	O
for	O
a	O
period	O
of	O
6	O
weeks	O
and	O
assessed	O
using	O
light	O
and	O
scanning	O
microscopy	O
.	O

Enhanced	O
endothelial	O
cell	O
growth	O
and	O
reduced	O
platelet	O
adhesion	O
were	O
observed	O
on	O
the	O
perlecan	O
coated	O
grafts	O
when	O
compared	O
to	O
uncoated	O
controls	O
implanted	O
in	O
the	O
same	O
sheep	O
(	O
n	O
=	O
5	O
)	O
.	O

Perlecan	O
was	O
also	O
found	O
to	O
stimulate	O
endothelial	O
cell	O
proliferation	O
in	O
vitro	O
over	O
a	O
period	O
of	O
6	O
days	O
in	O
the	O
presence	O
of	O
plasma	O
proteins	O
and	O
fibroblastic	O
growth	O
factor	O
2	O
(	O
FGF	O
-	O
2	O
)	O
,	O
however	O
in	O
the	O
absence	O
of	O
FGF	O
-	O
2	O
endothelial	O
cell	O
growth	O
could	O
not	O
be	O
maintained	O
during	O
this	O
period	O
.	O

Perlecan	O
was	O
found	O
to	O
be	O
anti	O
-	O
adhesive	O
for	O
platelets	O
,	O
however	O
after	O
removal	O
of	O
the	O
HS	O
chains	O
attached	O
to	O
perlecan	O
,	O
platelet	O
adhesion	O
and	O
aggregation	O
were	O
supported	O
.	O

These	O
results	O
suggest	O
a	O
role	O
for	O
HS	O
chains	O
of	O
perlecan	O
in	O
improving	O
graft	O
patency	O
by	O
selectively	O
promoting	O
endothelial	O
cell	O
proliferation	O
while	O
modulating	O
platelet	O
adhesion	O
.	O

Mechanical	O
regulation	O
of	O
the	O
proangiogenic	O
factor	O
CCN1	O
/	O
CYR61	O
gene	O
requires	O
the	O
combined	O
activities	O
of	O
MRTF	O
-	O
A	O
and	O
CREB	O
-	O
binding	O
protein	O
histone	O
acetyltransferase	O
.	O

Smooth	O
muscle	O
-	O
rich	O
tissues	O
respond	O
to	O
mechanical	O
overload	O
by	O
an	O
adaptive	O
hypertrophic	O
growth	O
combined	O
with	O
activation	O
of	O
angiogenesis	O
,	O
which	O
potentiates	O
their	O
mechanical	O
overload	O
-	O
bearing	O
capabilities	O
.	O

Neovascularization	O
is	O
associated	O
with	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
angiogenic	O
factors	O
such	O
as	O
CCN1	O
,	O
an	O
immediate	O
-	O
early	O
gene	O
-	O
encoded	O
matricellular	O
molecule	O
critical	O
for	O
vascular	O
development	O
and	O
repair	O
.	O

Here	O
we	O
have	O
demonstrated	O
that	O
mechanical	O
strain	O
-	O
dependent	O
induction	O
of	O
the	O
CCN1	O
gene	O
involves	O
signaling	O
cascades	O
through	O
RhoA	O
-	O
mediated	O
actin	O
remodeling	O
and	O
the	O
p38	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
.	O

Actin	O
signaling	O
controls	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
activity	O
via	O
SRF	O
interaction	O
with	O
the	O
myocardin	O
-	O
related	O
transcriptional	O
activator	O
(	O
MRTF	O
)	O
-	O
A	O
and	O
tethering	O
to	O
a	O
single	O
CArG	O
box	O
sequence	O
within	O
the	O
CCN1	O
promoter	O
.	O

Such	O
activity	O
was	O
abolished	O
in	O
mechanically	O
stimulated	O
mouse	O
MRTF	O
-	O
A	O
(	O
-	O
/	O
-	O
)	O
cells	O
or	O
upon	O
inhibition	O
of	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
either	O
pharmacologically	O
or	O
by	O
siRNAs	O
.	O

Mechanical	O
strain	O
induced	O
CBP	O
-	O
mediated	O
acetylation	O
of	O
histones	O
3	O
and	O
4	O
at	O
the	O
SRF	O
-	O
binding	O
site	O
and	O
within	O
the	O
CCN1	O
gene	O
coding	O
region	O
.	O

Inhibition	O
of	O
p38	O
SAPK	O
reduced	O
CBP	O
HAT	O
activity	O
and	O
its	O
recruitment	O
to	O
the	O
SRF	O
.	O
MRTF	O
-	O
A	O
complex	O
,	O
whereas	O
enforced	O
induction	O
of	O
p38	O
by	O
upstream	O
activators	O
(	O
e	O
.	O
g	O
.	O
MKK3	O
and	O
MKK6	O
)	O
enhanced	O
both	O
CBP	O
HAT	O
and	O
CCN1	O
promoter	O
activities	O
.	O

Similarly	O
,	O
mechanical	O
overload	O
-	O
induced	O
CCN1	O
gene	O
expression	O
in	O
vivo	O
was	O
associated	O
with	O
nuclear	O
localization	O
of	O
MRTF	O
-	O
A	O
and	O
enrichment	O
of	O
the	O
CCN1	O
promoter	O
with	O
both	O
MRTF	O
-	O
A	O
and	O
acetylated	O
histone	O
H3	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
signal	O
-	O
controlled	O
activation	O
of	O
SRF	O
,	O
MRTF	O
-	O
A	O
,	O
and	O
CBP	O
provides	O
a	O
novel	O
connection	O
between	O
mechanical	O
stimuli	O
and	O
angiogenic	O
gene	O
expression	O
.	O

Tumour	O
angiogenesis	O
:	O
its	O
mechanism	O
and	O
therapeutic	O
implications	O
in	O
malignant	O
gliomas	O
.	O

Angiogenesis	O
is	O
a	O
key	O
event	O
in	O
the	O
progression	O
of	O
malignant	O
gliomas	O
.	O

The	O
presence	O
of	O
microvascular	O
proliferation	O
leads	O
to	O
the	O
histological	O
diagnosis	O
of	O
glioblastoma	O
multiforme	O
.	O

Tumour	O
angiogenesis	O
involves	O
multiple	O
cellular	O
processes	O
including	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
reorganisation	O
of	O
extracellular	O
matrix	O
and	O
tube	O
formation	O
.	O

These	O
processes	O
are	O
regulated	O
by	O
numerous	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
growth	O
factors	O
.	O

Angiogenesis	O
inhibitors	O
have	O
been	O
developed	O
to	O
interrupt	O
the	O
angiogenic	O
process	O
at	O
the	O
growth	O
factor	O
,	O
receptor	O
tyrosine	O
kinase	O
and	O
intracellular	O
kinase	O
levels	O
.	O

Other	O
anti	O
-	O
angiogenic	O
therapies	O
alter	O
the	O
immune	O
response	O
and	O
endogeneous	O
angiogenesis	O
inhibitor	O
levels	O
.	O

Most	O
anti	O
-	O
angiogenic	O
therapies	O
for	O
malignant	O
gliomas	O
are	O
in	O
Phase	O
I	O
/	O
II	O
trials	O
and	O
only	O
modest	O
efficacies	O
are	O
reported	O
for	O
monotherapies	O
.	O

The	O
greatest	O
potential	O
for	O
angiogenesis	O
inhibitors	O
may	O
lie	O
in	O
their	O
ability	O
to	O
combine	O
safely	O
with	O
chemotherapy	O
and	O
radiotherapy	O
.	O

Regulation	O
of	O
thrombospondin	O
-	O
1	O
by	O
natural	O
and	O
synthetic	O
progestins	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

Our	O
recent	O
studies	O
show	O
that	O
progestins	O
induce	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
breast	O
cancer	O
cells	O
that	O
express	O
mutant	O
p53	O
protein	O
.	O

Here	O
,	O
we	O
show	O
that	O
natural	O
and	O
synthetic	O
progestins	O
also	O
induce	O
thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
mRNA	O
and	O
protein	O
in	O
T47	B
-	I
D	I
and	O
BT	B
-	I
474	I
breast	O
cancer	O
cells	O
.	O

Antiprogestin	O
RU	O
-	O
486	O
inhibits	O
the	O
induction	O
of	O
VEGF	O
and	O
TSP	O
-	O
1	O
by	O
progestins	O
,	O
suggesting	O
that	O
this	O
effect	O
of	O
progestin	O
is	O
mediated	O
by	O
the	O
progesterone	O
receptor	O
(	O
PR	O
)	O
.	O

Actinomycin	O
-	O
D	O
,	O
but	O
not	O
puromycin	O
,	O
also	O
blocks	O
progestin	O
-	O
dependent	O
induction	O
of	O
TSP	O
-	O
1	O
.	O

A	O
putative	O
progestin	O
-	O
response	O
element	O
was	O
identified	O
in	O
the	O
human	O
TSP	O
-	O
1	O
promoter	O
,	O
which	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
a	O
progestin	O
-	O
PR	O
complex	O
might	O
directly	O
regulate	O
transcription	O
of	O
the	O
TSP	O
-	O
1	O
gene	O
in	O
human	O
cells	O
.	O

Conditioned	O
medium	O
from	O
progestin	O
-	O
treated	O
breast	O
cancer	O
cells	O
stimulates	O
endothelial	O
cell	O
proliferation	O
in	O
the	O
absence	O
though	O
not	O
in	O
the	O
presence	O
of	O
antibody	O
to	O
TSP	O
-	O
1	O
,	O
indicating	O
that	O
TSP	O
-	O
1	O
secreted	O
by	O
breast	O
cancer	O
cells	O
could	O
be	O
pro	O
-	O
angiogenic	O
.	O

Since	O
tumor	O
cell	O
-	O
derived	O
TSP	O
-	O
1	O
has	O
the	O
potential	O
to	O
promote	O
angiogenesis	O
in	O
the	O
tumor	O
microenvironment	O
,	O
it	O
could	O
be	O
a	O
potential	O
target	O
for	O
breast	O
cancer	O
therapy	O
.	O

Angiogenesis	O
in	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
-	O
1	O
-	O
null	O
mice	O
.	O

Platelet	O
endothelial	O
cell	O
adhesion	O
molecule	O
(	O
PECAM	O
)	O
-	O
1	O
has	O
been	O
previously	O
implicated	O
in	O
endothelial	O
cell	O
migration	O
;	O
additionally	O
,	O
anti	O
-	O
PECAM	O
-	O
1	O
antibodies	O
have	O
been	O
shown	O
to	O
inhibit	O
in	O
vivo	O
angiogenesis	O
.	O

Studies	O
were	O
therefore	O
performed	O
with	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
to	O
further	O
define	O
the	O
involvement	O
of	O
PECAM	O
-	O
1	O
in	O
blood	O
vessel	O
formation	O
.	O

Vascularization	O
of	O
subcutaneous	O
Matrigel	O
implants	O
as	O
well	O
as	O
tumor	O
angiogenesis	O
were	O
both	O
inhibited	O
in	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
.	O

Reciprocal	O
bone	O
marrow	O
transplants	O
that	O
involved	O
both	O
wild	O
-	O
type	O
and	O
PECAM	O
-	O
1	O
-	O
deficient	O
mice	O
revealed	O
that	O
the	O
impaired	O
angiogenic	O
response	O
resulted	O
from	O
a	O
loss	O
of	O
endothelial	O
,	O
but	O
not	O
leukocyte	O
,	O
PECAM	O
-	O
1	O
.	O

In	O
vitro	O
wound	O
migration	O
and	O
single	O
-	O
cell	O
motility	O
by	O
PECAM	O
-	O
1	O
-	O
null	O
endothelial	O
cells	O
were	O
also	O
compromised	O
.	O

In	O
addition	O
,	O
filopodia	O
formation	O
,	O
a	O
feature	O
of	O
motile	O
cells	O
,	O
was	O
inhibited	O
in	O
PECAM	O
-	O
1	O
-	O
null	O
endothelial	O
cells	O
as	O
well	O
as	O
in	O
human	O
endothelial	O
cells	O
treated	O
with	O
either	O
anti	O
-	O
PECAM	O
-	O
1	O
antibody	O
or	O
PECAM	O
-	O
1	O
siRNA	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
PECAM	O
-	O
1	O
promoted	O
filopodia	O
formation	O
and	O
increased	O
the	O
protein	O
expression	O
levels	O
of	O
Cdc42	O
,	O
a	O
Rho	O
GTPase	O
that	O
is	O
known	O
to	O
promote	O
the	O
formation	O
of	O
filopodia	O
.	O

In	O
the	O
developing	O
retinal	O
vasculature	O
,	O
numerous	O
,	O
long	O
filamentous	O
filopodia	O
,	O
emanating	O
from	O
endothelial	O
cells	O
at	O
the	O
tips	O
of	O
angiogenic	O
sprouts	O
,	O
were	O
observed	O
in	O
wild	O
-	O
type	O
animals	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
the	O
PECAM	O
-	O
1	O
-	O
null	O
mice	O
.	O

Together	O
,	O
these	O
data	O
further	O
establish	O
the	O
involvement	O
of	O
endothelial	O
PECAM	O
-	O
1	O
in	O
angiogenesis	O
and	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
PECAM	O
-	O
1	O
may	O
stimulate	O
endothelial	O
cell	O
motility	O
by	O
promoting	O
the	O
formation	O
of	O
filopodia	O
.	O

Desipramine	O
inhibits	O
the	O
growth	O
of	O
a	O
mouse	O
skin	O
squamous	O
cell	O
carcinoma	O
cell	O
line	O
and	O
affects	O
glucocorticoid	O
receptor	O
-	O
mediated	O
transcription	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
tricyclic	O
antidepressant	O
desipramine	O
(	O
DMI	O
)	O
on	O
the	O
growth	O
inhibition	O
and	O
translocation	O
of	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
in	O
cancerous	O
and	O
noncancerous	O
cell	O
lines	O
and	O
the	O
effect	O
of	O
DMI	O
on	O
GR	O
-	O
mediated	O
transcription	O
.	O

Nontumorigenic	O
,	O
immortalized	O
keratinocytes	O
cell	O
line	O
(	O
3PC	B
)	O
,	O
papilloma	O
(	O
MT1	B
/	I
2	I
)	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
(	O
Ca3	B
/	I
7	I
)	O
cell	O
lines	O
were	O
initially	O
used	O
to	O
study	O
the	O
cell	O
growth	O
inhibition	O
by	O
DMI	O
.	O

Although	O
,	O
the	O
growth	O
of	O
all	O
three	O
cell	O
lines	O
was	O
suppressed	O
by	O
DMI	O
,	O
it	O
was	O
more	O
effective	O
in	O
Ca3	B
/	I
7	I
cells	O
.	O

Therefore	O
,	O
we	O
next	O
examined	O
the	O
effect	O
of	O
DMI	O
on	O
Ca3	B
/	I
7	I
cells	O
,	O
resistant	O
to	O
growth	O
inhibition	O
by	O
the	O
synthetic	O
glucocorticoid	O
fluocinolone	O
acetonide	O
(	O
FA	O
)	O
.	O

DMI	O
inhibited	O
cell	O
proliferation	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
translocation	O
of	O
GR	O
was	O
induced	O
by	O
FA	O
alone	O
,	O
DMI	O
alone	O
,	O
and	O
combination	O
of	O
both	O
agents	O
.	O

FA	O
induced	O
GR	O
-	O
mediated	O
transcription	O
in	O
Ca3	B
/	I
7	I
cells	O
transfected	O
with	O
a	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
,	O
but	O
DMI	O
alone	O
did	O
not	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O

However	O
,	O
DMI	O
inhibited	O
FA	O
-	O
induced	O
,	O
GR	O
-	O
mediated	O
transcription	O
when	O
both	O
agents	O
were	O
given	O
together	O
.	O

Pretreatment	O
with	O
DMI	O
followed	O
by	O
combination	O
of	O
DMI	O
and	O
FA	O
decreased	O
GR	O
-	O
mediated	O
transcription	O
more	O
than	O
pretreatment	O
with	O
FA	O
.	O

The	O
expression	O
of	O
metallothionein	O
-	O
1	O
(	O
Mt	O
-	O
1	O
)	O
gene	O
,	O
which	O
is	O
regulated	O
by	O
GR	O
,	O
was	O
induced	O
significantly	O
by	O
the	O
combination	O
of	O
DMI	O
and	O
FA	O
,	O
and	O
enhanced	O
significantly	O
by	O
pretreatment	O
with	O
FA	O
but	O
not	O
DMI	O
.	O

DMI	O
is	O
suggested	O
to	O
inhibit	O
the	O
growth	O
of	O
Ca3	B
/	I
7	I
cells	O
and	O
to	O
affect	O
GR	O
-	O
mediated	O
transcription	O
.	O

WNT	O
/	O
TCF	O
signaling	O
through	O
LEF1	O
and	O
HOXB9	O
mediates	O
lung	O
adenocarcinoma	O
metastasis	O
.	O

Metastasis	O
from	O
lung	O
adenocarcinoma	O
can	O
occur	O
swiftly	O
to	O
multiple	O
organs	O
within	O
months	O
of	O
diagnosis	O
.	O

The	O
mechanisms	O
that	O
confer	O
this	O
rapid	O
metastatic	O
capacity	O
to	O
lung	O
tumors	O
are	O
unknown	O
.	O

Activation	O
of	O
the	O
canonical	O
WNT	O
/	O
TCF	O
pathway	O
is	O
identified	O
here	O
as	O
a	O
determinant	O
of	O
metastasis	O
to	O
brain	O
and	O
bone	O
during	O
lung	O
adenocarcinoma	O
progression	O
.	O

Gene	O
expression	O
signatures	O
denoting	O
WNT	O
/	O
TCF	O
activation	O
are	O
associated	O
with	O
relapse	O
to	O
multiple	O
organs	O
in	O
primary	O
lung	O
adenocarcinoma	O
.	O

Metastatic	O
subpopulations	O
isolated	O
from	O
independent	O
lymph	O
node	O
-	O
derived	O
lung	O
adenocarcinoma	O
cell	O
lines	O
harbor	O
a	O
hyperactive	O
WNT	O
/	O
TCF	O
pathway	O
.	O

Reduction	O
of	O
TCF	O
activity	O
in	O
these	O
cells	O
attenuates	O
their	O
ability	O
to	O
form	O
brain	O
and	O
bone	O
metastases	O
in	O
mice	O
,	O
independently	O
of	O
effects	O
on	O
tumor	O
growth	O
in	O
the	O
lungs	O
.	O

The	O
WNT	O
/	O
TCF	O
target	O
genes	O
HOXB9	O
and	O
LEF1	O
are	O
identified	O
as	O
mediators	O
of	O
chemotactic	O
invasion	O
and	O
colony	O
outgrowth	O
.	O

Thus	O
,	O
a	O
distinct	O
WNT	O
/	O
TCF	O
signaling	O
program	O
through	O
LEF1	O
and	O
HOXB9	O
enhances	O
the	O
competence	O
of	O
lung	O
adenocarcinoma	O
cells	O
to	O
colonize	O
the	O
bones	O
and	O
the	O
brain	O
.	O

For	O
a	O
video	O
summary	O
of	O
this	O
article	O
,	O
see	O
the	O
PaperFlick	O
file	O
available	O
with	O
the	O
online	O
Supplemental	O
Data	O
.	O

c	O
-	O
Ski	O
overexpression	O
promotes	O
tumor	O
growth	O
and	O
angiogenesis	O
through	O
inhibition	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
in	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
.	O

c	O
-	O
Ski	O
,	O
originally	O
identified	O
as	O
a	O
proto	O
-	O
oncogene	O
product	O
,	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
family	O
signaling	O
through	O
interaction	O
with	O
Smad2	O
,	O
Smad3	O
,	O
and	O
Smad4	O
.	O

High	O
expression	O
of	O
c	O
-	O
Ski	O
has	O
been	O
found	O
in	O
some	O
cancers	O
,	O
including	O
gastric	O
cancer	O
.	O

We	O
previously	O
showed	O
that	O
disruption	O
of	O
TGF	O
-	O
beta	O
signaling	O
by	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
in	O
a	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
model	O
accelerated	O
tumor	O
growth	O
through	O
induction	O
of	O
tumor	O
angiogenesis	O
by	O
decreased	O
expression	O
of	O
the	O
anti	O
-	O
angiogenic	O
factor	O
thrombospondin	O
(	O
TSP	O
)	O
-	O
1	O
.	O

Here	O
,	O
we	O
examined	O
the	O
function	O
of	O
c	O
-	O
Ski	O
in	O
human	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
OCUM	B
-	I
2MLN	I
cells	O
.	O

Overexpression	O
of	O
c	O
-	O
Ski	O
inhibited	O
TGF	O
-	O
beta	O
signaling	O
in	O
OCUM	B
-	I
2MLN	I
cells	O
.	O

Interestingly	O
,	O
c	O
-	O
Ski	O
overexpression	O
resulted	O
in	O
extensive	O
acceleration	O
of	O
the	O
growth	O
of	O
subcutaneous	O
xenografts	O
in	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
female	O
mice	O
(	O
6	O
weeks	O
of	O
age	O
)	O
.	O

Similar	O
to	O
tumors	O
expressing	O
dominant	O
-	O
negative	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
,	O
histochemical	O
studies	O
revealed	O
less	O
fibrosis	O
and	O
increased	O
angiogenesis	O
in	O
xenografted	O
tumors	O
expressing	O
c	O
-	O
Ski	O
compared	O
to	O
control	O
tumors	O
.	O

Induction	O
of	O
TSP	O
-	O
1	O
mRNA	O
by	O
TGF	O
-	O
beta	O
was	O
attenuated	O
by	O
c	O
-	O
Ski	O
in	O
vitro	O
,	O
and	O
expression	O
of	O
TSP	O
-	O
1	O
mRNA	O
was	O
decreased	O
in	O
tumors	O
expressing	O
c	O
-	O
Ski	O
in	O
vivo	O
.	O

These	O
findings	O
suggest	O
that	O
c	O
-	O
Ski	O
overexpression	O
promotes	O
the	O
growth	O
of	O
diffuse	O
-	O
type	O
gastric	O
carcinoma	O
through	O
induction	O
of	O
angiogenesis	O
.	O

[	O
Quantitative	O
analysis	O
of	O
regional	O
cerebral	O
blood	O
flow	O
in	O
elderly	O
with	O
white	O
matter	O
lesions	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
observe	O
whether	O
the	O
severity	O
of	O
white	O
matter	O
lesions	O
(	O
WML	O
)	O
is	O
related	O
to	O
ischemia	O
in	O
elderly	O
.	O

METHODS	O
:	O

WML	O
were	O
divided	O
into	O
2	O
categories	O
(	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
)	O
and	O
four	O
grades	O
(	O
grade	O
0	O
,	O
grade	O
1	O
,	O
grade	O
2	O
and	O
grade	O
3	O
)	O
according	O
to	O
the	O
severity	O
of	O
WML	O
showing	O
on	O
the	O
FLAIR	O
sequence	O
of	O
MRI	O
using	O
modified	O
Fazekas	O
scale	O
.	O

The	O
values	O
of	O
regional	O
cerebral	O
blood	O
flow	O
(	O
rCBF	O
)	O
within	O
WML	O
and	O
other	O
brain	O
regions	O
were	O
measured	O
using	O
Xenon	O
contrast	O
CT	O
.	O

RESULTS	O
:	O

Mean	O
rCBF	O
(	O
ml	O
x	O
100	O
g	O
(	O
-	O
1	O
)	O
x	O
min	O
(	O
-	O
1	O
)	O
)	O
within	O
lesions	O
around	O
periventricular	O
areas	O
,	O
in	O
right	O
and	O
left	O
centrum	O
semiovale	O
were	O
20	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
8	O
,	O
22	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
and	O
22	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
1	O
in	O
grade	O
0	O
;	O
20	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
,	O
21	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
and	O
21	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
8	O
in	O
grade1	O
;	O
16	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
15	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7	O
and	O
15	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
in	O
grade	O
2	O
;	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
6	O
,	O
14	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
2	O
and	O
14	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
in	O
grade	O
3	O
respectively	O
.	O

The	O
severity	O
of	O
WML	O
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	O
both	O
in	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
rCBF	O
values	O
between	O
grade	O
0	O
and	O
1	O
,	O
but	O
significant	O
differences	O
existed	O
between	O
grade	O
0	O
and	O
grades	O
2	O
and	O
3	O
,	O
between	O
grade	O
1	O
and	O
grades	O
2	O
and	O
3	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Statistical	O
significance	O
also	O
existed	O
between	O
the	O
severity	O
of	O
white	O
matter	O
lesions	O
and	O
rCBF	O
in	O
bilateral	O
temporal	O
lobes	O
and	O
lentiform	O
nucleases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
severity	O
of	O
WML	O
both	O
in	O
centrum	O
semiovale	O
and	O
periventricular	O
regions	O
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	O
.	O

MEK5	O
/	O
ERK5	O
signaling	O
modulates	O
endothelial	O
cell	O
migration	O
and	O
focal	O
contact	O
turnover	O
.	O

The	O
formation	O
of	O
new	O
blood	O
vessels	O
from	O
pre	O
-	O
existing	O
ones	O
requires	O
highly	O
coordinated	O
restructuring	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
and	O
the	O
surrounding	O
extracellular	O
matrix	O
.	O

Directed	O
EC	O
migration	O
is	O
a	O
central	O
step	O
in	O
this	O
process	O
and	O
depends	O
on	O
cellular	O
signaling	O
cascades	O
that	O
initiate	O
and	O
control	O
the	O
structural	O
rearrangements	O
.	O

On	O
the	O
basis	O
of	O
earlier	O
findings	O
that	O
ERK5	O
deficiency	O
in	O
mouse	O
EC	O
results	O
in	O
massive	O
defects	O
in	O
vessel	O
architecture	O
,	O
we	O
focused	O
on	O
the	O
impact	O
of	O
the	O
MEK5	O
/	O
ERK5	O
signaling	O
pathway	O
on	O
EC	O
migration	O
.	O

Using	O
a	O
retroviral	O
gene	O
transfer	O
approach	O
,	O
we	O
found	O
that	O
constitutive	O
activation	O
of	O
MEK5	O
/	O
ERK5	O
signaling	O
strongly	O
inhibits	O
EC	O
migration	O
and	O
results	O
in	O
massive	O
morphological	O
changes	O
.	O

The	O
area	O
covered	O
by	O
spread	O
EC	O
was	O
dramatically	O
enlarged	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
focal	O
contacts	O
and	O
altered	O
organization	O
of	O
actin	O
filaments	O
.	O

Consequently	O
,	O
cells	O
were	O
more	O
rigid	O
and	O
show	O
reduced	O
motility	O
.	O

This	O
phenotype	O
was	O
most	O
likely	O
based	O
on	O
decreased	O
focal	O
contact	O
turnover	O
caused	O
by	O
reduced	O
expression	O
of	O
p130Cas	O
,	O
a	O
key	O
player	O
in	O
directed	O
cell	O
migration	O
.	O

We	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
ERK5	O
signaling	O
not	O
only	O
is	O
involved	O
in	O
EC	O
survival	O
and	O
stress	O
response	O
but	O
also	O
controls	O
migration	O
and	O
morphology	O
of	O
EC	O
.	O

The	O
Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
short	O
variant	O
promoters	O
direct	O
vascular	O
bed	O
-	O
specific	O
gene	O
expression	O
during	O
inflammation	O
in	O
mice	O
.	O

Down	O
syndrome	O
critical	O
region	O
gene	O
1	O
(	O
DSCR	O
-	O
1	O
)	O
short	O
variant	O
(	O
DSCR	O
-	O
1s	O
)	O
is	O
an	O
inhibitor	O
of	O
calcineurin	O
/	O
NFAT	O
signaling	O
encoded	O
by	O
exons	O
4	O
-	O
7	O
of	O
DSCR1	O
.	O

We	O
previously	O
reported	O
that	O
VEGF	O
induces	O
DSCR	O
-	O
1s	O
expression	O
in	O
endothelial	O
cells	O
,	O
which	O
in	O
turn	O
negatively	O
feeds	O
back	O
to	O
attenuate	O
endothelial	O
cell	O
activation	O
.	O

Here	O
,	O
in	O
order	O
to	O
characterize	O
the	O
role	O
of	O
the	O
promoter	O
that	O
drives	O
DSCR	O
-	O
1s	O
expression	O
in	O
mediating	O
inducible	O
expression	O
in	O
vivo	O
and	O
to	O
determine	O
the	O
functional	O
relevance	O
of	O
DSCR	O
-	O
1s	O
in	O
inflammation	O
,	O
we	O
targeted	O
a	O
DNA	O
construct	O
containing	O
1	O
.	O
7	O
kb	O
of	O
the	O
human	O
DSCR1s	O
promoter	O
coupled	O
to	O
the	O
lacZ	O
reporter	O
to	O
the	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
Hprt	O
)	O
locus	O
of	O
mice	O
.	O

We	O
determined	O
that	O
lacZ	O
was	O
uniformly	O
expressed	O
in	O
the	O
endothelium	O
of	O
transgenic	O
embryos	O
but	O
was	O
markedly	O
downregulated	O
postnatally	O
.	O

Systemic	O
administration	O
of	O
VEGF	O
or	O
LPS	O
in	O
adult	O
mice	O
resulted	O
in	O
cyclosporine	O
A	O
-	O
sensitive	O
reactivation	O
of	O
the	O
DSCR1s	O
promoter	O
and	O
endogenous	O
gene	O
expression	O
in	O
a	O
subset	O
of	O
organs	O
,	O
including	O
the	O
heart	O
and	O
brain	O
.	O

The	O
DSCR1s	O
promoter	O
was	O
similarly	O
induced	O
in	O
the	O
endothelium	O
of	O
tumor	O
xenografts	O
.	O

In	O
a	O
mouse	O
model	O
of	O
endotoxemia	O
,	O
DSCR	O
-	O
1s	O
-	O
deficient	O
mice	O
demonstrated	O
increased	O
sepsis	O
mortality	O
,	O
whereas	O
adenovirus	O
-	O
mediated	O
DSCR	O
-	O
1s	O
overexpression	O
protected	O
against	O
LPS	O
-	O
induced	O
lethality	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
DSCR1s	O
promoter	O
directs	O
vascular	O
bed	O
-	O
specific	O
expression	O
in	O
activated	O
endothelium	O
and	O
that	O
DSCR	O
-	O
1s	O
serves	O
to	O
dampen	O
the	O
host	O
response	O
to	O
infection	O
.	O

[	O
The	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
by	O
cognitive	O
,	O
behavioral	O
,	O
and	O
temperamental	O
variables	O
in	O
a	O
six	O
-	O
month	O
time	O
interval	O
]	O
.	O

Several	O
models	O
have	O
been	O
proposed	O
to	O
explain	O
the	O
depressive	O
phenomenon	O
,	O
such	O
as	O
the	O
theory	O
of	O
dysfunctional	O
attitudes	O
,	O
the	O
hopelessness	O
theory	O
,	O
the	O
behavioral	O
model	O
of	O
activity	O
level	O
,	O
or	O
temperamental	O
models	O
.	O

This	O
article	O
presents	O
data	O
about	O
the	O
role	O
of	O
those	O
models	O
in	O
the	O
prediction	O
of	O
the	O
level	O
of	O
depression	O
in	O
a	O
sample	O
of	O
414	O
college	O
students	O
,	O
assessed	O
over	O
a	O
temporal	O
interval	O
of	O
six	O
months	O
.	O

Dysfunctional	O
attitudes	O
,	O
attributional	O
styles	O
,	O
the	O
level	O
of	O
activity	O
,	O
and	O
the	O
five	O
-	O
factors	O
of	O
personality	O
were	O
assessed	O
.	O

The	O
BDI	O
-	O
II	O
was	O
the	O
depression	O
level	O
measure	O
.	O

The	O
results	O
showed	O
that	O
these	O
variables	O
predict	O
depression	O
levels	O
,	O
but	O
with	O
low	O
coefficients	O
.	O

The	O
dimensions	O
of	O
Need	O
of	O
Achievement	O
(	O
a	O
dysfunctional	O
attitude	O
)	O
and	O
Neuroticism	O
had	O
particularly	O
greater	O
weight	O
in	O
the	O
prediction	O
,	O
but	O
only	O
Neuroticism	O
seems	O
to	O
behave	O
like	O
a	O
vulnerability	O
element	O
.	O

Attributional	O
styles	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
prediction	O
of	O
depression	O
.	O

Activity	O
level	O
lost	O
its	O
predictive	O
role	O
during	O
the	O
6	O
-	O
month	O
interval	O
.	O

These	O
results	O
are	O
discussed	O
according	O
to	O
the	O
role	O
of	O
the	O
proposed	O
models	O
and	O
the	O
need	O
for	O
a	O
deeper	O
explanation	O
of	O
the	O
variance	O
of	O
depression	O
scores	O
.	O

EPOX	O
inhibits	O
angiogenesis	O
by	O
degradation	O
of	O
Mcl	O
-	O
1	O
through	O
ERK	O
inactivation	O
.	O

PURPOSE	O
:	O
Antiangiogenic	O
therapy	O
is	O
considered	O
as	O
an	O
effective	O
strategy	O
for	O
controlling	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	O
.	O

Among	O
a	O
myriad	O
of	O
biological	O
activities	O
described	O
for	O
xanthone	O
derivatives	O
,	O
the	O
anticancer	O
activity	O
is	O
quite	O
remarkable	O
,	O
but	O
the	O
molecular	O
mechanism	O
is	O
not	O
clearly	O
resolved	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
antiangiogenic	O
mechanism	O
of	O
3	O
,	O
6	O
-	O
di	O
(	O
2	O
,	O
3	O
-	O
epoxypropoxy	O
)	O
xanthone	O
(	O
EPOX	O
)	O
,	O
a	O
novel	O
Mcl	O
-	O
1	O
targeting	O
drug	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
To	O
evaluate	O
the	O
antiangiogenic	O
activity	O
of	O
EPOX	O
,	O
we	O
did	O
cell	O
viability	O
,	O
cell	O
cycle	O
,	O
tube	O
formation	O
assay	O
in	O
vitro	O
,	O
and	O
Matrigel	O
plug	O
assay	O
in	O
vivo	O
.	O

To	O
evaluate	O
the	O
effect	O
of	O
EPOX	O
on	O
the	O
endothelial	O
signaling	O
pathway	O
,	O
we	O
did	O
immunoblotting	O
,	O
immunoprecipitation	O
,	O
and	O
immunofluorescence	O
analysis	O
.	O

Intracellular	O
glutathione	O
levels	O
were	O
determined	O
with	O
the	O
use	O
of	O
monochlorobimane	O
,	O
a	O
glutathione	O
-	O
specific	O
probe	O
.	O

RESULTS	O
:	O
EPOX	O
induced	O
endothelial	O
cell	O
apoptosis	O
in	O
association	O
with	O
proteasome	O
-	O
dependent	O
Mcl	O
-	O
1	O
degradation	O
.	O

Down	O
-	O
regulation	O
of	O
Mcl	O
-	O
1	O
resulted	O
in	O
an	O
increase	O
in	O
Mcl	O
-	O
1	O
-	O
free	O
Bim	O
,	O
activation	O
of	O
Bax	O
,	O
and	O
then	O
signaling	O
of	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

Additionally	O
,	O
glutathione	O
depletion	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
inactivation	O
was	O
observed	O
in	O
EPOX	O
-	O
treated	O
cells	O
.	O

Glutathione	O
supplementation	O
reversed	O
the	O
inhibitory	O
effects	O
of	O
EPOX	O
on	O
ERK	O
,	O
which	O
increases	O
the	O
phosphorylation	O
of	O
Mcl	O
-	O
1	O
at	O
T	O
(	O
163	O
.	O
)	O
Overexpression	O
of	O
mitogen	O
-	O
activated	O
protein	O
/	O
ERK	O
kinase	O
(	O
MEK	O
)	O
partially	O
reversed	O
the	O
effect	O
of	O
EPOX	O
on	O
Mcl	O
-	O
1	O
dephosphorylation	O
,	O
ubiquitination	O
,	O
and	O
degradation	O
,	O
further	O
implicating	O
ERK	O
in	O
the	O
regulation	O
of	O
Mcl	O
-	O
1	O
stability	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
evidence	O
that	O
EPOX	O
induces	O
glutathione	O
depletion	O
,	O
ERK	O
inactivation	O
,	O
and	O
Mcl	O
-	O
1	O
degradation	O
on	O
endothelial	O
cells	O
,	O
which	O
leads	O
to	O
inhibition	O
of	O
angiogenesis	O
.	O

Our	O
results	O
suggest	O
that	O
EPOX	O
is	O
a	O
novel	O
antiangiogenic	O
agent	O
,	O
making	O
it	O
a	O
promising	O
lead	O
compound	O
for	O
further	O
development	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
related	O
pathologies	O
.	O

Angiogenesis	O
-	O
a	O
novel	O
therapeutic	O
approach	O
for	O
ischemic	O
heart	O
disease	O
.	O

Angiogenesis	O
is	O
the	O
biologic	O
process	O
of	O
forming	O
new	O
blood	O
vessels	O
.	O

Undoubtedly	O
,	O
blood	O
vessels	O
growth	O
regulation	O
is	O
a	O
vital	O
aspect	O
in	O
health	O
and	O
disease	O
.	O

Under	O
physiological	O
conditions	O
,	O
angiogenesis	O
is	O
regulated	O
by	O
local	O
balance	O
between	O
endogenous	O
stimulators	O
and	O
inhibitors	O
of	O
this	O
process	O
.	O

In	O
many	O
diseases	O
state	O
body	O
loses	O
control	O
over	O
angiogenesis	O
.	O

Angiogenesis	O
-	O
dependent	O
diseases	O
result	O
when	O
new	O
blood	O
vessels	O
either	O
grow	O
excessively	O
or	O
insufficiently	O
.	O

Insufficient	O
angiogenesis	O
occurs	O
in	O
diseases	O
such	O
as	O
coronary	O
artery	O
disease	O
,	O
stroke	O
and	O
chronic	O
wounds	O
.	O

Myocardial	O
ischemia	O
both	O
acute	O
and	O
chronic	O
has	O
been	O
clearly	O
shown	O
to	O
stimulate	O
angiogenesis	O
in	O
many	O
experimental	O
models	O
.	O

Therapeutic	O
angiogenesis	O
is	O
the	O
biological	O
agents	O
or	O
bioactive	O
material	O
to	O
stimulate	O
the	O
growth	O
of	O
new	O
blood	O
vessels	O
.	O

Traditional	O
coronary	O
revascularization	O
therapies	O
such	O
as	O
coronary	O
angioplasty	O
or	O
bypass	O
graft	O
surgery	O
,	O
act	O
by	O
restoring	O
blood	O
flow	O
through	O
the	O
preexisting	O
coronary	O
vessels	O
.	O

One	O
limitation	O
of	O
these	O
approaches	O
,	O
however	O
,	O
may	O
be	O
the	O
failure	O
to	O
normalize	O
myocardial	O
perfusion	O
,	O
due	O
to	O
the	O
concomitant	O
presence	O
or	O
small	O
of	O
resistance	O
vessel	O
disease	O
.	O

In	O
contrast	O
,	O
therapeutic	O
angiogenesis	O
is	O
based	O
on	O
the	O
concept	O
that	O
coronary	O
collateral	O
development	O
may	O
be	O
stimulated	O
by	O
pharmacological	O
or	O
molecular	O
means	O
and	O
can	O
limit	O
myocardial	O
ischemia	O
.	O

Studies	O
,	O
both	O
in	O
human	O
and	O
animal	O
models	O
support	O
the	O
notion	O
that	O
,	O
various	O
angiogenic	O
growth	O
factors	O
and	O
progenitor	O
cells	O
can	O
enhance	O
new	O
blood	O
vessels	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
,	O
recombinant	O
proteins	O
and	O
bone	O
marrow	O
stem	O
cells	O
are	O
currently	O
used	O
therapeutic	O
stimulators	O
for	O
angiogenesis	O
.	O

As	O
coronary	O
artery	O
disease	O
is	O
the	O
major	O
cause	O
of	O
death	O
in	O
the	O
developed	O
societies	O
and	O
also	O
an	O
emerging	O
health	O
problem	O
in	O
developing	O
countries	O
like	O
Bangladesh	O
therapeutic	O
angiogenesis	O
may	O
provide	O
hope	O
as	O
a	O
new	O
treatment	O
modality	O
for	O
ischemic	O
heart	O
disease	O
with	O
or	O
in	O
place	O
of	O
current	O
therapies	O
.	O

Nicked	O
{	O
beta	O
}	O
2	O
-	O
glycoprotein	O
I	O
binds	O
angiostatin	O
4	O
.	O
5	O
(	O
plasminogen	O
kringle	O
1	O
-	O
5	O
)	O
and	O
attenuates	O
its	O
antiangiogenic	O
property	O
.	O

Angiostatin	O
was	O
first	O
discovered	O
as	O
a	O
plasminogen	O
fragment	O
with	O
antitumor	O
/	O
antiangiogenic	O
property	O
.	O

One	O
of	O
the	O
angiostatin	O
isoforms	O
,	O
that	O
is	O
,	O
angiostatin	O
4	O
.	O
5	O
(	O
AS4	O
.	O
5	O
)	O
,	O
consisting	O
of	O
plasminogen	O
kringle	O
1	O
to	O
4	O
and	O
a	O
most	O
part	O
of	O
kringle	O
5	O
,	O
is	O
produced	O
by	O
autoproteolysis	O
and	O
present	O
in	O
human	O
plasma	O
.	O

beta2	O
-	O
glycoprotein	O
I	O
(	O
beta2GPI	O
)	O
is	O
proteolytically	O
cleaved	O
by	O
plasmin	O
in	O
its	O
domain	O
V	O
(	O
nicked	O
beta2GPI	O
)	O
,	O
resulting	O
in	O
binding	O
to	O
plasminogen	O
.	O

Antiangiogenic	O
properties	O
have	O
been	O
recently	O
reported	O
in	O
nicked	O
beta2GPI	O
as	O
well	O
as	O
in	O
intact	O
beta2GPI	O
at	O
higher	O
concentrations	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
significant	O
binding	O
of	O
nicked	O
beta2GPI	O
to	O
AS4	O
.	O
5	O
(	O
K	O
(	O
D	O
)	O
=	O
3	O
.	O
27	O
x	O
10	O
(	O
6	O
)	O
M	O
(	O
-	O
1	O
)	O
)	O
.	O

Via	O
this	O
binding	O
,	O
nicked	O
beta2GPI	O
attenuates	O
the	O
antiangiogenic	O
functions	O
of	O
AS4	O
.	O
5	O
in	O
the	O
proliferation	O
of	O
arterial	O
/	O
venous	O
endothelial	O
cells	O
,	O
in	O
the	O
extracellular	O
matrix	O
invasion	O
and	O
the	O
tube	O
formation	O
of	O
venous	O
endothelial	O
cells	O
,	O
and	O
in	O
vivo	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
intact	O
beta2GPI	O
does	O
not	O
bind	O
to	O
AS4	O
.	O
5	O
or	O
inhibit	O
its	O
antiangiogenic	O
activity	O
.	O

Thus	O
,	O
nicked	O
beta2GPI	O
exerts	O
dual	O
effects	O
on	O
angiogenesis	O
,	O
that	O
is	O
,	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
in	O
the	O
presence	O
of	O
AS4	O
.	O
5	O
,	O
whereas	O
nicked	O
beta2GPI	O
inhibits	O
angiogenesis	O
at	O
concentrations	O
high	O
enough	O
to	O
neutralize	O
AS4	O
.	O
5	O
.	O

Our	O
data	O
suggest	O
that	O
plasmin	O
-	O
nicked	O
beta2GPI	O
promotes	O
angiogenesis	O
by	O
interacting	O
with	O
plasmin	O
-	O
generated	O
AS4	O
.	O
5	O
in	O
sites	O
of	O
increased	O
fibrinolysis	O
such	O
as	O
thrombus	O
.	O

Use	O
of	O
uteroglobin	O
for	O
the	O
engineering	O
of	O
polyvalent	O
,	O
polyspecific	O
fusion	O
proteins	O
.	O

We	O
report	O
a	O
novel	O
strategy	O
to	O
engineer	O
and	O
express	O
stable	O
and	O
soluble	O
human	O
recombinant	O
polyvalent	O
/	O
polyspecific	O
fusion	O
proteins	O
.	O

The	O
procedure	O
is	O
based	O
on	O
the	O
use	O
of	O
a	O
central	O
skeleton	O
of	O
uteroglobin	O
,	O
a	O
small	O
and	O
very	O
soluble	O
covalently	O
linked	O
homodimeric	O
protein	O
that	O
is	O
very	O
resistant	O
to	O
proteolytic	O
enzymes	O
and	O
to	O
pH	O
variations	O
.	O

Using	O
a	O
human	O
recombinant	O
antibody	O
(	O
scFv	O
)	O
specific	O
for	O
the	O
angiogenesis	O
marker	O
domain	O
B	O
of	O
fibronectin	O
,	O
interleukin	O
2	O
,	O
and	O
an	O
scFv	O
able	O
to	O
neutralize	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
we	O
expressed	O
various	O
biologically	O
active	O
uteroglobin	O
fusion	O
proteins	O
.	O

The	O
results	O
demonstrate	O
the	O
possibility	O
to	O
generate	O
monospecific	O
divalent	O
and	O
tetravalent	O
antibodies	O
,	O
immunocytokines	O
,	O
and	O
dual	O
specificity	O
tetravalent	O
antibodies	O
.	O

Furthermore	O
,	O
compared	O
with	O
similar	O
fusion	O
proteins	O
in	O
which	O
uteroglobin	O
was	O
not	O
used	O
,	O
the	O
use	O
of	O
uteroglobin	O
improved	O
properties	O
of	O
solubility	O
and	O
stability	O
.	O

Indeed	O
,	O
in	O
the	O
reported	O
cases	O
it	O
was	O
possible	O
to	O
vacuum	O
dry	O
and	O
reconstitute	O
the	O
proteins	O
without	O
any	O
aggregation	O
or	O
loss	O
in	O
protein	O
and	O
biological	O
activity	O
.	O

Targeting	O
angiogenesis	O
:	O
progress	O
with	O
anti	O
-	O
VEGF	O
treatment	O
with	O
large	O
molecules	O
.	O

Angiogenesis	O
-	O
-	O
one	O
of	O
the	O
hallmarks	O
of	O
cancer	O
-	O
-	O
has	O
emerged	O
as	O
a	O
valid	O
therapeutic	O
target	O
in	O
oncology	O
.	O

The	O
VEGF	O
system	O
represents	O
a	O
key	O
mediator	O
of	O
tumor	O
-	O
initiated	O
angiogenesis	O
and	O
the	O
first	O
target	O
of	O
antiangiogenesis	O
agents	O
introduced	O
in	O
clinical	O
practice	O
.	O

Although	O
anti	O
-	O
VEGF	O
therapies	O
have	O
clearly	O
demonstrated	O
antitumor	O
efficacy	O
in	O
various	O
malignancies	O
,	O
especially	O
when	O
combined	O
with	O
conventional	O
cytotoxic	O
chemotherapy	O
,	O
their	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
.	O

This	O
Review	O
will	O
discuss	O
the	O
rationale	O
for	O
using	O
antiangiogenic	O
compounds	O
and	O
will	O
focus	O
on	O
large	O
molecules	O
,	O
such	O
as	O
antibodies	O
,	O
that	O
target	O
the	O
VEGF	O
system	O
.	O

Clinical	O
data	O
on	O
bevacizumab	O
is	O
discussed	O
in	O
detail	O
.	O

Predictive	O
markers	O
for	O
anti	O
-	O
VEGF	O
agents	O
have	O
not	O
yet	O
been	O
identified	O
and	O
questions	O
regarding	O
the	O
usefulness	O
of	O
bevacizumab	O
in	O
the	O
adjuvant	O
setting	O
as	O
well	O
as	O
its	O
continued	O
use	O
beyond	O
progression	O
remain	O
unanswered	O
,	O
in	O
spite	O
of	O
negative	O
data	O
on	O
bevacizumab	O
in	O
treating	O
patients	O
with	O
adjuvant	O
colon	O
cancer	O
.	O

Nonetheless	O
,	O
anti	O
-	O
VEGF	O
therapy	O
has	O
enhanced	O
the	O
arsenal	O
of	O
anticancer	O
therapies	O
and	O
has	O
provided	O
new	O
insights	O
into	O
the	O
biology	O
of	O
malignancy	O
.	O

[	O
An	O
experimental	O
study	O
on	O
angiogenesis	O
of	O
non	O
-	O
vascularized	O
autogenous	O
bone	O
graft	O
with	O
vascular	O
bundle	O
implantation	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
vascular	O
bundle	O
implantation	O
in	O
autogenous	O
bone	O
graft	O
on	O
angiogenesis	O
.	O

METHODS	O
:	O
Thirty	O
-	O
six	O
New	O
Zealand	O
white	O
rabbits	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

A	O
portion	O
of	O
bilateral	O
radial	O
bones	O
of	O
a	O
rabbit	O
were	O
removed	O
as	O
free	O
bone	O
grafts	O
,	O
whose	O
periostea	O
were	O
peeled	O
off	O
.	O

In	O
test	O
group	O
,	O
the	O
external	O
maxillary	O
artery	O
bundle	O
was	O
passed	O
through	O
the	O
marrow	O
cavity	O
of	O
the	O
bone	O
.	O

In	O
control	O
group	O
,	O
there	O
was	O
no	O
vascular	O
bundle	O
implantation	O
.	O

Each	O
bone	O
was	O
placed	O
in	O
masseter	O
muscle	O
separately	O
.	O

The	O
rabbits	O
were	O
sacrificed	O
and	O
the	O
specimens	O
were	O
procured	O
at	O
3	O
days	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
6	O
weeks	O
after	O
surgery	O
for	O
histological	O
observation	O
,	O
Chinese	O
ink	O
perfusion	O
and	O
CD34	O
immunohistochemistry	O
.	O

Microvessel	O
density	O
(	O
MVD	O
)	O
was	O
assessed	O
in	O
order	O
to	O
evaluate	O
angiogenesis	O
of	O
autogenous	O
bone	O
grafts	O
.	O

RESULTS	O
:	O
The	O
bone	O
grafts	O
were	O
found	O
revascularization	O
in	O
3	O
days	O
after	O
surgery	O
in	O
the	O
test	O
group	O
,	O
whereas	O
at	O
2	O
weeks	O
in	O
the	O
control	O
group	O
.	O

In	O
3	O
days	O
,	O
1	O
week	O
,	O
2	O
weeks	O
,	O
3	O
weeks	O
and	O
4	O
weeks	O
after	O
surgery	O
,	O
the	O
MVD	O
of	O
test	O
group	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

In	O
4	O
weeks	O
after	O
surgery	O
,	O
angiogenesis	O
of	O
test	O
group	O
reached	O
to	O
peak	O
.	O

CONCLUSION	O
:	O
Vascular	O
bundle	O
implantation	O
improved	O
angiogenesis	O
in	O
non	O
-	O
vascularized	O
autogenous	O
bone	O
graft	O
in	O
this	O
study	O
.	O

[	O
Ambiguity	O
role	O
of	O
neutrophils	O
in	O
oncogenesis	O
]	O

The	O
review	O
is	O
focused	O
on	O
the	O
participation	O
of	O
polymorphonuclear	O
granulocytes	O
(	O
neutrophils	O
)	O
in	O
development	O
and	O
spreading	O
of	O
a	O
tumor	O
.	O

We	O
consider	O
both	O
the	O
well	O
known	O
functions	O
of	O
neutrophils	O
(	O
degranulation	O
,	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
)	O
and	O
the	O
recently	O
shown	O
one	O
(	O
presentation	O
of	O
an	O
antigene	O
)	O
.	O

The	O
special	O
attention	O
is	O
focused	O
on	O
the	O
ambiguity	O
of	O
the	O
neutrophil	O
role	O
in	O
oncogenesis	O
.	O

The	O
dominant	O
view	O
is	O
that	O
neutrophils	O
display	O
exclusively	O
antitumor	O
properties	O
.	O

The	O
update	O
information	O
testifies	O
about	O
protumoral	O
activity	O
of	O
neutrophils	O
:	O
they	O
migrate	O
to	O
a	O
tumor	O
and	O
promote	O
angiogenesis	O
and	O
metastasis	O
at	O
late	O
stages	O
of	O
the	O
tumor	O
.	O

It	O
is	O
interesting	O
that	O
certain	O
components	O
of	O
neutrophil	O
cytotoxic	O
arsenal	O
(	O
ROS	O
,	O
cytokines	O
,	O
specific	O
enzymes	O
)	O
participate	O
both	O
in	O
antitumoral	O
defenses	O
of	O
an	O
organism	O
and	O
protumoral	O
activity	O
.	O

Targeting	O
glucose	O
consumption	O
and	O
autophagy	O
in	O
myeloma	O
with	O
the	O
novel	O
nucleoside	O
analogue	O
8	O
-	O
aminoadenosine	O
.	O

Multiple	O
myeloma	O
,	O
an	O
incurable	O
plasma	O
cell	O
malignancy	O
,	O
is	O
characterized	O
by	O
altered	O
cellular	O
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
.	O

Recent	O
connections	O
between	O
glucose	O
metabolism	O
and	O
resistance	O
to	O
apoptosis	O
provide	O
a	O
compelling	O
rationale	O
for	O
targeting	O
metabolic	O
changes	O
in	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
the	O
ability	O
of	O
the	O
purine	O
analogue	O
8	O
-	O
aminoadenosine	O
to	O
acutely	O
reduce	O
glucose	O
consumption	O
by	O
regulating	O
localization	O
and	O
expression	O
of	O
key	O
glucose	O
transporters	O
.	O

Myeloma	O
cells	O
counteracted	O
the	O
metabolic	O
stress	O
by	O
activating	O
autophagy	O
.	O

Co	O
-	O
treatment	O
with	O
inhibitors	O
of	O
autophagy	O
results	O
in	O
marked	O
enhancement	O
of	O
cell	O
death	O
.	O

Glucose	O
consumption	O
by	O
drug	O
-	O
resistant	O
myeloma	O
cells	O
was	O
unaffected	O
by	O
8	O
-	O
aminoadenosine	O
,	O
and	O
accordingly	O
,	O
no	O
activation	O
of	O
autophagy	O
was	O
observed	O
.	O

However	O
,	O
these	O
cells	O
can	O
be	O
sensitized	O
to	O
8	O
-	O
aminoadenosine	O
under	O
glucose	O
-	O
limiting	O
conditions	O
.	O

The	O
prosurvival	O
autophagic	O
response	O
of	O
myeloma	O
to	O
nutrient	O
deprivation	O
or	O
to	O
nucleoside	O
analogue	O
treatment	O
has	O
not	O
been	O
described	O
previously	O
.	O

This	O
study	O
establishes	O
the	O
potential	O
of	O
metabolic	O
targeting	O
as	O
a	O
broader	O
means	O
to	O
kill	O
and	O
sensitize	O
myeloma	O
and	O
identifies	O
a	O
compound	O
that	O
can	O
achieve	O
this	O
goal	O
.	O

Endothelial	O
cell	O
migration	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
are	O
the	O
result	O
of	O
loss	O
of	O
breast	O
tissue	O
polarity	O
.	O

Recruiting	O
a	O
new	O
blood	O
supply	O
is	O
a	O
rate	O
-	O
limiting	O
step	O
in	O
tumor	O
progression	O
.	O

In	O
a	O
three	O
-	O
dimensional	O
model	O
of	O
breast	O
carcinogenesis	O
,	O
disorganized	O
,	O
proliferative	O
transformed	O
breast	O
epithelial	O
cells	O
express	O
significantly	O
higher	O
expression	O
of	O
angiogenic	O
genes	O
compared	O
with	O
their	O
polarized	O
,	O
growth	O
-	O
arrested	O
nonmalignant	O
counterparts	O
.	O

Elevated	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
by	O
malignant	O
cells	O
enhanced	O
recruitment	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
in	O
heterotypic	O
cocultures	O
.	O

Significantly	O
,	O
phenotypic	O
reversion	O
of	O
malignant	O
cells	O
via	O
reexpression	O
of	O
HoxD10	O
,	O
which	O
is	O
lost	O
in	O
malignant	O
progression	O
,	O
significantly	O
attenuated	O
VEGF	O
expression	O
in	O
a	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
-	O
independent	O
fashion	O
and	O
reduced	O
EC	O
migration	O
.	O

This	O
was	O
due	O
primarily	O
to	O
restoring	O
polarity	O
:	O
forced	O
proliferation	O
of	O
polarized	O
,	O
nonmalignant	O
cells	O
did	O
not	O
induce	O
VEGF	O
expression	O
and	O
EC	O
recruitment	O
,	O
whereas	O
disrupting	O
the	O
architecture	O
of	O
growth	O
-	O
arrested	O
,	O
reverted	O
cells	O
did	O
.	O

These	O
data	O
show	O
that	O
disrupting	O
cytostructure	O
activates	O
the	O
angiogenic	O
switch	O
even	O
in	O
the	O
absence	O
of	O
proliferation	O
and	O
/	O
or	O
hypoxia	O
and	O
restoring	O
organization	O
of	O
malignant	O
clusters	O
reduces	O
VEGF	O
expression	O
and	O
EC	O
activation	O
to	O
levels	O
found	O
in	O
quiescent	O
nonmalignant	O
epithelium	O
.	O

These	O
data	O
confirm	O
the	O
importance	O
of	O
tissue	O
architecture	O
and	O
polarity	O
in	O
malignant	O
progression	O
.	O

Aging	O
affects	O
the	O
cardiovascular	O
responses	O
to	O
cold	O
stress	O
in	O
humans	O
.	O

Cardiovascular	O
-	O
related	O
mortality	O
peaks	O
during	O
cold	O
winter	O
months	O
,	O
particularly	O
in	O
older	O
adults	O
.	O

Acute	O
physiological	O
responses	O
,	O
such	O
as	O
increases	O
in	O
blood	O
pressure	O
,	O
in	O
response	O
to	O
cold	O
exposure	O
may	O
contribute	O
to	O
these	O
associations	O
.	O

To	O
determine	O
whether	O
the	O
blood	O
pressure	O
-	O
raising	O
effect	O
(	O
pressor	O
response	O
)	O
of	O
non	O
-	O
internal	O
body	O
temperature	O
-	O
reducing	O
cold	O
stress	O
is	O
greater	O
with	O
age	O
,	O
we	O
measured	O
physiological	O
responses	O
to	O
20	O
min	O
of	O
superficial	O
skin	O
cooling	O
,	O
via	O
water	O
-	O
perfused	O
suit	O
,	O
in	O
12	O
younger	O
[	O
25	O
+	O
/	O
-	O
1	O
(	O
SE	O
)	O
yr	O
old	O
]	O
and	O
12	O
older	O
(	O
65	O
+	O
/	O
-	O
2	O
yr	O
old	O
)	O
adults	O
.	O

We	O
found	O
that	O
superficial	O
skin	O
cooling	O
elicited	O
an	O
increase	O
in	O
blood	O
pressure	O
from	O
resting	O
levels	O
(	O
pressor	O
response	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
and	O
older	O
adults	O
.	O

However	O
,	O
the	O
magnitude	O
of	O
this	O
pressor	O
response	O
(	O
systolic	O
and	O
mean	O
blood	O
pressure	O
)	O
was	O
more	O
than	O
twofold	O
higher	O
in	O
older	O
adults	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
younger	O
adults	O
)	O
.	O

The	O
magnitude	O
of	O
the	O
pressor	O
response	O
was	O
similar	O
at	O
peripheral	O
(	O
brachial	O
)	O
and	O
central	O
(	O
estimated	O
in	O
the	O
aorta	O
)	O
measurement	O
sites	O
.	O

Regression	O
analysis	O
revealed	O
that	O
aortic	O
pulse	O
wave	O
velocity	O
,	O
a	O
measure	O
of	O
central	O
arterial	O
stiffness	O
obtained	O
before	O
cooling	O
,	O
was	O
the	O
best	O
predictor	O
of	O
the	O
increased	O
pressor	O
response	O
to	O
superficial	O
skin	O
cooling	O
in	O
older	O
adults	O
,	O
explaining	O
approximately	O
63	O
%	O
of	O
its	O
variability	O
.	O

These	O
results	O
indicate	O
that	O
there	O
is	O
a	O
greater	O
pressor	O
response	O
to	O
non	O
-	O
internal	O
body	O
temperature	O
-	O
reducing	O
cold	O
stress	O
with	O
age	O
in	O
humans	O
that	O
may	O
be	O
mediated	O
by	O
increased	O
levels	O
of	O
central	O
arterial	O
stiffness	O
.	O

Metronomic	O
5	O
-	O
fluorouracil	O
,	O
oxaliplatin	O
and	O
irinotecan	O
in	O
colorectal	O
cancer	O
.	O

Metronomic	O
chemotherapy	O
(	O
the	O
frequent	O
,	O
long	O
term	O
,	O
low	O
dose	O
administration	O
of	O
chemotherapeutic	O
drugs	O
)	O
is	O
a	O
promising	O
therapy	O
because	O
it	O
enhances	O
the	O
anti	O
-	O
endothelial	O
activity	O
of	O
conventional	O
chemotherapeutics	O
,	O
but	O
with	O
lower	O
or	O
no	O
toxic	O
effects	O
compared	O
to	O
maximum	O
tolerated	O
dose	O
administration	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
were	O
to	O
compare	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
the	O
antiangiogenic	O
and	O
antitumor	O
activities	O
of	O
metronomic	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
,	O
oxaliplatin	O
(	O
L	O
-	O
OHP	O
)	O
and	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
in	O
colorectal	O
cancer	O
and	O
to	O
investigate	O
the	O
metronomic	O
combination	O
of	O
these	O
drugs	O
.	O

In	O
vitro	O
cell	O
proliferation	O
,	O
combination	O
studies	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
secretion	O
analyses	O
were	O
performed	O
on	O
endothelial	O
(	O
HMVEC	B
-	I
d	I
)	O
and	O
colorectal	O
cancer	O
(	O
HT	B
-	I
29	I
)	O
cells	O
exposed	O
for	O
144	O
h	O
to	O
metronomic	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
the	O
active	O
metabolite	O
of	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
and	O
5	O
-	O
FU	O
.	O

HT	B
-	I
29	I
human	O
colorectal	O
cancer	O
xenograft	O
model	O
was	O
used	O
and	O
tumour	O
growth	O
,	O
microvessel	O
density	O
and	O
VEGF	O
quantification	O
were	O
performed	O
in	O
tumours	O
after	O
the	O
administration	O
of	O
metronomic	O
CPT	O
-	O
11	O
,	O
L	O
-	O
OHP	O
,	O
5	O
-	O
FU	O
and	O
their	O
simultaneous	O
combination	O
.	O

Low	O
concentrations	O
of	O
SN	O
-	O
38	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
preferentially	O
inhibited	O
endothelial	O
cell	O
proliferation	O
.	O

Simultaneous	O
and	O
continuous	O
exposure	O
of	O
HT	B
-	I
29	I
and	O
HMVEC	B
-	I
d	I
cells	O
to	O
low	O
concentrations	O
SN	O
-	O
38	O
+	O
L	O
-	O
OHP	O
+	O
5	O
-	O
FU	O
for	O
144	O
h	O
showed	O
a	O
strong	O
antagonism	O
and	O
an	O
unfavorable	O
dose	O
-	O
reduction	O
index	O
.	O

Moreover	O
,	O
the	O
ternary	O
combination	O
resulted	O
in	O
a	O
significant	O
increase	O
of	O
VEGF	O
secretion	O
in	O
HT	B
-	I
29	I
cancer	O
cells	O
.	O

In	O
a	O
xenograft	O
model	O
metronomic	O
CPT	O
-	O
11	O
,	O
but	O
not	O
5	O
-	O
FU	O
and	O
L	O
-	O
OHP	O
,	O
significantly	O
inhibits	O
HT	B
-	I
29	I
tumor	O
growth	O
and	O
microvessel	O
density	O
in	O
the	O
absence	O
of	O
toxicity	O
.	O

On	O
the	O
contrary	O
,	O
metronomic	O
5	O
-	O
FU	O
+	O
L	O
-	O
OHP	O
+	O
CPT	O
-	O
11	O
therapy	O
did	O
not	O
affect	O
the	O
microvascular	O
count	O
.	O

The	O
metronomic	O
concept	O
might	O
not	O
universally	O
apply	O
to	O
every	O
cytotoxic	O
drug	O
in	O
colorectal	O
cancer	O
and	O
metronomic	O
combination	O
regimens	O
should	O
be	O
used	O
with	O
caution	O
.	O

A	O
key	O
role	O
for	O
the	O
integrin	O
alpha2beta1	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O

The	O
alpha2beta1	O
integrin	O
receptor	O
plays	O
a	O
key	O
role	O
in	O
angiogenesis	O
.	O

Here	O
we	O
investigated	O
the	O
effects	O
of	O
small	O
molecule	O
inhibitors	O
(	O
SMIs	O
)	O
designed	O
to	O
disrupt	O
integrin	O
alpha2	O
I	O
or	O
beta1	O
I	O
-	O
like	O
domain	O
function	O
on	O
angiogenesis	O
.	O

In	O
unchallenged	O
endothelial	O
cells	O
,	O
fibrillar	O
collagen	O
induced	O
robust	O
capillary	O
morphogenesis	O
.	O

In	O
contrast	O
,	O
tube	O
formation	O
was	O
significantly	O
reduced	O
by	O
SMI496	O
,	O
a	O
beta1	O
I	O
-	O
like	O
domain	O
inhibitor	O
and	O
by	O
function	O
-	O
blocking	O
anti	O
-	O
alpha2beta1	O
but	O
not	O
-	O
alpha1beta1	O
antibodies	O
.	O

Endothelial	O
cells	O
bound	O
fluorescein	O
-	O
labeled	O
collagen	O
I	O
fibrils	O
,	O
an	O
interaction	O
specifically	O
inhibited	O
by	O
SMI496	O
.	O

Moreover	O
,	O
SMI496	O
caused	O
cell	O
retraction	O
and	O
cytoskeletal	O
collapse	O
of	O
endothelial	O
cells	O
as	O
well	O
as	O
delayed	O
endothelial	O
cell	O
wound	O
healing	O
.	O

SMI	O
activities	O
were	O
examined	O
in	O
vivo	O
by	O
supplementing	O
the	O
growth	O
medium	O
of	O
zebrafish	O
embryos	O
expressing	O
green	O
fluorescent	O
protein	O
under	O
the	O
control	O
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
promoter	O
.	O

SMI496	O
,	O
but	O
not	O
a	O
control	O
compound	O
,	O
interfered	O
with	O
angiogenesis	O
in	O
vivo	O
by	O
reversibly	O
inhibiting	O
sprouting	O
from	O
the	O
axial	O
vessels	O
.	O

We	O
further	O
characterized	O
zebrafish	O
alpha2	O
integrin	O
and	O
discovered	O
that	O
this	O
integrin	O
is	O
highly	O
conserved	O
,	O
especially	O
the	O
I	O
domain	O
.	O

Notably	O
,	O
a	O
similar	O
vascular	O
phenotype	O
was	O
induced	O
by	O
morpholino	O
-	O
mediated	O
knockdown	O
of	O
the	O
integrin	O
alpha2	O
subunit	O
.	O

By	O
live	O
videomicroscopy	O
,	O
we	O
confirmed	O
that	O
the	O
vessels	O
were	O
largely	O
nonfunctional	O
in	O
the	O
absence	O
of	O
alpha2beta1	O
integrin	O
.	O

Collectively	O
,	O
our	O
results	O
provide	O
strong	O
biochemical	O
and	O
genetic	O
evidence	O
of	O
a	O
central	O
role	O
for	O
alpha2beta1	O
integrin	O
in	O
experimental	O
and	O
developmental	O
angiogenesis	O
.	O

Mapping	O
of	O
the	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
gene	O
to	O
mouse	O
chromosome	O
17	O
.	O

In	O
humans	O
,	O
methylmalonyl	O
acidemia	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
L	O
-	O
methylmalonyl	O
-	O
CoA	O
mutase	O
(	O
MUT	O
)	O
controlled	O
by	O
a	O
gene	O
that	O
has	O
been	O
mapped	O
to	O
chromosome	O
6	O
.	O

The	O
mouse	O
homolog	O
of	O
this	O
gene	O
has	O
now	O
been	O
mapped	O
to	O
mouse	O
chromosome	O
17	O
.	O

Recombinant	O
inbred	O
and	O
congenic	O
strains	O
place	O
the	O
mouse	O
Mut	O
locus	O
1	O
.	O
06	O
cM	O
distal	O
to	O
H	O
-	O
2	O
,	O
between	O
Pgk	O
-	O
2	O
and	O
Ce	O
-	O
2	O
.	O

The	O
relative	O
order	O
of	O
syntenic	O
probes	O
flanking	O
H	O
-	O
2	O
on	O
mouse	O
chromosome	O
17	O
and	O
HLA	O
on	O
human	O
chromosome	O
6	O
is	O
shown	O
to	O
be	O
different	O
.	O

Dopamine	O
regulates	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
by	O
engaging	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
2	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
induced	O
receptor	O
phosphorylation	O
is	O
the	O
crucial	O
step	O
for	O
initiating	O
downstream	O
signaling	O
pathways	O
that	O
lead	O
to	O
angiogenesis	O
or	O
related	O
pathophysiological	O
outcomes	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
neurotransmitter	O
dopamine	O
could	O
inhibit	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGF	O
receptor	O
2	O
(	O
VEGFR	O
-	O
2	O
)	O
,	O
endothelial	O
cell	O
proliferation	O
,	O
migration	O
,	O
microvascular	O
permeability	O
,	O
and	O
thus	O
,	O
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
address	O
the	O
mechanism	O
by	O
which	O
VEGFR	O
-	O
2	O
phosphorylation	O
is	O
regulated	O
by	O
dopamine	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
D2	O
dopamine	O
receptor	O
(	O
D2DR	O
)	O
colocalizes	O
with	O
VEGFR	O
-	O
2	O
at	O
the	O
cell	O
surface	O
.	O

Dopamine	O
pretreatment	O
increases	O
the	O
translocation	O
and	O
colocalization	O
of	O
Src	O
-	O
homology	O
-	O
2	O
-	O
domain	O
-	O
containing	O
protein	O
tyrosine	O
phosphatase	O
(	O
SHP	O
-	O
2	O
)	O
with	O
D2DR	O
at	O
the	O
cell	O
surface	O
.	O

Dopamine	O
administration	O
leads	O
to	O
increased	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
SHP	O
-	O
2	O
and	O
this	O
increased	O
phosphorylation	O
parallels	O
the	O
increased	O
phosphatase	O
activity	O
of	O
SHP	O
-	O
2	O
.	O

Active	O
SHP	O
-	O
2	O
then	O
dephosphorylates	O
VEGFR	O
-	O
2	O
at	O
Y951	O
,	O
Y996	O
and	O
Y1059	O
,	O
but	O
not	O
Y1175	O
.	O

We	O
also	O
observe	O
that	O
SHP	O
-	O
2	O
knockdown	O
impairs	O
the	O
dopamine	O
-	O
regulated	O
inhibition	O
of	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
VEGFR	O
-	O
2	O
and	O
,	O
subsequently	O
,	O
Src	O
phosphorylation	O
and	O
migration	O
.	O

Our	O
data	O
establish	O
a	O
novel	O
role	O
for	O
SHP	O
-	O
2	O
phosphatase	O
in	O
the	O
dopamine	O
-	O
mediated	O
regulation	O
of	O
VEGFR	O
-	O
2	O
phosphorylation	O
.	O

[	O
The	O
value	O
of	O
intermittent	O
ultrasound	O
treatment	O
in	O
subacromial	O
impingement	O
syndrome	O
]	O
.	O

OBJECTIVES	O
:	O

The	O
role	O
of	O
intermittent	O
ultrasound	O
in	O
the	O
conservative	O
treatment	O
of	O
subacromial	O
impingement	O
syndrome	O
(	O
SIS	O
)	O
has	O
not	O
been	O
clarified	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
efficacy	O
of	O
ultrasound	O
treatment	O
in	O
SIS	O
.	O

METHODS	O
:	O

Thirty	O
-	O
six	O
patients	O
(	O
29	O
females	O
,	O
7	O
males	O
;	O
mean	O
age	O
51	O
years	O
;	O
range	O
40	O
to	O
69	O
years	O
)	O
with	O
type	O
II	O
SIS	O
were	O
randomized	O
to	O
two	O
groups	O
to	O
receive	O
intermittent	O
ultrasound	O
(	O
group	O
1	O
,	O
n	O
=	O
20	O
)	O
and	O
placebo	O
ultrasound	O
(	O
group	O
2	O
,	O
n	O
=	O
16	O
)	O
for	O
three	O
weeks	O
(	O
15	O
sessions	O
)	O
.	O

All	O
the	O
patients	O
received	O
the	O
same	O
standard	O
physical	O
therapy	O
and	O
rehabilitation	O
modalities	O
besides	O
ultrasound	O
treatment	O
.	O

Evaluations	O
were	O
made	O
before	O
and	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
.	O

Functional	O
results	O
were	O
assessed	O
by	O
the	O
Constant	O
score	O
,	O
pain	O
was	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
and	O
range	O
of	O
motion	O
was	O
measured	O
.	O

RESULTS	O
:	O

Within	O
-	O
group	O
comparisons	O
showed	O
significant	O
improvements	O
in	O
both	O
groups	O
three	O
and	O
six	O
weeks	O
after	O
treatment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Comparison	O
between	O
pretreatment	O
and	O
6	O
-	O
week	O
values	O
were	O
as	O
follows	O
:	O
the	O
mean	O
flexion	O
increased	O
from	O
148	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
4	O
degrees	O
to	O
175	O
.	O
6	O
+	O
/	O
-	O
6	O
.	O
0	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
165	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
1	O
degrees	O
to	O
177	O
.	O
4	O
+	O
/	O
-	O
4	O
.	O
4	O
degrees	O
in	O
group	O
2	O
;	O
internal	O
and	O
external	O
rotation	O
increased	O
from	O
66	O
.	O
8	O
+	O
/	O
-	O
20	O
.	O
7	O
degrees	O
and	O
61	O
.	O
9	O
+	O
/	O
-	O
22	O
.	O
9	O
degrees	O
to	O
83	O
.	O
2	O
+	O
/	O
-	O
10	O
.	O
9	O
degrees	O
and	O
84	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
6	O
degrees	O
in	O
group	O
1	O
,	O
and	O
from	O
75	O
.	O
0	O
+	O
/	O
-	O
17	O
.	O
3	O
degrees	O
and	O
70	O
.	O
0	O
+	O
/	O
-	O
19	O
.	O
8	O
degrees	O
to	O
87	O
.	O
1	O
+	O
/	O
-	O
6	O
.	O
8	O
degrees	O
and	O
84	O
.	O
6	O
+	O
/	O
-	O
8	O
.	O
4	O
degrees	O
in	O
group	O
2	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
the	O
range	O
of	O
motion	O
at	O
the	O
end	O
of	O
six	O
weeks	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
Constant	O
score	O
improved	O
from	O
43	O
.	O
7	O
+	O
/	O
-	O
12	O
.	O
9	O
to	O
65	O
.	O
7	O
+	O
/	O
-	O
7	O
.	O
7	O
in	O
group	O
1	O
,	O
and	O
from	O
43	O
.	O
9	O
+	O
/	O
-	O
16	O
.	O
4	O
to	O
65	O
.	O
3	O
+	O
/	O
-	O
7	O
.	O
6	O
in	O
group	O
2	O
.	O

Pain	O
scores	O
decreased	O
from	O
5	O
.	O
5	O
to	O
2	O
and	O
from	O
5	O
to	O
1	O
in	O
group	O
1	O
and	O
2	O
,	O
respectively	O
.	O

Improvements	O
in	O
Constant	O
scores	O
and	O
pain	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O

Our	O
findings	O
suggest	O
that	O
intermittent	O
ultrasound	O
added	O
to	O
conservative	O
treatment	O
of	O
SIS	O
do	O
not	O
provide	O
an	O
additional	O
benefit	O
to	O
the	O
patients	O
.	O

Netrin	O
-	O
1	O
up	O
-	O
regulation	O
in	O
inflammatory	O
bowel	O
diseases	O
is	O
required	O
for	O
colorectal	O
cancer	O
progression	O
.	O

Chronic	O
inflammation	O
and	O
cancer	O
are	O
intimately	O
associated	O
.	O

This	O
is	O
particularly	O
true	O
for	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
,	O
such	O
as	O
ulcerative	O
colitis	O
and	O
Crohn	O
'	O
s	O
disease	O
,	O
which	O
show	O
a	O
major	O
increased	O
risk	O
for	O
colorectal	O
cancer	O
.	O

While	O
the	O
understanding	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
IBD	O
has	O
recently	O
improved	O
,	O
the	O
mechanisms	O
that	O
link	O
these	O
chronic	O
inflammatory	O
states	O
to	O
colorectal	O
cancer	O
development	O
are	O
in	O
large	O
part	O
unknown	O
.	O

One	O
of	O
these	O
mechanisms	O
is	O
NF	O
-	O
kappaB	O
pathway	O
activation	O
which	O
in	O
turn	O
may	O
contribute	O
to	O
tumor	O
formation	O
by	O
providing	O
anti	O
-	O
apoptotic	O
survival	O
signals	O
to	O
the	O
epithelial	O
cells	O
.	O

Based	O
on	O
the	O
observation	O
that	O
netrin	O
-	O
1	O
,	O
the	O
anti	O
-	O
apoptotic	O
ligand	O
for	O
the	O
dependence	O
receptors	O
DCC	O
and	O
UNC5H	O
is	O
up	O
-	O
regulated	O
in	O
colonic	O
crypts	O
in	O
response	O
to	O
NF	O
-	O
kappaB	O
,	O
we	O
show	O
here	O
that	O
colorectal	O
cancers	O
from	O
inflammatory	O
bowel	O
diseases	O
patients	O
have	O
selected	O
up	O
-	O
regulation	O
of	O
netrin	O
-	O
1	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
this	O
inflammation	O
-	O
driven	O
netrin	O
-	O
1	O
up	O
-	O
regulation	O
is	O
causal	O
for	O
colorectal	O
cancer	O
development	O
as	O
interference	O
with	O
netrin	O
-	O
1	O
autocrine	O
loop	O
in	O
a	O
mouse	O
model	O
for	O
ulcerative	O
colitis	O
-	O
associated	O
colorectal	O
cancer	O
,	O
while	O
showing	O
no	O
effect	O
on	O
inflammation	O
,	O
inhibits	O
colorectal	O
cancer	O
progression	O
.	O

